ahead curve annual report ahead curve environment constant technological disruption success hinge ability stay ahead curve strike ahead biocon broke pack ahead curve annual report biocon limited w e evaluated prospect pitfall technology pioneer took eclectic scientific face market skepticism encouraged culture experimentation constantly acquired bet generate new knowledge new knowhow focused breakthrough plunged uncharted water innovation ran rd program innovationled biotechnology research bring new drug potential believed audacious wager change course disease making today would pay disproportionately tomorrow evenly spread risk reward sought right partner forged path chose capital intensive enduring relationship pursued researchintensive ipintensive incisive ip strategy create robust inherently long gestational time intellectual capital line product commercialization undaunted made countercyclical market place leadership investment took proactive step transient innovation king futureready equipped biocon stand ahead curve manage uncertainty committed make difference economic cycle global healthcare ahead curve biocons strength derived r e g c c l r n n v e e n co e n robust infrastructure capability expertise proprietary technology based talent pool extensive global array expression platform pichia pastoris platform product development experience include microbial mammalian expression recombinant system protein robust analytical capability scientifically rigorous ethically member strong scientific anchored cuttingedge tool compliant stage gatebased team including md phd latest orthogonal approach structured preclinical clinical master degree holder drawn world class technology development strategy within india global biopharma organization product approved key strategic global regional globalscale complex biologics regulatory agency u partnership across novel manufacturing capability eu japan france brazil mexico molecule biosimilars turkey gulf country ahead curve annual report biocon limited strong foundation process science enables development biologics economical scalability high productivity comprehensive presentation biologics across drug substance drug product liquid vial lyophilized vial cartridge prefilled syrinx delivery device reusable disposable prefilled pen wide presence marketing footprint across country key strength ahead curve annual report biocon limited b c n di f f e r e n tiat e p l e r n h e g l ba l p h ar c e uti c l pa c e among handful indian first listed pure play globally recognized pharma company working biopharmaceuticals company biopharmaceuticals enterprise area biologics india unique business model straddle product service extensive experience diversified portfolio biosimilar rd strategy cover early mid demonstrated expertise taking insulin analog antibody latestage novel asset two novel biologics five advanced stage development biosimilars lab market inhouse expertise across incisive intellectual property experience multiple global drug value chain pipeline strategy recognized several regulatory filing insulin includes proprietary national international award biosimilar antibody partnered program complex generic formulation key differentiator motivation enter niche area strategy perceive potential collaborative model profitably smart moderate cost allows u share socially good widen patient access risk reward drug provide affordable development access advanced research partnership biopharmaceuticals extend global global patient footprint local population marketing alliance biocons business model woven around business philosophy unwavering commitment built around core commitment stringent value quality core quality control affordability reliability value compliance bestin innovation class global standard relentless focus obligation develop chronic disease space portfolio approach affordable blockbuster like diabetes cancer focused chronic drug potential autoimmune disease segment benefit billion inflammation integrating well validated patient targettoclinictocounter capability ahead curve annual report biocon limited global biologics landscape present good opportunity biocon top worldwide worldwide global pharma prescription drug biotechnology drug brand revenue market market projected forecasted grow grow biologics u trillion u billion global biosimilars market projected u billion u billion emerging market market u action historically seen u eu japan payer regulatory high penetration defined regulatory level increased generic drug similar requirement political noise around trend could apply registration biosimilar drug pricing biosimilars product payer encouraging towards pushing contain cost acceptance biosimilars source genetic engineering biotechnology news evaluate pharma allied market research key opportunity first indian company manufacture export enzyme u europe first biotechnology company india get iso certification german authority rwtuv india first custom research service organization syngene set india first clinical research biocon organization clinigene set grown first indian company get u fda year approval manufacturing lovastatin c n e n ly investing first indian company submit dmf drug master file rhinsulin api u fda planning ahead first company globally commercialize rhinsulin curve manufactured pichia fermentation technology first biotech company india list indian stock exchange india first indigenously produced novel monoclonal antibody head neck cancer biomab egfr launched india ahead curve annual report biocon park india first private corporate biotechnology sez became operational signed mylan one earliest partnership global pharma industry codevelopment biosimilars evertor india first generic everolimus treatment advanced renal cell carcinoma launched world first novel anticd monoclonal antibody psoriasis alzumab itolizumab launched india first indian biopharmaceuticals company venture exciting space sirnabased small interfering rna therapeutic partnership quark pharma first biosimilar trastuzumab approved anywhere world launched canmab india first biosimilar approved mexico per biocomparable approval pathway biocons insulin glargine first indian company launch biosimilar insulin glargine pen japan biocons insugen first locally manufactured biosimilar product approved sale malaysian drug regulator key achievement f g l n c e revenue profit year ebitda margin h million h million rd spend gross eps employee h million h business revenue mix geographic distribution small molecule h million international biologics h million domestic branded formulation h million research service h million others h million ahead curve annual report biocon limited content chairperson review branded formulation qa ceo global marketing financial review cfo research service board director enablers scientific advisory board research development core committee quality vision mission value supply chain management financial highlight human resource business segment review environment health safety biologics corporate social responsibility biosimilars biocon foundation novel biologics biocon academy small molecule financial report content chairperson review kiran mazumdarshaw chairperson ahead curve annual report biocon limited dear shareholder era biologics global pharmaceutical industry noteworthy top drug sale biologics witnessing transformative change forecast biologics contribute value biologic drug protein therapeutic top drug product sold globally global sale biotechnology like antibody interleukin vaccine drug projected grow usd billion derived microbial mammalian cell ushered paradigm shift getting ahead curve treating chronic disease targeted turn millennium biocon chose embark biologicsled therapy precision medicine pharmaceutical journey differentiated business strategy invested poised disrupt future disease ahead curve promising future targeted biologics management revolutionizing treatment chronic disease recognized indian pharmaceutical sector built company size audacious plan took plunge global scale leadership reverse believed would provide u head start overcrowded generic engineering expensive chemically market place decided take complex development manufacturing synthesized small molecule drug regulatory challenge inherent biologics confident produce cost effective generic capability stemmed knowledge expertize enzyme alternative earned technology started biotechnology business pursued label pharmacy innovation strategy rooted affordability leveraging india cost base world dominating traditional generic drug industry decade many set address unfolding opportunity choosing lead rather indian company race follow able transform scientific discovery advance create generic version biologic human healthcare generate incremental value shareholder drug biosimilars far biologics cutting edge complex make offer large global opportunity biocon earned distinction first company india launch novel biologic nimotuzumab humanized antiegfr epidermal biocon ahead pursuit develop growth factor receptor monoclonal antibody mab head neck cancer first wave biosimilars global patient market expand access number essential lifesaving biologic drug followed launch second novel biologic itolizumab facing patent expiry psoriasis patient india pathbreaking anticd mab also developing pipeline patented offered less aggressive dosing regimen longer treatment free biologics address unmet medical period need entered codevelopment partnership usbased mylan source portfolio biosimilars collaboration led launch genetic engineering biotechnology news world first biosimilar trastuzumab patient suffering evaluate pharma world preview chairperson review herpositive metastatic breast cancer india gained access affordable version lifesaving drug rest emerging world put three recourse expensive innovator product advanced biocon mylan one longeststanding partnership global biosimilar asset biosimilars space leveraged mutual strength build one track anticipated largest diverse biosimilar pipeline spanning insulin analog regulatory approval monoclonal antibody developed market first block early mover biosimilars space put three advanced biosimilar asset track anticipated regulatory approval developed market address aggregate market opportunity usd billion fy filed two biologics license application blas u three marketing authorization application maas eu first file regulatory application proposed biosimilar trastuzumab u eu positioned biocon mylan among first company able address critical need highquality biosimilar treat certain herpositive breast cancer u eu application biosimilar pegfilgrastim also accepted review u eu submitted marketing authorization application biosimilar bevacizumab indian drug regulator completing emerging markettargeted india clinical trial maa recently granted global clinical trial biosimilar adalimumab plaque psoriasis completed expect regulatory submission various geography start fy biosimilars development capability endorsed year publication heritage study prestigious journal american medical association jama study result confirmed efficacy safety ahead curve annual report biocon limited immunogenicity proposed biosimilar trastuzumab codeveloped biocon mylan comparison reference product moving presentation study result american society clinical steadfastly towards oncology asco annual meeting chicago u european society aspiration medical oncology esmo congress copenhagen denmark providing insulin dr hope rugo appreciated immensely scientific community one five insulindependent consolidating market leadership people diabetes built market leadership insulin back global around world manufacturing scale moving steadfastly towards aspiration providing insulin one five insulindependent people diabetes around world achieved key milestone journey towards visionary goal launched readytouse disposable insulin glargine pen japan partner fujifilm pharma insulin glargine first biosimilar india launched japan also first biosimilar developed market confidence product gained among prescribers patient japan endorsed quality efficacy product enhanced brand biocons reputation across world also started commercial supply first overseas insulin manufacturing facility malaysia year recombinant human insulin rhinsulin became malaysia first locally manufactured biosimilar product sold southeast asian nation signed threeyear myr million offtake agreement malaysian government looking forward insulin foray larger developed market following submission acceptance filing insulin glargine european medicine agency ema u fda commercialization malaysia facility fy strengthen position among top biosimilar player globally insulin term volume market shareunits source ims year end chairperson review novel molecule poised leap practitioner frontier science built pipeline novel biologics successful address local well global unmet medical need diabetes cancer journey itolizumab autoimmune disease basket novel asset clinical development laboratory represents interesting combination early advanced stage asset market india believe insulin tregopil firstinclass oral prandial insulin put u ahead advanced program global oral insulin space promise transform race anticd diabetes management set stage pivotal study insulin antibody unlock tregopil different diabetic population india form potential foundation broad global program envisioned novel molecular entity unique mechanism action multiple successful journey itolizumab laboratory market india autoimmune put u ahead race unlock potential unique mechanism indication action multiple autoimmune indication fy reported encouraging progress test patientfriendly subcutaneous form itolizumab small molecule enabling partner significant brand equity built worldwide fermentationderived small molecule apis across statin immunosuppresants specialty product made u leading global supplier product built reputation emerge among first wave supplier rosuvastatin api partner u launch upon patent expiry year received first generic formulation approval rosuvastatin calcium u fda become vertically integrated player niche space difficultto make generic formulation leveraged strength fermentation technology molecular characterization branded formulation india uae initiated branded formulation business india launch country first indigenously developed rhinsulin brought cost insulin therapy third since aimed staying ahead curve deftly balancing innovation affordability ahead curve annual report biocon limited intent bring costeffective biologics differentiated small molecule formulation chronic condition patient india uae frontrunner select market contract year business reported overall growth like like research service basis segment marginally compared last year though sale space syngene india sluggish continued improve prescription share expanded key brand insugen basalog canmab robust growth role fy uae placed u among top pharma company year innovation partner product ranked among top brand respective segment recently announced leadership change across india branded formulation business provide u ability pursue strong growth trajectory syngene integrated research service provider syngene research service subsidiary publicly listed contract research organization cro india offer endtoend drug discovery development service novel molecular entity global life science sector front runner contract research space syngene expanded role fy innovation partner new strategic partnership amgen herbalife nutrition dedicated rd center december fire accident one syngenes research block bengaluru affected strong revenue momentum business syngenes value proposition customer remains strong expanded capacity acquired new capability year important acquisition effect bioinformatics business bengaluru based genomics company strand lifesciences standalone basis reported revenue growth healthy ebitda margin quality unwavering focus culture quality excellence helped biocon maintain strong compliance track record regulatory inspection year fy underwent multiple regulatory audit various international regulator chairperson review best employer brand continue asian company global best biotech continue employer list brought prestigious science career magazine asian believe great testament work culture opportunity company scientist get within company featured among top global best biotech employer globally employer list financial highlight matched operational performance fy equally strong financial performance grew topline h million simultaneously improving quality earnings ebitda margin year expanded year ago adjusting exceptional item boosted bottomline fy net profit fy jumped h million declaration bonus share final dividend board director company recommended issue two bonus share every one share held biocon subsequently approved shareholder board also recommended final dividend h per share fy pre bonus work h per share post approval socially responsible strongly believe use technology address several challenge associated public health delivery country biocon foundation csr arm biocon taken ahead belief develop unique ehealthcare model introduced elaj smart clinic year ago clinic designed facilitate effective preventive primary healthcare intervention rural area india benefit community poor access healthcare foundation currently run elaj smart clinic covering gram panchayat across karnataka rajasthan elaj smart clinic paving way evidencebased public health intervention location enabling multiple diagnostic test generation electronic medical record emrs patient ahead curve annual report biocon limited past year patient footfall elaj clinic gone month elaj elaj model facilitating ontime treatment helping reduce outofpocket smart clinic healthcare spending cutting need trip tertiary hospital paving line commitment enable right healthcare way evidence every citizen based public health intervention using biocon academy oneofakind initiative area skill development technology delivered commitment prepare industryready student biotech sector fy saw successful completion three batch multiple diagnostic biocon kgi certificate program bioscience second batch bit test generation biocon program applied industrial microbiology academy maintained electronic medical placement record year even company record emrs visited recruiting fresh talent student patient employed outside biocon syngene looking ahead fy promise exciting year biocon developed market regulatory submission biosimilars could translate marketing approval opening immense growth opportunity company finally would like thank shareholder trust placed u humanitarian business making difference people life mission spurred u fight way year credibility challenge market skepticism emerge leading indian company working cuttingedge sphere biosimilars best wish kiran mazumdarshaw chairperson managing director june chairperson review qa ceo dr arun chandavarkar ceo joint managing director ahead curve annual report biocon limited biocon consistently stayed ahead curve biocons focus innovation differentiation predates entry pharmaceutical sector entrepreneurial culture rooted building strength nascent field biotechnology instrumental u identifying opportunity based market technology trend initial year enzyme company subsequent foray biopharmaceuticals led u proactively invest capability aligned opportunity ahead curve biocon commenced pharma journey leveraging capability fermentation technology derived long experience manufacturing enzyme unlike company india largely focused generic made chemical synthesis furthermore amongst early mover developing portfolio fermentation derived statin gave u leadership position segment simultaneously chose expand strategic option small molecule like statin recombinant protein like insulin address growing healthcare challenge associated diabetes hesitate exploit differentiated technology proprietary yeast platform based pichia pastoris create portfolio insulin initiated work mammalian cell culture based expression system develop monoclonal antibody mabs targeting cancer autoimmune disease product portfolio limited generic biosimilars sought opportunity ahead curve addressing unmet need therapeutic segment novel biologics novel target marked high entry barrier wherein early anticipation required make significant investment full range rd increasing capability spanning process analytical development preclinical dominance clinical research biologics global early anticipation increasing dominance biologics global development development pipeline helped u ahead curve crafting pipeline helped u differentiated product portfolio based fermentation recombinant ahead technology believe would provide u sustainable competitive curve advantage year ahead ceo qa ahead curve translate tangible achievement biocon strategic choice focusing biotech fermentationderived biopharmaceuticals resulted unique differentiated product portfolio straddling fermentationderived small molecule recombinant protein including insulin mabs biocons growth mid triggered first approval statin api facility u fda driven early mover advantage lovastatin pravastatin simvastatin amongst company approved apis fermentationderived statin helped lower competitive intensity otherwise typical chemistrybased apis expanded portfolio fermentationderived apis establish strong competitive position immunosuppressant certain speciality apis likewise one among two nonoriginator company commercialize recombinant human insulin india subsequently rapidly expand footprint multiple emerging market year followed launch insulin glargine india recently gone important endorsement product quality account demonstrated approval launch glargine disposable pen japan capability also pioneer developing manufacturing launching couple dossier novel biologics india namely antiegfr mab nimotuzumab head submission neck cancer anticd mab itolizumab psoriasis europe partner mylan three biosimilar embarked biosimilar journey anticipated product based risk long gestation period development evolving regulatory diverse technology landscape significant financial outlay rd manufacturing platform scale infrastructure proactively mitigated risk entering operation regional global partnering agreement one mylan ahead curve annual report biocon limited biosimilar mabs expanded insulin analog partnership structured sharing risk reward leveraged complementary strength partner forerunner many global partnership exist today biosimilar space including involving many innovator company believe partnering strategic choice early investment cycle biosimilars another example ahead curve tangible outcome partnership mylan launch biosimilar trastuzumab india emerging market collaboration also reached important milestone fy trastuzumab pegfilgrastim dossier accepted review u fda ema followed glargine filing europe biocons ahead curve strategy mean prospect biocons annual report shareholder fy highlighted effort initial success credibly capable based first approval biosimilar product namely insulin glargine demanding developed market like japan progress made advancing biosimilar program clinic year gone demonstrated capability dossier submission europe partner mylan three biosimilar product based diverse technology platform scale operation namely trastuzumab pegfilgrastim insulin glargine last year also u fda accept dossier trastuzumab pegfilgrastim review insulin glargine follow early fy three product target market opportunity usd billion current innovator pricing continue develop biosimilar asset collaboration mylan nearterm growth biosimilars driven expanding footprint key emerging market strong local partnership product approval ceo qa commercial success developed market u europe would significant milestone help company reinvent lay strong foundation stay ahead curve next decade supported capacity expansion needed phased manner addition product portfolio cater next wave opportunity continue adopt riskbalanced approach advance promising firstinclass novel biologics target critical unmet need strive remain ahead curve developing fermentation derived complex potent niche small molecule generic apis forward integrate finished dosage form believe strategy ahead curve well diversified portfolio small molecule biosimilars novel biologics help u overcome headwind facing generic pharmaceutical sector today term pricing pressure tougher regulatory expectation increased competition biocons key priority fy fy position u key inflection point journey amongst successful first wave successful entrant global biosimilar arena look commissioning forward receiving approval u europe biosimilar filing malaysian facility done fy launch product market also insulin fy expect couple additional filing fy market threeyear myr million successful commissioning malaysian facility insulin fy contract threeyear myr million contract malaysian ministry malaysian ministry health augur well seek approval key emerging market health augur well approval commercial launch thereafter expected seek approval latter part fy would help partly defray annual fixed cost key emerging usd million associated malaysian facility approval also debottleneck capacity constraint insulin indian facility market ahead curve annual report biocon limited continue seek approval expand commercial footprint biosimilars key emerging market latam mena ci southeast asia unlock value first set asset whilst waiting developed market open expect break ground new brownfield mabs facility bengaluru rd front continue invest progressing biosimilars novel biologics whilst completed rowfocused phase iii trial metastatic colorectal cancer proposed biosimilar bevacizumab fy separate global phase iii trial nonsmall cell lung cancer track patient recruitment continue develop rapidacting insulin analog enable progress clinical stage shortly initiate significant clinical study novel insulin tregopil oral insulin validate positioning orallydelivered rapidacting prandial insulin establish safety efficacy type diabetes patient expect conclude stage study novel anticd mab itolizumab australia provide valuable data term subcutaneous route administration small molecule segment expected see steady growth back increased volume offtake base product comprising statin small molecule immunosuppressant continue invest developing segment expected next portfolio small molecule forward integrating apis see steady growth finished dosage form expect newly constructed oral solid back formulation facility operational latter part fy increased volume reduce current dependence outsourced manufacturing offtake base key focus fy rebooting branded formulation business product comprising recently revamped leadership team intent gaining market statin share profitably anchor brand augmented immunosuppressant new launch inhouse inlicensed product ceo qa financial review cfo siddharth mittal presidentfinance cfo revenue ebitda h million h million net profit ebitda margin h million ahead curve annual report biocon limited comment transition new indian accounting standard fy biocon amongst early adopter new indian accounting standard referred commonly ind transition older standard ind starting april applied standalone consolidated financial statement line ind changed segment reporting better reflect way view measure overall business started reporting four segment small molecule biologics branded formulation research service instead two biopharmaceuticals research service used report previous accounting standard line growth strategy represented four business segment provides clearer picture segment shareholder earlier rate performance year overall financial performance year satisfactory line expectation fy consolidated revenue h million grew net profit h million reported growth adjusting exceptional income fy net profit actually jumped h million year earnings interest tax depreciation amortization ebitda year rose h million ebitda margin markedly improved last year extraordinary gain recorded previous year account deferred revenue recognition pertaining rhinsulin development impairment intangible asset biocon sa adjusting company strong performance year led small exceptional income molecule business reporting growth h million fy net profit biologics business h million reporting growth branded actually jumped formulation business includes sale uae reported growth h million h million research service syngene contributed year h million biocons sale financial review operating margin trajectory look like medium term company core operating margin operating margin adjusted licensing income rd expense forex gain loss continue remain healthy spite increased operational expense like salary cost fy ebitda margin core operating margin stood resulting growth small molecule business biosimilars business emerging market mediumterm endeavor maintain core operating margin level despite increase rd expense inclusion malaysian expense pl anticipate margin improve launch biosimilar product developed market enjoy reasonable penetration reflects optimum utilization manufacturing asset good service tax gst expected rolled nationwide july would anticipated impact biocon longterm perspective gst good nation replace number different tax company deal currently single nationwide tax would simplify operation expect shortterm impact branded formulation india business anticipated distribution channel could destock market inventory gst rollout hence sale q fy could impacted impact could rollover q fy well depending quickly channel becomes gstready compliant expect thing normalize second half fiscal mediumterm gst company claim input credit certain item endeavor possible earlier tax structure however saving would maintain core ultimately passed customer given antiprofiteering operating margin clause gst bill level despite increase expected tax rate biocon consolidated level rd expense fy inclusion consolidated level effective tax rate fy malaysian expense adjusting onetime deferred tax benefit company availed pl effective tax rate year ahead curve annual report biocon limited rate expected go bps bps fy due expiry year tax holiday manufacturing facility government gradually phasing rd tax benefit availed biocon thus far weighted deduction reduce fy completely eliminated next couple year biocon stopped capitalization expense malaysia plant end fy affect bottomline fy stopped capitalizing preoperating expense relating malaysia plant end fy consequently depreciation fixed expense related malaysia plant charged pl account starting q fy estimate annual depreciation approximately usd million fixed plant operating expense includes finance cost approximately usd million already commenced commercialization malaysia plant supply rhinsulin domestic market fy also anticipate approval followed commercial supply emerging market previously india plant qualified lastly partly utilize plant development pipeline insulin product wherein cost shared partner mylan accounted rd expense result expect adverse impact bottomline malaysian operation fy however endeavour minimize impact trajectory rd expenditure across foreseeable future company continue focus development biosimilars complex generic novel biologics program require intensive rd effort long gestation period guided gross annual rd expense range sale excluding syngene expect rd expense fy line guidance financial review rationale behind capitalization rd expense select biosimilar product accordance requirement ind intangible asset development cost capitalized intangible asset based recognition parameter summarized product technically commercially feasible ie future economic benefit probable group intends complete development intent use sell asset establish technical feasibility demonstrated biosimilarity product term safety efficacy various preclinical clinical activity occurs upon receipt regulatory approval product major territory establish commercial feasibility demonstrated intangible asset generate probable future economic benefit occurs probable able successfully commercialize product intended market technical commercial feasibility established believe adequate technical financial resource complete development activity capitalize future development cost incurred also sufficient leverage b expenditure measured reliably balance cost development identified product level hence sheet raise development cost eligible capitalization measured reliably additional debt broad category expense capitalized include cost material fund remaining salary appropriate overhead used product validation cost portion capex conducting clinical trial etc foresee raising fresh equity biocons capex plan fy funding nearing completion two capex project oral solid dosage capital market facility biologics fillfinish line bengaluru expected fund commissioned fy commence qualification shortterm capex process maintenance capex estimated h million requirement h billion year ahead curve annual report biocon limited term new large project expect start construction second monoclonal antibody facility bengaluru fy receipt regulatory approval investment phased period three four year associated capex shared partner mylan debt position company biocon plan fund upcoming capex would biocon need raise fund market fund future growth plan biocon consolidated gross debt long term plus short term debt h million march corresponding cash liquid investment h million excluding syngene gross debt cash liquid investment stood h million h million respectively cash liquid investment balance sheet coupled free cash flow operation used fund significant portion capex also sufficient leverage balance sheet raise additional debt fund remaining portion capex foresee raising fresh equity funding capital market fund shortterm capex requirement longterm perspective restructured legal entity reflect key business segment new structure provides u flexibility unlock value raise capital required business segment future biocon specific dividend policy yes biocon dividend policy dividend distributed shareholder depending upon multiple factor including limited future earnings financial condition cash flow planned capital expenditure working capital requirement declaration payment dividend recommended board director approved shareholder discretion subject provision article association company act detail please read page financial review board director sitting left dr vijay kuchroo john shaw mary harney kiran mazumdarshaw russell wall daniel bradbury standing left dr jeremy levin damodaran dr arun chandavarkar prof ravi mazumdar ahead curve annual report biocon limited kiran mazumdarshaw people across globe played pivotal role evolution chairperson managing director field medicine recognized biocon last year first generation entrepreneur consecutively third year since phd biochemical engineering nearly year experience massachusetts institute biotechnology conferred highest french technology mit cambridge usa well recognized global business distinction chevalier de lordre btech chemical engineering leader national de la légion dhonneur indian institute technology knight legion honour independent member board mumbai infosys limited chairman confederation indian recently bestowed chairperson board industry national committee advancing woman science governor indian institute biotechnology medicine awsm award management bangalore excellence feinstein prof ravi mazumdar recipient two prestigious institute medical research usa nonexecutive director national award padma shri university research chair professor john shaw padma bhushan department electrical vice chairman wholetime recipient othmer gold medal computer engineering university director u based chemical waterloo canada foreign promoter wholetime heritage foundation jd gandhi distinguished visiting director recipient global economy professor iit mumbai master degree art economic prize business germany member several advisory hons history political kiel institute committee working group economy glasgow university featured powerful uk including u congress sub woman asiapacifics committee science served finance managing hero philanthropy forbes technology director coat viyella group magazine fellow royal statistical served senior corporate position recognized leading society around world global thinker u referred publication based foreign policy magazine former chairman madura coat ltd ph university fortune magazine top dr arun chandavarkar california los angeles ucla powerful woman asiapacific chief executive officer joint msc dic imperial college managing director london featured among top core member biocons leadership team btech electrical engineering medicine maker power list iit mumbai index influential board director russell wall daniel bradbury independent director independent director chairman aviva life holding ltd board trustee keck experience year graduate institute california usa field finance member san diegos rady school fellow member association management advisory council chartered certified accountant uk member miami innovation board mytrah energy ltd aviva corporate advisory council italia holding spa signet life science executive jeweler ltd year experience creating mary harney implementing strategy independent director transforming business tánaiste deputy prime minister honoured corporate irish republic director forum director year award enhancing economic longest serving woman ever value irish parliament year ernst young entrepreneur member board crann year finalist trinity college dublin largest research institute hold postgraduate diploma management study chair amber advanced material bioengineering diploma chartered institute research centre trinity joint marketing harrow ealing research enterprise university college higher education uk college cork royal college bachelor degree pharmacy surgeon ireland industry hons nottingham university honorary member uk international womens forum dr jeremy levin economics graduate trinity independent director college dublin former president ceo teva pharmaceutical ahead curve annual report biocon limited former executive committee center immunologic disease chairing government india task member bristolmyers squibb harvard medical school usa force set resolution corporation india responsible global codirector center infection strategy alliance operational immunity brigham research former chairman security transaction institute boston exchange board india sebi unit trust india uti industrial led string pearl strategy named distinguished eberly development bank india idbi bm helped transform lecturer company pipeline former chief secretary government obtained nobel laureate peter tripura served global head strategic doherty lecture prize alliance novartis set excellence enablers private hold patent limited eepl corporate recognized among top founded different biotech governance board advisory influential people company including costim consultancy firm biopharmaceutical industry pharmaceutical tempero board leading indian recipient kermode prize work pharmaceutical corporates well novel hypertension drug published original research advisory board foreign albert einstein award leadership paper field immunology entity life science awarded mr costimulation role th shimon peres cell officer cross order merit fred z eager research prize republic hungary medal phd research work university queensland bachelor degree zoology master art doctorate phil specialization pathology university oxford university queensland brisbane australia obtained phd degree bachelor medicine bachelor surgery mb b chir damodaran university cambridge independent director dr vijay kuchroo founder chairman indian institute independent director management tiruchirappalli samuel l wasserstrom professor chairman glocal healthcare system neurology director evergrande private limited board director scientific advisory board prof alan cherrington dr brian kotzin phd professor chairman molecular physiology medical degree postdoctoral fellowship biophysics professor medicine diabetes immunology rheumatology stanford university research vanderbilt university past president vice president global clinical development head american diabetes association inflammation therapeutic area amgen vice president head medical science member dr david essayan advisory council national institute arthritis md key research interest clinical regulatory musculoskeletal skin disease nih associate editor development small molecule biologics clinical clinical investigation immunologist former fda supervisory medical officer former executive director amgen dr brian daniel md b mit venture partner dr g alexander fleming venture management llc former svp bm directed md president ceo kinexum llc member conducted clinical research merck research numerous scientific advisory board expert laboratory genentech extensive experience committee clinical development medical affair corporate strategy across broad range therapeutic area dr harold e lebovitz md face professor medicine endocrinology dr jugnu jain diabetes division state university new york health phd cambridge university launched sapien science center brooklyn saarum india molecular geneticist cell biologist led vertex global immune inflammation team dr lawrence steinman research cytokine gene regulation harvard md key research interest remission relapse published paper patent vaccine brain inflammation coinventor leading drug natalizumab several new therapy prof huub schellekens autoimmune disease md phd professor medical biotechnology utrecht university published paper dr vijay kuchroo development therapeutic protein member dvm phd key research interest multiple sclerosis dutch medicine evaluation board national expert costimulation th currently scientific review ema board national multiple sclerosis society new york ahead curve annual report biocon limited core committee kiran mazumdarshaw dr narendra chirmule chairperson managing director sr vice president head rd founder biocon limited siddharth mittal john shaw president finance cfo vice chairman ravi limaye dr arun chandavarkar president marketing chief executive officer amitava saha joint managing director sr vice president head human resource scientific advisory board core committee vision mission value vision discovery research management research development business partnership enhance global healthcare stateoftheart manufacturing innovative affordable capability value biopharmaceuticals patient partner healthcare system integrity ethical behaviour internationally benchmarked across globe quality regulatory system performance driven work culture new medical insight value creation innovation mission disease specific clinical research differentiation integrated biotechnology customer relationship quality compliance enterprise global distinction outstanding product service best practice essential mission human resource development collaboration team work excellence training mentoring mutual respect intellectual asset creation empowering ahead curve annual report biocon limited financial highlight segmentwise revenue small molecule biologics branded formulation h million h million h million research service others total revenue h million h million h million figure per ind financial highlight profit debt equity h million h million debt equity total asset current ratio h million h million includes exceptional income year figure per ind ahead curve annual report biocon limited net worth eps book value per share eps dividend per share h million h million h million eps dividend per share book value per share eps gross rd spend return net asset return net equity h million h million h million return net asset return equity net asset average equity pat pat includes exceptional income year figure per ind financial highlight sitting left suresh subramanian sr vice president head branded formulation india dr narendra chirmule sr vice president head rd novel biologics standing left paul thomas vice president head biosimilars mabs prasad bsv sr vice president head small molecule shreehas tambe sr vice president head insulin ahead curve annual report biocon limited business segment review biologics total small branded research biosimilars revenue molecule formulation service novel growth growth growth growth growth h h h h h million million million million million biocons greenfield audit conducted canmab featured expanded business insulin manufacturing u fda mexico among top two additional facility malaysia cofepris korean oncology brand dedicated rd center commercialized fda country amgen herbalife nutrition regulatory filing continued work oral paper biosimilar trastuzumab development niche presentation expanded capability pegfilgrastim marginaccretive alzumab bioinformatics accepted review api molecule international purchase asset u fda ema conference psoriasis strand life science development u related system heritage study laboratory oncology biology heptox data biosimilar apis commissioned initiated physician pharma bioinformatics trastuzumab published centric registry progressed service jama program construction biocons alzumab progressed first oral solid dosage cytosorb key clinical study facility subcutaneous version neobiocon jumped itolizumab australia five place ranked among top pharma company uae segmental review biologics biocons innovationled strategy aligned global trend increased growth use biologics address unmet medical need one earliest h million player realm biologics india created rich pipeline novel biosimilar asset available patient india emerging market revenue biocon poised enter developed market biosimilar product time increasing acceptance biosimilars u pharmacy benefit manager pbms taken step exclude originator product formulary favour biosimilars group european regulator published paper supporting appropriateness switching patient originator biosimilar study conducted norwegian government established evidence supporting safety biosimilar source biodrugs interchangeability scandinavian country also taken apr doi strong national level step encourage biosimilar uptake time lancet volume issue emerging market also showing inclination wider biosimilars use june page expected launch pilot project prequalifying biosimilars ahead curve annual report biocon limited step towards making expensive pen business recorded strong treatment cancer doubledigit growth year chronic disease widely available low middleincome led higher offtake existing market expansion one leading global player insulin committed deliver affordable country commercial presence diabetes therapy option market worldwide including japan range basal rapid fy biologics segment intermediate acting generic reported strong growth revenue growth emerging insulin insulin portfolio h million driven largely market propelled robust complemented highend patientfriendly device sale biosimilars including sale rhinsulin cartridge offer ease use people rhinsulin insulin glargine reusable insulin pen ministry diabetes resulting improved trastuzumab global market health moh malaysia compliance therapy novel biologics also advanced threeyear myr million contract clinical development year shreehas tambe sr vice president head insulin program year besides malaysia also launched insulin glargine rhinsulin augur well insulin glargine biosimilars emerging market region latin america africa address usd billion global biocon portfolio market opportunity current middle east biosimilars spanning insulin innovator pricing monoclonal antibody japan readytouse prefilled disposable insulin glargine pen marketing authorization recombinant protein address well accepted prescribers application maa insulin critical chronic disease patient second glargine submitted european diabetes cancer autoimmune player received regulatory medicine agency first disorder collectively target approval sell biosimilar insulin filing developed market global market opportunity glargine estimated usd incorporates product validated usd billion million source ims year end new stateoftheart malaysia facility insulin analog market successful japan launch molecule insulin biocon among top biosimilar enhanced credibility expand analog portfolio insulin aspart player globally insulin term footprint developed insulin lispro preclinical volume market share measured market european union development number unit sold source ims year end company canada australia accepted commercialization malaysia diversified portfolio spanning review regulatory submission insulin facility recombinant human insulin insulin glargine codeveloped important milestone longacting insulin analog glargine mylan expect file fiscal commercialization complemented comprehensive marketing authorization application greenfield insulin product presentation across vial insulin glargine u fda manufacturing facility malaysia cartridge disposable reusable shortly key development biologics one largest asia diabetes management pegfilgrastim accepted malaysian government contract affordable biosimilar insulin review u fda ema enabled u start supplying inulin analog mark key milestone product overseas facility business fy india made significant invested nearly investment capacity global addressable market usd million debottlenecking meet projected opportunity trastuzumab rhinsulin malaysia first demand insulin drug indicated treating herpositive locally manufactured biosimilar substance drug product breast gastric cancer product approved emerging market usd billion pegfilgrastim commercial sale country administered patient insulin glargine manufactured monoclonal antibody undergoing chemotherapy india also approved recombinant market opportunity usd sale malaysia protein billion biocon distributing insulin biocon mylan codeveloping biocon mylan first file insulin delivery device highvalue portfolio six regulatory approval biosimilar leading local pharmaceutical player biosimilar mabs recombinant trastuzumab u eu extensive supply protein trastuzumab bevacizumab fda target action date chain network service primary adalimumab pegfilgrastim trastuzumab pegfilgrastim healthcare clinic hospital etanercept filgrastim targeting september october across malaysia chronic disease cancer respectively indicates range autoimmune disorder could one first biosimilar product enabling entrant product u malaysian government expand commenced sale eu market access affordable insulin therapy biosimilar trastuzumab emerging nearly million people market fy year regulatory submission diabetes southeast asian took product newer biosimilar pegfilgrastim also country geography including accepted australia larger emerging market canada several regulatory filing audit underway malaysian trastuzumab boosted biologics bevacizumab adalimumab manufacturing facility expect business revenue well fy completed emerging facility qualified licensing income year market targeted clinical trial emerging market continue seek regulatory proposed biosimilar bevacizumab ramp commercial sale approval trastuzumab metastatic colorectal cancer patient site fy increase presence submitted marketing emerging market unlocking additional capacity authorization application india malaysia emerging market trastuzumab pegfilgrastim additional global phase iii approval would help accelerate regulatory submission trial nonsmall cell lung cancer journey making global impact proposed biosimilar trastuzumab commenced late fy ahead curve annual report biocon limited global clinical trial biosimilar result trial first conjunction chemotherapy adalimumab plaque psoriasis presented american society patient treated patient complete begin clinical oncology asco annual positive metastatic breast cancer regulatory submission meeting chicago u completion sample data analysis european society medical expect submission various oncology esmo congress geography start fy copenhagen denmark presentation made biocon mylan study published dr hope rugo chair jama steering committee year result heritage study biosimilar heritage study appreciated immensely scientific b iocon vision global leader field biosimilars several year ago trastuzumab published community manifesting prestigious journal american several biosimilar asset jama recognized result track anticipated regulatory medical association jama heritage study approval developed market flagship publication real tribute last major step multiphased american medical association team biocon able program demonstrate accomplish complex area significant development bioconmylans proposed biosimilar relatively short period considering study published time trastuzumab meet criterion jama highly respected equivalence comparison undergo rigorous peer review paul thomas reference product used vice president head biosimilarmabs process global generic insulin biosimilars portfolio category molecule status regular acting insulin recombinant human insulin preclinical u market marketed emerging market long acting insulin analog insulin glargine filed eu australia canada u filing h fy marketed japan since july emerging market rapid acting insulin analog insulin aspart preclinical rapid acting insulin analog insulin lispro preclinical cancer trastuzumab filed u eu marketed emerging market autoimmune adalimumab global phase iii completed neutropenia pegfilgrastim filed u eu canada australia cancer bevacizumab indiaemerging market phase iii completed global phase iii commenced neutropenia filgrastim early development autoimmune etanercept early development biologics novel biologics insulin tregopil treating type type biocons lead program diabetes diabetes pivotal phase iii study biocon developing novel type diabetes expected insulin tregopil firstinclass biologics aimed addressing local start india fy clinical trial oral insulin molecule post well global unmet medical application cta filed prandial glycaemic control need area diabetes indian regulator announced successful result autoimmune inflammation study multiple ascending dose phase clinical study oncology basket novel study type diabetes patient drug candidate concluded asset clinical development population also planned fy u fy study represents interesting collaboration juvenile established target product combination early advanced diabetes research foundation profile molecule including stage asset combined study different food effect drugdrug interaction program generating diabetes population form pkpd profile fy encouraging exciting data foundation broad global followed positive ultimate success program program envisioned insulin phase data continue bring transformational growth tregopil development program business ahead curve annual report biocon limited itolizumab organization india anticd autoimmune inflammatory forayed exciting space second generation disease space novel first sirnabased small interfering rna humanized antibody targeting cd inclass anticd humanized therapeutic path ind monoclonal antibody itolizumab fy made progress one mapped plan advance marketed alzumab high potential novel asset asset neuroinflammatory treatment chronic plaque qpi developing disease eg multiple sclerosis psoriasis india since biocon asset sirna platform first company quark pharma rare world clinically validate cd ophthalmology indication target autoimmune disease pivotal global phase iiiii study fy progressed nonarteritic ischemic optic key clinical study using sub neuropathy naion initiated cutaneous version itolizumab quark pharma fy u australia evaluation multiple includes patient randomized indication bridging phase pk india safety study normal healthy fmab fusion protein volunteer australia seek immunooncology lead evaluate pharmacokinetics molecule fmab combine pharmacodynamics sub monoclonal antibody egfr cutaneous route administration tgf receptor fragment itolizumab comparison bind neutralizes tgf intravenous route fusion antibody currently company marketing preclinical development work approval india stage concept preferentially dosing subcutaneous route delivering immune modulators administration showed equivalent tumor site thus enhancing efficacy bioavailability drug plan delivering larger tgf initiate stage dosing shortly w tumor microenvironment e developing novel understanding cd pathway ind molecule planned biologics aimed led scientist biocon addressing local well fy currently ready potential developing novel global unmet medical need pharmacology mechanism area diabetes therapy patient immune action moa established autoimmune inflammation dysfunction vitro invivo tumor model oncology qpi sirna provides u potentially broad dr narendra chirmule biocon first biopharma clinical opportunity multiple sr vice president head rd novel biologics tumor type biologics small molecule audit entrenched presence complex immunosuppressant growth chronic therapy space recently generic h million made u preferred partner pharma customer india overseas formulation strategy hinge leveraging strength revenue characterization manufacturing lovastatin went patent biologics build robust biocon one leading global biocon one pipeline difficulttomake niche supplier complex small molecule three company world formulation chronic condition active pharmaceutical ingredient get u fda approval supply order address global need apis spanning cardiovasculars anti api drug since affordable therapy obesity agent immunosuppressant emerged world narrowspectrum antibiotic largest statin manufacturer apis antifungal drug substance used biocons ability stay ahead unique strength fermentation produce one every three statin curve placed among first wave technology complex chemistry pill globally year supplier rosuvastatin api successful track record regulatory also emerged leading player partner acquisition new ahead curve annual report biocon limited customer statin generic made progress immunosuppressant apis helped construction first oral solid formulation drive healthy performance dosage facility play business year part strategy sustain important role generic longterm growth small formulation strategy work sale rosuvastatin api molecule business working facility track u start key customer targeting u building robust pipeline exhibit batch various post patent expiry differentiated generic finished product qualification activity supplemented higher offtake dosage global market fy immunosuppressant apis especially commercial perspective latin american market strategy give biocon competitive maintained momentum advantage enable u regulatory filing drug integrated player offering master file dmfs submitted drug substance drug u key regulated market product niche area year successfully generic formulation business completed audit u fda obtained first anda approval mexico cofepris korean fda u fda rosuvastatin calcium tablet going ahead regulatory submission eight approval plan leverage experience received key apis scale regulatory u eu augur well submission u fda business file andas launch generic formulation u differentiated apis player focus provide partner meet increase demand add profitability best class statin complex expanded capacity statin business already enjoys immunosuppressant immunosuppressant specialty molecule thus healthy operating margin year enabling formulation completion fullcycle business committed endeavour expand exploit new opportunity development generic drug small molecule oncology within small molecule product positioned u file space niche portfolio portfolio development regulatory approval five generic formulation laboratory oncology api six molecule every year across enhance access affordable commissioned therapy chronic disease emerging market developed investment towards enhancing market u eu prasad bsv manufacturing capability sr vice president head small molecule progress small molecule branded formulation biocons branded formulation growth business ahead curve h million anticipating critical need affordable therapy chronic b iocons unique combination world class product personalized patient support disease india physician engagement revenue emerging market accordingly initiative enabled u prepared address make impact therapeutic area diabetology challenge differentiated oncology immunology world class biopharmaceuticals india focused execution personalized medical support new launch enable u deliver superior result year branded company going forward formulation business enabled biocon carve niche suresh subramanian sr vice president head branded biologicsled specialty formulation india pharmaceutical company ahead curve annual report biocon limited india enabled biocons brand publication result assume leadership position heritage trial involving pioneer bringing fy brand featured biosimilar trastuzumab journal innovative globally benchmarked among top brand american medical association biologics patient india respective category india helped build additional strategy highest quality top brand india portfolio confidence product among lowest cost enabled u accounted medical fraternity india build premium brand chronic revenue year stopped offering abraxane key therapeutic area diabetes inlicensed oncology molecule cancer endstage renal disease fy witnessed significant patient fy due decision immune disorder life increase prescription share taken licensor discontinue threatening condition insugen basalog supply flagship brand metabolics year extended division basalog ranked tacrograf key presence niche area number two insulin glargine immunosuppressant brand reported saw potential moderate brand india registered strong double digit growth fy cost widen patient access doubledigit sale growth number three tacrolimus brand introduced patientcentric initiative year insugen retained position india disease awareness prevention among top brand rhinsulin management partnered psorid one key available india key stakeholder like government immunotherapy brand continued healthcare professional biomab egfr canmab prescribed brand advocacy group increase access evertor nufil cyclosporine india lifesaving medicine licensed oncotherapeutics portfolio featured novel biologic alzumab product global innovator among top brand itolizumab made psoriasis core therapeutic area bring respective category continuing management easier several latest therapeutic advance make significant impact hundred patient india since india engaged physician realm cancer care india launch fy oral targeted educational biomab egfr novel biologic paper role itolizumab program related best treatment head neck cancer witnessed psoriasis management practice complex medical new enrollment presented international condition adopted evidence fy canmab biosimilar conference psoriasis skin based engagement strategy trastuzumab brand helped treat specialist meeting dallas u key opinion leader leveraging several thousand herpositive data generated patient clinical experience novel metastatic breast cancer patient treated alzumab also biologics biosimilars india since launch accepted publication unique combination specialty fy canmab continued gain indian dermatology online journal product patient support traction featured among top multicenter panindia study physician engagement program oncology brand country initiated identify potential volume market share nearly biomarkers treating subgroup branded formulation jumped five place ranked among top pharma company uae uae business supported brand sale diversified across portfolio includes cardiovascular drug anti histamine proton pump inhibitor oral antidiabetic chronic plaque psoriasis patient based approach abide helped several brand ranked alzumab physician improve practice among top respective enriched patient connect cytosorb firstinclass therapy segment uae market enhanced clinical outcome since extracorporeal cytokine filter used one key product statix inception abide empowered manage wide range life atorvastatin generic nearly physician spread threatening condition seen brand feature among uaes top across townscities across india intensive care unit underwent cardiovascular brand segment panindia study evaluate clinical abide conferred award dominated innovator product outcome administered recognition prestigious research society study jalra jalram two patient suffering sepsis diabetes india rssdi licensed innovator brand septic shock benefit coverage impeccable novartis made significant inroad also initiated physiciancentric antidiabetes space since quality delivery th registry program alzumab launch fy positioning u one annual conference rssdi held cytosorb year key player segment hyderabad abide awarded rssdi uae recognition rssdi biocon introduced largest organization diabetes strengthened alliance abide unique education initiative researcher healthcare novartis fy medical practitioner treat professional asia validation transaction inlicense diabetes regular basis positive impact biocon company second brand exforge conduct basic course primary enrich healthcare ecosystem high blood pressure medication care physician advanced india launched shortly course consultant physician launch expected diabetologists course uae strengthen position uae delivered noncommercial branded formulation business cardiovascular market setting offer learning uae represented neobiocon currently rank among top opportunity experience sustained momentum company sharing small group engagement increase sale fy pragmatic application source ims fy fy ahead curve annual report biocon limited global marketing biocons global marketing team sale asiapacific apac ahead curve commonwealth independent anticipating growing worldwide state ci region almost doubled need affordable high quality previous year revenue drug address increasing africa middle east burden noncommunicable turkey afmet latin america disease consistently latam region witnessed strong aligned increasing doubledigit growth started trend among government adopt executing strategic roadmap generic formulation cut enter top emerging healthcare spends market insulin mabs portfolio multiple licensing fy revenue agreement came international market global marketing increasing global biosimilars widening scope furthered mission footprint differentiated small molecule provide affordable access worldwide biocons expertise biologics portfolio therapy chronic disease given firstmover advantage scaled leadership position biosimilars portfolio statin immunosuppressant enable partner launch following success biocons formulation nafta afmet insulin glargine launch japan latam region made inroad emerging market position biocon emerged among first u greater play addressing wave supplier rosuvastatin market opportunity usd api partner u million also introduced brand market upon patent expiry insugen one ci market enabled partner currently market capture double digit share leader generic rhinsulin rosuvastatin market also space experienced revival sale fidaxomicin api increased apac region strengthened traction tacrolimus api position successfully winning u year antiobesity exclusive malaysian government product orlistat api made contract supply insugen significant inroad emerging also introduced insulin glargine market due safety profile also introduced rhinsulin insulin glargine highend quality ur ability make impact global market strong portfolio another differentiated complex latam nafta market cuttingedge chronic api product glatiramer acetate therapeutic hold key fy multiple sclerosis introduced unlocking next level significantly benefited key emerging market nafta growth biocon plan breast cancer patient india address market region partner synergistic alliance biosimilar trastuzumab diversified portfolio year built strong increased product penetration reflects strong global regional partnership orientation towards difficult algeria thus capturing dominant provide affordable small molecule tomake small molecule market share also prepared speciality apis generic insulin generic biosimilars market entry biosimilars thus giving payer licensing partnership ravi limaye physician patient greater president marketing latam apac country choice treatment option fy ahead curve annual report biocon limited research service syngene began journey million sq ft syngene growth early india first contract positioned address global research organization cro drug discovery outsourcing market h million time industry country still infancy opportunity expected grow compounded annual rate revenue year evolved usd billion integrated discovery research service business development service provider syngene reported revenue new molecular entity across h million fy multiple platform like small standalone basis syngenes total large molecule antibody drug revenue rose h conjugate oligonucleotides million growth broad today syngene publicly based across three business listed pure play cro india vertical dedicated rd center talented pool discovery service development scientist worldclass manufacturing service infrastructure spread across research service capability expansion also help meet customer u fda audit without growing need bioinformatics observation last three year year company data analytics support expanded business include company also received two new dedicated rd center stateofthe art gmp good environmental clearance one amgen herbalife manufacturing practice commercialscale manufacturing nutrition syngene glp good laboratory practice facility setting five dedicated rd center compliant viral testing facility mangalore manufacture novel including bm abbott also set address need small molecule innovator nutrition baxter several pharma biotech client company area growth business driven fire incident addition new customer key rd program number syngenes client december well extension ongoing move advanced phase fire one syngenes research collaboration development open new facility bengaluru facility syngene amgen research including office laboratory opportunity expanding development center sarc space contributed approximately scope work line staffed team total revenue strategy syngene commissioned highly qualified syngene scientist fire caused due chemical first phase new work closely amgen reaction conducted formulation facility researcher around world facility injury loss capable manufacturing clinical discovery development life part business commercial supply small innovative medicine dedicated continuity plan client volume niche technology product nutrition research center set related project redeployed complies regulatory herbalife develop formulate lab enhanced shift requirement u fda ema worldclass nutrition product working introduced minimize health authority indian consumer enable revenue impact lead healthier life syngene year company also also extended collaboration commissioned first phase abbott nutrition till end cy syngene research center spread year company also added new capability across sq ft fully commissioned center w e made good progress year strategic priority total area sq ft bioinformatics acquiring syngenes track record support integrated discovery building successful longterm asset related system biology development program relationship client heptox pharma bioinformatics newly expanded capability service bengalurubased strand syngenes clinical development worldclass scientist life science deal also brought facility successfully underwent infrastructure look forward onboard team highly skilled u fda ema audit accelerating growth coming year data scientist year company commitment complement syngenes existing quality compliance reflected jonathan hunt scientific intellectual capability track record clearing six chief executive officer syngene ahead curve annual report biocon limited enablers r e e ar c h development supp ly c h ai n n g e e n hu n r e ur c e e n v ir n e n h e lt h sa f e c rp rat e c ia l r e p n ibi l enablers research development biocon rd poised lead advent genomics future biotechnology heralded future therapy several successful regulatory filing difficulttotreat human disease biologics dossier ich regulated region biocon established biocon one leading player developing manufacturing r esearch development form bedrock biocons endeavour deliver affordable wellrecognized significant analytical process small therapeutic globally address unmet patient need biocons player drug development interfering rna sirna technology unique rd story built led way development unique method treatment worldclass competence biosimilars worked interferes nuclear capability robust infrastructure leading edge science top machinery cell enable talent pool extensive global product global regulatory agency development novel molecule development experience u fda ema exemplified target many disease unmet firsttosubmit biosimilar medical need dr narendra chirmule sr vice president head rd trastuzumab antiher monoclonal biocon leveraged cuttingedge antibody treatment breast technology since inception cancer ahead curve annual report biocon limited first set biologics rd capability enablers v regulatory science helped commercial bioreactor india driven passion impact u position biocon ahead many today country largest global health built pharma player india bioreactors developing protein differentiated rd capability process product development therapeutic ability create year area biologics global scale made biocon one expertise array development novel top insulin manufacturer expression platform biosimilars leveraged world time include microbial capability among first established india mammalian system biocons successfully complete submission foremost innovative science pichia pastoris platform key biosimilars several technology driven organization expression recombinant protein jurisdiction across world constantly working address proprietary technology including u eu global disease burden consistent scalable mammalian structured approach incorporate cho nso cellbased expression biocon rd nurtured pool cuttingedge science technology platform used deliver highly talented scientist order deliver exciting novel biosimilar monoclonal expert field ranging portfolio biologics brought antibody bacterial host bioengineering molecular u reliability credibility system utilized numerous small biology analytical science clinical innovationled organization focussed molecule apis peptide science regulatory science providing affordable healthcare intellectual property management impressive pipeline approved highly robust process science biocons reputation enabled indevelopment biosimilars significantly augment ability collaboration leading academic novel molecule testimony develop worldclass biologics institution across world biocon rds vision ahead economical scalability combination high technology curve high productivity coupled high talent culture deep science quality upstream process support exciting deliverable biocon potential involving fermentation technology molecule pipeline transform field biotechnology downstream process technological enablers world protein purification develop capability rd always bulk drug substance india top biotech company strength excellence established decade effort constant focus platform technology spanning prepare next decade ahead curve process product development exponential growth working instrumental establishing ii analytical bioanalytical improving process efficiency india among top biotech capability iii preclinical novel approach destination world clinical development strength flexible continuous second asia iv intellectual property research development manufacturing high quality consistency formulation transferred working collaboration leading product learning vial cartridge make drug academic institution extensive regulatory interaction product process requires indian institute technology previous year evolved extensive science complex iit national institute process development technology understanding pharmaceutical educational process resulted exponential protein structure product stability research niper india well improvement ahead extractableleachables study harvard university massachusetts curve future process expertise formulation institute technology mit product science enabled u formulation product science several reputed international manufacture high quality drug essential part drug university analytical capability product patient worldwide development process biologics anchored cuttingedge biosimilars bulk tool latest orthogonal approach drug substance converted world class technology ensure biological process science molecular upstream formulation biology cell culture development recombinant clone process development scaleup development scaleup liquid gene knockout pcr based analytical perfusion fed batch technology suspension high concentration method control post translational lyophilized formulation modification cell culture purification upstream purification cell culture microbial microbial development purification process process development scaleup scaling high pressure match characteristic biosimiliar bacteria fungi yeast primary chromatography large column protein secondary metabolite recombinant protein peptide fermentation ahead curve annual report biocon limited analytical bioanalytical science pioneer process product development turn result biocons stateoftheart equipment deep technical expertise nearly year experience analytical bioanalytical science physicochemical functional analytical technology key component process product analytical tool applied inprocess well finished drug substance drug product analysis additionally major percentage method routed towards quality group manufacturing utilized product release assay analytical science characterization bioanalytical molecular method mass characterization development spectrometry characterization protein small method development peptide development method quantifying molecule nlinked olinked quality control expertise method peptide small molecule glycosylation glycations post development showing clearance biological fluid translation modification identification process related impurity characterization low abundance impurity establishing similarity analytics rd strength biosimilar primary structure higher order structure biologics development focused strategic qbd driven approach variant charge orthogonal technique glycosylation size sequence fingerprint similarity functional characteristic fab physiochemical fc function mabs characteristic research development drug discovery preclinical able achieve structure moreover science relevant pharmacokinetic introducing innovative way selecting right molecule pharmacodynamic endpoint predictive toxicology adaptive clinical development establish safety efficacy clinical trial design hopefully prerequisite drug development product courtesy would significantly reduce cost successful regulatory approval scientifically rigorous ethically increase quality trial compliant stage gatebased future translational research development science cell based binding bioanalytical assay assay development qualification valuation potency assay insulin peptide development validation using pk immunogenicity measure mab mab conjugate biacore radioligand binding flow using elisa msd format cell based cytometry potency assay neutralizing antibody determination drug invivo toxicology discovery pharmacology preclinical mechanism action moa study protocol development glp moa pkpd clinical pd patient development invitro assay proof nonglp study evaluation selection marker assay enable concept animal model study histopathology animal tissue pharmacodynamic response diabetes autoimmune disease interpretation pk pd ihc biomarkers development companion oncology preclinical clinical sample diagnostics ahead curve annual report biocon limited intellectual property process country strong regulatory capability biocon understands importance formidable task drug regulator rd coupled focused team ip biopharmaceutical u fda european union effort resulted u sector ip assumes much greater ema australia tga canada first file proposed biosimilar significance guide rd health canada brazil anvisa trastuzumab u fda ema commercialization strategy japan pmda etc unique regulatory filing two key company enables protection country specific process biosimilar mabs trastuzumab invention innovation followed mandatorily pegfilgrastim reviewed also help build credibility patent expiring novel u fda ema insulin enabling first mover advantage biologics several country glargine review europe many case ip also enables product articulated guideline launch insulin glargine positioning lifecycle management ensuring biosimilarity field japan major milestone well asset monetization evolving new regulatory since country reputed valuation biocon rd submission industry player stringent highly regulated market consistently created intellectual regulator payer physician scientific culture rd wealth incisive ip pharmacist learning biocons rd regulatory culture science strategy recognizes team playing key role dna always valued innovative potential product knowledge exchange cherished role part process till date filed evolution regulatory pathway rich scientific ecosystem nearly patent application establishing comparability rd employee access hold patent interchangeability extrapolation special club statistic trademark registration indication among biosimilars medical writing forum access globally ip team brought international journal journal recognition biocon various award biocon indian biopharma company make prestigious asia ip elite list also awarded th national ip award category top indian company creating global brand along prestigious wipo user trophy regulatory science regulatory science team large number talented individual interface company regulator understanding guideline rule research development club focus learning product approval launch quality curve put u ahead curve country excellence quality manufacturing facility small collaboration compliance essence molecule apis also underwent biocon belief strength biocons strategy ahead number regulatory audit strategic partnership curve rigorously follow including inspection u fda invested various partnership good manufacturing practice good fy underwent global pharma company like laboratory practice good international regulatory mylan quark pharma several documentation practice throughout audit receive respective cgmp project since imperative operation compromise approval agency collaborate academia compliance turn ensures approved site include anvisa government institution highest standard quality brazil cofepris mexico mcc biocon rd lay lot emphasis time south africa ministry industry establishing relationship fy biocons manufacturing trade russian federation npra national international site underwent several regulatory malaysia ministry health institution collaboration inspection agency different ukraine include trinity country across world part college ireland queensland expect see increase new product approval process institute medical research regulatory inspection account verification compliance australia indian institute new product submission technology among others scope strong regulatory quality well periodic verification collaborative research includes manufacturing capability gmp compliance agency process development preclinical ensured continued global jurisdiction supply animal model exploratory acceptance complex small quality team fully geared meet biomarker study fundamental molecule biosimilar product intensified quality scrutiny science research project successful conclusion address increasingly demanding collaboration happen regulatory audit biologics benchmark regulatory agency different level critical drug substance drug product around globe growth robust rd organization manufacturing site facilitated ahead curve annual report biocon limited supply chain management supply chain management scm year scm function demand biocons biologic function put biocon ahead enabled u build product also partnered curve focusing operational reputation trusted established global logistic excellence space characterized partner global pharmaceutical company meet need complex manufacturing process company rely apis effective cold chain system stringent regulatory norm formulation scm enabled ensure shipment safety built global scale end successful foray biologic created dedicated toend supply chain process product several emerging logistics team ensure business encompassing multiple business market readiness new market vertical several manufacturing strengthening scm practice enabled u shipping location diverse product channel ready ahead business portfolio meticulous planning smart scm function focused initiation new key sourcing disciplined monitoring building regulatory compliant market enabled u ensure ontime system process meet delivery customer demand imposed supply fy initiated implementation country chain increased global ctpat custom trade supply chain management strategic leverage supplier position global reach create competitive advantage develop supplier new strategic region lead industry bestinclass practice focus supply assurance mapping critical material financial cost management initiative predict market price trend buildup strategic inventory address price fluctuation price benchmarking strategy key cost driver functional operational p e r v e cultivate dynamic planning capability enhance performance reduce transactional complexity identify scope improvement extend supplier performance meet customer satisfaction focus green initiative integrated malaysia uniform sourcing operation platform training development promote employee engagement encourage disruptive idea identify meet training need employee certificate program high performing employee inclusive talent pool malaysia maintaining diversity partnership terrorism priority custom clearance increased complexity logistics guideline published u requirement implemented malaysia made good custom border protection system check balance progress tying local ensure aligned area packaging sustainability vendor helped reduce enhanced drug supply security terrainspecific transportation logistical challenge well requirement key u mode material safety delivery bridge sociocultural difference market simplify logistics efficiency procedure help biocon obtain address rising market diversity ahead curve annual report biocon limited also ensured seamless operation key product using best class logistics service provider packaging vendor warehouse facility consolidation one site helped enhance capacity better align business requirement functioning responsibility singleminded focus achieving business goal target biocons scm maintains high level ethic integrity sourcing vendor consolidation iii periodic vendor evaluation process orientation enabled u maintain spotless record reduce multiplicity biocon developed process meeting mandatory compliance transaction minimize periodically evaluate level process operational load vendor critical material internal external audit consolidated vendor basis selected metric year warehouse team plant bengaluru also contributing local supported facilitated helped better planning economy facility audit including u effective negotiation biocon always strived create fda ema completed ii green supply chain strong local ecosystem procuring without critical observation moving animalorigin good availing service also working continuously recombinant supply base small medium size vendor improving operation key product based around manufacturing six sigma practice ensure better contributed significantly location working condition improved effort ensuring ecofriendly total supplier base small safety standard supply chain sourcing team medium enterprise local sourcing also focusing use green capability earn u multiple benefit sustainable sourcing initiative solvent eg ethanol majority term shorter turnaround time creation stable sourcing business unit thereby delivery quicker resolution platform critical biologics reducing dependence non issue pertaining material quality portfolio scm taken renewable form energy return help vendor step ensure longterm supply consolidating vendor solvent plan long term capacity sharing sustainability space delivery reduced forecast month initiative taken include fuel cost per unit solvent contributing local economy consumed biocon also enhance sustainability operation supply chain management g l ba l ur c n g fra e w rk strategic sourcing procurement ops vendor risk mitigation sourcing process execution operational dedicated team created compliance discipline managing sourcing risk drug substance drug cost management securing logistics product alignment budgetary timely delivery constraint geographic risk mapped coordinating vendor development crossfunctional interface supporting global vendor platform address longterm supply development plan risk sourcing constraint supply assurance monthly procurement review vendor sustainability org level procurement data integrated planning evaluation builtin analytics procurement crossfunctional team identify mitigate operational dynamism activated review progress sourcing risk riskmitigation activity top house risk mapped corporate level continuous improvement program review performance compliance award biocon conferred award overall excellence procurement sourcing excellence procurement transformation cpo forum india ahead curve annual report biocon limited u n g n c w rk f r c e p u h n g h e e n v e l p k e e p b c n h e ad f h e cur v e human resource human resource biocon innovative spirit put excellence high degree helping bring key u ahead competitor empowerment instilled project closer realization believe employing fostering confidence high sense best talent believe ownership people global employee base vital health driven make difference company year quality led u attracted brightest recognized among top global mind challenged biotech employer annual survey status quo pushed conducted science science boundary science develop career magazine ranked u affordable therapy previous impact global health skill year distinction helped transform goal company asia reality create new model feature prestigious list success sustain high level growth work culture past month hr total india malaysia syngene unconventional thinking focus team played significant role biocon march ahead curve annual report biocon limited attracting talent fy increased hiring year used social last fiscal within pool new hire b medium extensively attract iocon wellrecognized best talent today techsavvy rise seniorlevel appointment among top global generation hold highest increase workplace diversity biotech employer highly also recruited country like regarded scientific talent brand index linkedin community u amongst peer making u u hong kong uae germany europe performance employer choice following malaysia driven work culture encourages digital integration recruitment unconventional thinking modified internship incubation exciting new idea tool receiving program year target young pursuit excellence application per month promising life science talent making biocon innovationled linkedin social medium international university organization comparable best world platform enabled u target addition various indian academic talent group almost zero cost institute niper iit amitava saha offered internship student sr vice president head hr biocons positioning world class employer brand enabled u university college cork recruit top talent ireland university glasgow country premier institute several imperial college london university candidate indian school california san diego university business accepted biocons offer melbourne university priority campus queensland among recruitment candidate interned u offered job nearly fy learning development manage lead change several addition program learning development play employee underwent focussed close employee attended critical role knowledgedriven group training program various training program organized organization like biocon isurge year learning development leadership development program team learning people biowin isurge womens implemented several initiative hour clocked year leadership program also conducted around business excellence focussed workshop several interpersonal excellence designed woman leader human resource young organization checkup practice introduced biocon malaysia joined biocon preferred free thyroid health checkup industryacademia panel destination young aspiring woman employee universiti teknologi malaysia biotech professional fact utm universiti kebangsaan intent provide employee reflected age profile malaysia ukm industry platform pursue interest employee almost half size academia collaboration enable beyond work connect like human capital year university tailor curriculum minded people launched make biocon incubator emerging industry trend biocon adventure sport club exciting new idea talent requirement industrial basc various event ideated visit new integrated insulin executed employee employee age profile manufacturing facility malaysia received good response across student several public organization private malaysian university invivo annual day provided practical celebration biocon syngene insight working marked great fanfare biopharmaceutical industry runup invivo several event conducted effective performance employee showcase talent management employee felicitated robust performance long service several others management program designed recognized valuable encourage reward talent contribution organization harmonizes achievement organizational goal personal employee engagement initiative biocon malaysia growing aspiration milestone employee engagement strength comprehensive talent management initiative year biocon malaysia manpower framework identifies develops aimed motivating employee strength gone critical talent crucial biocons give best stay committed nearly employee last growth strategy organizational goal year learning initiative value enhanced sense intensified leveraging award wellbeing biocon academy program biocon recognized best address specific technical corporate hr practice apart regular employee functional training need nhrd comprehensive engagement activity year talent management framework conducted customized program biocon malaysia also company also felicitated aimed addressing early burnout making significant contribution world hrd congress healthy living build biotechnology industry excellence human resource wellness initiative biopulse ecosystem southeast asian management extension annual health nation three senior leader ahead curve annual report biocon limited environment health safety biocon staying ahead safety integral part received iso ohsas curve extends beyond business broader environment core accreditation tüv adopting best global practice leadership decision process nord successful transition environment health focused providing safe earlier standard safety ehs comprehensive healthy work environment biocon line new globally governance system bolstered singleminded pursuit harmonized system ghs hazard bestinclass infrastructure philosophy ensured communication migrated specialized ehs system competent reportable incident safety data sheet sd team comprehensive program biocon year review ehs risk assessment sustainable thinking ehs management system ehs risk assessment program cornerstone corporate responsible corporate methodically detect evaluate responsibility biocon organization established risk various parameter ranging helped u move beyond statutory best class environment effect full organization compliance create responsible management system minimize potential impact individual business practice guarantee ecological footprint fy biocon employee also help efficiently environmental sustainability health environment health safety prioritize risk determine industrial hygiene management resource yielded significant best way remove transfer committed industrial cost saving year mitigate risk based hygiene excellence aligning biocon believe small assessment define practice global standard step yield big result document ehs role strengthening achieved power saving responsibility employee part new biocon integrated kwh year operating facility fy industrial hygiene system installation ie motor switching conducted comprehensive implementation initiative carried led light improving efficiency enterprise risk assessment productwise industrial hygiene filter press reduction block addition evaluation study exposure reduction operation hour project line business continuity drive also upgraded reduce chemical consumption management existing sewage treatment unit effluent treatment led cost new bioremediation technology saving year ehs training introduced dspa dry ehs training program multiple plant operating sprinkler powder aerosol fire emphasizes safety practice simultaneously round year suppression system chemical enables employee identify imperative effectively synthesis block mitigate workplace safety manage environmental impact hazard ensure zero reportable energy conservation find way reduce carbon incident fy energy conservation initiative footprint successfully cut carbon person hour invested ehs helped u restrict rise energy dioxide emission ton training consumption despite year sourcing nearly yoy growth business million unit green power today employee actively participated fy identification low green power account several external training cost power source optimization total energy consumption program covering safety aspect pharmaceutical industry prevention dust explosion best practice storage transportation hazardous chemical onsite also organized lead auditor internal auditor training iso well symposium leadership safety management additionally steered various activity event across biocon facility mark national safety week fire service week chemical disaster prevention week ahead curve annual report biocon limited award recognition fy received recognition state national level progressive ehs practice initiative included first prize best fuel efficient industrial boiler category adopting best safe practice karnataka state safety institute star rating ehs best practice confederation indian industry biocon volunteer revive dense vegetation lake resulted shrinking waterbody water inlet hebbagodi lake cleaned covered screen included biocon taken initiative contribute prevent debris washed lake lake revival mission bengaluru biocon foundation land cleared make place childrens took lead sign expression interest playground fencing cleared stretch eoi rejuvenation hebbagodi lake undertaken information board streetlight bring back lake workshop organized installed karnataka lake conservation development result effort water catchment area authority klcda detailed project report grown seen bird return submitted team working closely habitat motivates u push klcda relevant administrative body stakeholder enable fullfledged lake revival like district commissioner govt karnataka plan hebbagodi hebbagodi city municipal corporation cmc obtain necessary approval implementing also engaged local community detailed lake revival plan sensitize importance water body role preserving best civic meanwhile biocon cleaned area removed behaviour critical local community play debris weed around lake including active role lake conservation revival environment health safety community program team hope biocon accord high importance health safety stakeholder including neighboring community fy biocon employee came together aegis namma biocommunity community connect initiative biocon make difference people life urban rural area focus ensuring clean green safe environment member strong team biocon volunteer men woman spearheaded several drive year clean renovate number underpass around hosur road hebbagodi huskur hennagara bommasandra etc poor state thus making impossible use public added safety hazard namma biocommunity encouraged pedestrian area use underpass avert road accident namma biocommunity volunteer also helped renovate government high school neighboring area encouraged community participate tree plantation drive ahead curve annual report biocon limited corporate social responsibility biocon foundation sustainable solution area treatment centre systematic basic health addressing documentation patient data biocon foundation csr arm burden chronic disease like biocon engaged cancer diabetes hypertension elaj smart clinic developing innovative solution elaj clinic technologyenabled given propensity address critical gap healthcare smart clinic equipped multi stay ahead curve education sanitation make parameter monitoring device extensively leveraged information enduring impact amongst enables multiple diagnostic test communication technology marginalized community india generation electronic medical develop unique ehealthcare various initiative record emrs patient model bring healthcare foundation aim empowering elaj model designed service doorstep integrating underprivileged deliver databased healthcare need social economic mainstream basis sociodemographic designed elaj smart clinic strengthen primary healthcare health indicator obtained healthcare delivery india converting communitybased screening public health initiative primary health center phcs innovative health delivery model successful providing comprehensive singlepoint facilitating effective preventive corporate social responsibility primary healthcare intervention software connected secure secure server elaj emr system rural area karnataka server introduction elaj mapped unique id ensure rajasthan benefit model phcs provide access continuum care community poor access affordable healthcare service providing clinical consultation quality healthcare remote rural area essential diagnostic service clinic staffed diagnostic centre elaj fair price patient elaj doctor technician pharmacist smart clinic perform clinic reduce outofpocket trained handle test result available expense improved diagnostics stateoftheart diagnostic hour patient record elaj clinic also reduce equipment clinic management digitized stored central burden tertiary hospital objective elaj continuum care quality monitor disease protocol examine generation healthcare profile trigger care delivery prevalence risk report alert case followed factor initiate stakeholder disease outbreak preventive health different level education ahead curve annual report biocon limited biocons elaj model addressing gap public health delivery india infrastructure training data entry operator quality care improving upgrading collect health information ensured iphs norm infrastructure phcs efficiently related infrastructure training anms health worker manpower facility renovating toilet labor room data collection immunization followed installing diagnostic centre antenatal checkup upgraded labor room ensure phc institutional delivery electronic medical record providing laptop phc patient record digitized ensured proper power backup proper documentation mapped unique id ensure water supply staffing continuum care provided laptop pregnancy recruiting doctor auxiliary child tracking health service secure server store data nurse midwife anms general management system pct data patient privacy maintained nurse midwife gnms data entry entry operator pharmacist lab multiparameter monitor installed record vitals ensured water sanitation technician support staff hygiene wash practice ensuring vacancy three interconnected module followed filled registration clinical consultation diagnostics working government ensuring phcs running set biomedical waste disposal per indian public health dashboard capture data protocol standard iphs norm disease profile community staffing notification help tackle seasonal disease outbreak training capacity building training lab technician use dashboard ensure followup semiautomatic lab device disease surveillance patient treatment insurance profile community disease bengaluru scheme trend dashboard sends disease pilot huskur provided notification alert organic workflow pattern proof concept scale administrator enables forward start baseline indicator model elsewhere end planning implementation preventive health culminates elaj smart clinic model needbased healthcare program treatment enables surveillance installed eight clinic moreover notification help monitoring evaluation karnataka run exclusively healthcare provider plan health status population biocon foundation seasonal disease outbreak data individual clinic group clinic available elaj smart clinic scaling health administrator live biocon foundation set first dashboard capture patient elaj smart clinic huskur footfall vital parameter disease corporate social responsibility smart clinic patient doctor interface elaj smart clinic patient registration ehr vitals mpm doctor pharmacy diagnostics test report referral secondarytertiary care smart clinic footprint ahead curve annual report biocon limited biocon foundation smart clinic model government secondary healthcare completed adoption five run phcs karnataka first effective use technology biocon government phcs rajasthan flagged foundation recognized widely public private partnership ppp february implementing innovative healthcare government rajasthan ppp biocon foundation aim model create sustainable strengthening present public health ecosystem joining hand january biocon foundation healthcare system karnataka government aspire government karnataka providing solution around primary benefit many village signed mou install elaj disease profile patient visiting elaj smart clinic fy past year patient footfall elaj smart clinic gone month patient footfall spiked july october seasonal illness hitting peak september overall data show majority patient visit elaj clinic prompted infectious disease fever pain rajasthan run five elaj smart clinic also saw jump patient footfall julyoctober period patient diagnosed clinic mostly suffering pyrexia diarrhoea also infectious disease fever pain seeing good traction laboratory test conducted non communicable disease elaj clinic rajasthan number soaring trauma orthopedics time april february ent others corporate social responsibility karnataka elaj model per government requirement officer health department combine good infrastructure collect data monitor hrps latest technology best elaj phcs collaborate dashboard help available medical expertise private doctor part monitor hrp case ensure foundation currently run pmsma proper preparation done elaj clinic covering gram case referral phcs provided fetal panchayat across karnataka doppler foundation case highrisk pregnancy case rajasthan check fetal heart rate elaj phcs follow action plan pradhan mantri surakshit glucometers strip referral higher institution matritva abhiyaan anc camp provided phcs track blood delivery hrps whose india rank first list sugar level pregnant woman delivery due next two country account month referred higher creating monthly action plan preterm birth yet india little institution health centre smooth antenatal care management highrisk birth emergency coverage order tackle issue pregnancy hrp case preparedness plan pregnant premature birth low birth weight woman expected deliver baby stillbirth essential recommended hrps next two month special increase coverage antenatal pmsma guideline elaj health focus high risk case care country enable centre use red sticker ministry health family highrisk individual mamta card referral higher institution welfare government india iron sucrose severe anaemia elaj phcs provide vehicle launched program called pradhan case referred either pick drop pregnant mantri surakshit matritva abhiyaan inpatient phc facility woman antenatal checkup pmsma available higher elaj dashboard given institution aim program provide medical officer senior comprehensive package antenatal care service pregnant woman second third trimester government health institution biocon foundation helping rajasthan government implement pmsma efficiently elaj phcs biocon foundation ensuring smooth implementation pmsma elaj phcs use unique prescription form designed ahead curve annual report biocon limited referral higher institution multipronged approach ncd breast cancer treatment pregnant management elaj smart clinic biocon foundation run breast woman identified includes cancer screening program clinical condition association ue life science health promotion prevention treatment cant provided phc screening includes clinical strategy healthy lifestyle fy nearly pregnant prevent ncds associated breast examination examination woman attended pmsma camp risk factor handheld device found intelligent breast examination ibe garner evidence action high risk pregnancy case novel u fda approved medical disease surveillance ironfolic acid tablet instrument prescreening monitoring research distributed anaemic woman breast lesion found biocon foundation also identified psychosocial counselling meet lesion referred woman family emotional social mental ultrasoundmammography planning counselling need patient device able identify high priority patient require human resource non communicable capacity building prevention ultrasound mammography disease treatment ncds first level therefore reducing risk developing breast cancer noncommunicable disease ncds early diagnosis periodic also known chronic disease person screened opportunistic screening passed person person breast cancer year population long duration found lesion breast treatment care ncd among underwent generally slow progression patient special health camp mammography india transiting speedily handholding referral lifestyle disease ncds contribute required around million death account death india urgent need put ncds centre country health policy plan program biocon foundation believe integrated community based risk factor management program costeffective efficient approach tackling ncds conducting populationbased screening oral cervical breast cancer corporate social responsibility oral cancer risk profiling data generated malnutrition early detection prevention help characterize health status global hunger index ghi oral cancer drastically reduce community identify new ncd report ranked india th amongst mortality economic burden case assess vulnerability leading country serious community nearly associated risk factor year hunger situation one major patient screened individual cause malnutrition india year third tested positive screened economic inequality due low potentially malignant lesion ncd health camp social status population fortunately positive case oral biocon foundation also conduct group diet often lack cancer detected monthly health camp type quality quantity woman cervical cancer diabetes hypertension suffer malnutrition less phcs located across karnataka likely healthy baby cervical cancer often early diagnosis carried india mother generally lack good successfully treated diagnosed along health screening nutritional knowledge consequently early nearly woman camp health checkup newborn infant unable get screened tested positive free medicine lab adequate amount nutrition reproductive tract infection investigation subsidized mother abnormal pap smear one case cervical cancer detected year year witnessed total footfall well baby clinic ncd health diabetes hypertension malnutrition prevented camp diabetes adequate primary healthcare biocon foundation developed hypertension case managed community education comprehensive program camp year behavior change order detection management type camp also provide test hypothesis biocon diabetes hypertension psychosocial counselling stress foundation established pediatric phcs foundation routinely management blood glucose control clinic austin town bengaluru conduct survey community quitting tobacco use collaboration st john community health department clinic provides general pediatric consultative service followup ill child support physical emotional wellbeing child family adopted communitybased management acute malnutrition cmam approach enables u identify initiate treatment ahead curve annual report biocon limited child severe acute progress monthly health fy role supplementary malnutrition sam camp organized clinic government integrated become seriously ill four also provide home counselling child development service icds main component approach program developed referral required comprehensive strategy curb community mobilization child medical complication malnutrition area community health worker chws referred inpatient medical sensitize community treatment year organized total child anthropometric assessment health camp managed year organized eight health identify acute malnutrition case total case malnutrition camp malnutrition sam case showed supplementary feeding program case managed improvement upward growth sfp provide readytouse total five sam case identified trend recorded therapeutic food rutf child balaspandandana bagalkot reduction anemia case rutf energy dense program micronutrient enhanced paste used therapeutic feeding biocon foundation started nutrition intervention child outpatient therapeutic program five year bagalkot district otp monitor childrens education selfreliance child government school karnataka closely aligned directorate year biocon foundation keenly secondary research training student across school aware fact quality curriculum standard vii karnataka received workbook education child receive since distributed also trained teacher school determines quality workbook initiative future critical gap learning underserved child various language numeracy skill could affect ability attain sustainable livelihood lead productive healthy life biocon foundation attempted plug critical gap mathematics learning chinnara ganitha workbook developed collaboration macmillan publisher india workbook approach mathematics activity game local language thereby inculcating corporate social responsibility biocon academy biocon took leadership role career biotech industry producing highly skilled bio field biotechnology forward collaborated leading scientist year talented establish biocon academy global institute like keck graduate pool student graduated premier center excellence institute kgi california u bit biocon academy advanced applied learning pilani india offer global quality successfully placed bioscience bengaluru learning indian student leading life science company graduate academy biocon academy csr initiative short span three year biocon hired diverse role production leveraged rich industry academy instrumental quality assurance regulatory affair experience biocon domain shaping career research development knowledge international aspiring bioscientists marketing academic partner empower imparting requisite experiential experienced well recent life learning serf bridge company science graduate translational existing industryacademia gap participated academy education industrial proficiency campus placement program academy jobskills development year contributed immensely enrich essential build promising graduate found job outside life science ecosystem india ahead curve annual report biocon limited biocon rest placed training biocons quality control global life science industry various department biocon production laboratory opportunity bioscientists syngene cgmp training biocon widen india abroad scope handson training biocon kgi certificate program bit biocon program applied student academy bioscience industrial microbiology collaborated bengalurubased academy flagship program biopharmaceutical service company building success offered collaboration keck biozeen new horizon first batch bit biocon program graduate institute premier college engineering offer quality control microbiology american school bioscience practical training session academy broadened education saw successful facility course curriculum modified completion three batch program rename bit academy also introduced fy fulltime certificate biocon program applied industrial special mentorship session program spread week microbiology student faculty includes classroom session best alumnus kgi california exclusive program designed application biotechnology enhance knowledge skill well industry assignment fy student successfully aspiring microbiologist pharmacy handson training completed program including biotech graduate seek eight malaysia classroom session involve accelerate learning fast placed leading pharma synchronous transmission course growing field microbiology biopharma company learning material developed boost job prospect student offered faculty kgi alumnus meet microbiology bioscience california session highly program offer experiential learning biocon kgi program alumnus interactive create personalized combining real world insight introduced kgi connect learning environment kgi classroom learning various aspect alumnus portal kgi student faculty member student microbiology intensive california portal give biocon engage real time conversation curriculum delivered renowned academy graduate opportunity faculty bit pilani biocon broadbased international network kgi alumnus well academy subject matter expert curriculum program provide access extensive smes biocon addition encompasses domain rd learning resource honing technical skill program production quality assurance academy also organized also sharpens professional regulatory science product second alumnus meet skill candidate provides development additionally attended graduate opportunity holistic development professional skill training prepares event chaired kiran mazumdar biotech student necessary fy batch student shaw chief mentor biocon academy knowledge skill make completed bit biocon program dr sheldon schuster president employable industry placed kgi california provided interesting leading pharma biopharma student undergo functional insight new trend company biocon academy international event event witnessed faculty development program biocon academy association participation scientist seek empower biotech american chemical society organization globally faculty various educational medicinal chemistry division institute helping upgrade new program pharma innovation sourcing knowledge emerging biocon academy developed industryspecific technology center u organized medicinal two new program biocon program rolled fy chemistry drug discovery kgi certificate program clinical development india mcaddi biocon offer scholarship upto development biocon residential course student take academyfaculty development medicinal chemistry drug care major portion cost program expand offering discovery campus bengaluru expensive international biotech world clinical mcaddi presented program development program principle medicinal chemistry designed equip pharmacy drug discovery development graduate postgraduate format designed industrial diploma holder skill academic participant needed build successful career currently working area plan realm clinical development ahead curve annual report financial report board report management discussion analysis corporate governance report business responsibility report standalone financial statement consolidated financial statement board report biocon limited biocon limited board report dear shareholder present thirtyninth annual report business operation along audited financial statement auditor report company financial year ended march financial highlight million except eps particular standalone result consolidated result fy fy fy fy total revenue expense share net profit joint venture profit tax exceptional item exceptional item profit tax income tax income tax exceptional item noncontrolling interest profit year comprehensive income net total comprehensive income earnings per share eps exceptional item earnings per share eps exceptional item standalone consolidated financial statement standalone consolidated financial statement company prepared accordance indian accounting standard ind notified company indian accounting standard rule period including year ended march company along subsidiary associate joint venture prepared financial statement accordance accounting standard notified section company act read together paragraph company account rule indian gaap financial statement year ended march first prepared company subsidiary associate accordance ind statement containing salient feature financial statement subsidiary pursuant subsection section company act prescribed form aoc appended annexure board report statement also provides detail performance financial position subsidiary board report state affair highlight company standalone performance revenue operation grew mn mn fy income fy mn fy mn primarily due foreign exchange gain mn dividend subsidiary mn fy core operating margin ebidta excluding rd forex dividend subsidiary remained similar level compared fy exceptional item previous year company gain net tax sale equity share company subsidiary syngene international limited syngene mat credit gain recorded previous year due uncertainty utilization current year pursuant change income tax law business restructuring company belief able utilize mat credit entitlement accordingly year ended march company recorded mat credit entitlement mn standalone financial statement however consolidated financial statement entitlement recognised credit equity along underlying dilution gain sale equity stake syngene impact group control profit year stood mn fy pat excluding exceptional income net tax mn fy mn effective tax rate etr year due mat credit recorded exceptional income fy etr exceptional item year consolidated revenue registered growth mn mn fy segment perspective small molecule recorded growth research service business registered yearonyear increase biologics branded formulation recorded annual growth respectively consolidated profit year grew mn mn profit fy included tax exceptional income mn exceptional gain mn net tax fy explained detail section management discussion analysis bonus view encouraging participation small investor making equity share company affordable increasing liquidity equity share expand retail shareholder base director meeting held april recommended issue bonus share two equity share every one equity share held member record date determined board director board consequent proposal issue bonus share authorised share capital company proposed increased crore crore equity share crore crore equity share director decided seek approval shareholder proposal way postal ballot dividend director pleased recommend final dividend prebonus per equity share face value per equity share financial year ended march amounting mn view net cash generated operation substantially deployed capex taking account future capital commitment director consider prudent propose dividend dividend payout subject approval member ensuing annual general meeting agm dividend paid member whose name appear register member record date determined board respect share held dematerialised form paid member whose name furnished national security depository limited central depository service india limited beneficial owner record date dividend distribution policy per provision regulation sebi lodr top listed company shall formulate dividend distribution policy accordingly policy adopted set parameter circumstance taken account board determining distribution dividend shareholder retaining profit earned company policy appended herewith annexure board report also available company website httpwwwbioconcomdocsdividend_distribution_policypdf transfer unpaid unclaimed amount iepf pursuant provision section company act dividend remains unpaid unclaimed period seven year date transfer unpaid dividend account required transferred company investor education protection fund iepf established central government provision section company act year review company credited unpaid unclaimed dividend financial year amounting lying unpaid dividend account investor education protection fund iepf subsidiary joint venture company formulated policy determining material subsidiary pursuant provision listing agreement said policy available company website httpwwwbioconcomdocspolicydocument_materialsubsidiarypdf year biocon biologics india limited incorporated june wholly owned subsidiary biocon biologics limited uk buk march company subsidiary report performance financial position subsidiary presented ahead curve annual report biocon limited syngene international limited india syngene international limited syngene one india leading contract research organisation offering suite integrated endtoend discovery development service novel molecular entity nmes across industrial sector including pharmaceutical biopharmaceutical biotechnology amongst others syngene help client conducting discovery hit candidate selection development including preclinical clinical study analytical bioanalytical evaluation formulation development stability study pilot manufacturing scaleup preclinical clinical supply distinctive economic advantage unlike traditional business model service offered flexible business model ranging fulltime equivalent fte feeforservice ffs model combination customized client specific requirement year ended march syngene registered revenue growth mn fy fy mn ebidta margin year operating margin mn fy mn registering growth pursuant fire incident december syngene certain fixed asset inventory content one building damaged syngene lodged initial estimate loss insurance company survey currently ongoing year ended march syngene written net book value asset aggregating mn recognised minimum amount insurance claim receivable equivalent amount addition group process determining claim business interruption accordingly recorded claim arising therefrom stage april board director syngene recommended dividend per equity share fy entailing payout mn dividend payout subject approval member ensuing annual general meeting agm biocon research limited india biocon research limited brl subsidiary company undertakes discovery development research work biologics provides scientific support various development programme group brls current business largely directed towards rd service monoclonal antibody molecule protein mabs insulin tregopil formally referred insulin product behalf group company research program undertaken brl made significant inroad next level global clinical trial brl continues hold shareholding syngene fy brl registered turnover mn reported net profit mn compared turnover mn net profit mn fy fy turnover included outlicensing development commercialisation right mabs buk consideration mn biocon pharma limited india biocon pharma limited bpl wholly owned subsidiary company bpl would engaged development manufacture generic formulation sale global market especially opportunity u eu bpl process setting formulation manufacturing facility oral solid dosage biocon sez bengaluru fy mn equity share face value issued biocon limited face value march bpl commenced commercial operation capital workinprogress mn fy mn biocon pharma inc usa biocon pharma inc bpi wholly owned subsidiary biocon pharma limited incorporated july united state america bpi engaged commercialization generic formulation united state march bpi commenced commercial operation biocon biologics limited uk biocon biologics limited buk wholly owned subsidiary company incorporated united kingdom march buk house biocons biosimilar biologics business biocon sdn bhd wholly owned subsidiary buk year ended march buk earned mn revenue reported net loss mn biocon sdn bhd malaysia biocon sdn bhd malaysia step subsidiary company wholly owned buk biocon sdn bhd established objective set group first overseas manufacturing facility malaysia facility located within bioxcell biotechnology park nusajaya johor promoted malaysian government manufacturing facility designed manufacture recombinant human insulin insulin analog received local cgmp certification national pharmaceutical control bureau plant capitalised mn end current year based readiness start commercial supply average useful life plant expected year biocon sdn bhd seek approval leading regulatory agency across globe marketing product rest world fy approval developed market expected coming year biocon sdn bhd also continue research development activity pertaining human insulin analogue acquired biocon sa biocon sdn bhd reported total revenue mn net profit mn fy biocon biologics india limited india biocon biologics india limited bbil step subsidiary company wholly owned buk bbil incorporated june india objective set green field biosimilar biologics facility march bbil commenced commercial operation board report biocon sa switzerland biocon sa wholly owned subsidiary company primarily engaged identifying developing novel molecule commercial product licensable asset strategic partnership current year biocon sa registered net profit mn mn fy exceptional gain explained resulted increased net profit fy exceptional item comprises amount mn net tax released deferred balance pursuant contract laboratory pisa sa de cv pisa mexico codevelopment commercialization generic recombinant human insulin rhinsulin u market b impairment charge mn marketing right th product u canada region territory due uncertainty commercialisation product territory owing ofac sanction c year ended march biocon sa biocon sdn bhd entered assignment license agreement pursuant biocon sa transferred right interest obligation insulin analog ipr biocon sdn bhd consequent transfer bsa recorded gain mn net tax mn biocon fz llc uae biocon fz llc wholly owned subsidiary company based dubai incorporated june biocon fz llc established marketing entity pharmaceutical product target market middle east gcc year ended march biocon fz llc earned mn revenue reported net loss mn biocon academy india biocon academy spearhead biocons csr initiative technical professional education segment academy established centre excellence advanced learning bioscience biocon academy leverage rich industry experience biocon subject matter expertise international education partner keck graduate institute claremont california usa academy dedicated exclusively industry oriented bioscience education program offered academy aim empower biotechnology engineering graduate advanced learning industrial proficiency jobskills development essential build promising career biotech industry management discussion analysis term provision regulation sebi listing obligation disclosure requirement regulation sebi lodr management discussion analysis set annual report corporate governance company committed maintain highest standard corporate governance believe sound corporate governance critical enhance retain investor trust disclosure seek attain best practice corporate governance prevalent globally implemented several best corporate governance practice company enhance longterm shareholder value respect minority right business decision corporate governance report fy form part annual report requisite certificate auditor company confirming compliance condition corporate governance stipulated sebi lodr annexed corporate governance report business responsibility report business responsibility report brr company year form part annual report required regulation f sebi listing obligation disclosure requirement regulation employee stock option plan esop nomination remuneration committee board inter alia administers monitor company employee stock option plan plan accordance sebi share based employee benefit regulation sbeb regulation plan implemented biocon india limited employee welfare trust esop trust year ended march total share transferred esop trust eligible employee company prevailing esop plan march esop trust held equity share company year ended march material change company existing plan plan compliance sbeb regulation information required sbeb regulation read sebi circular circfdpolicy cell dated june uploaded company website accessed weblink httpwwwbioconcombiocon_invrelation_annualreportsaspsublinkfinance applicable disclosure stipulated sbeb regulation march appended herewith annexure board report company received certificate statutory auditor scheme implemented accordance sbeb regulation resolution passed shareholder certificate would placed agm inspection member ahead curve annual report biocon limited deposit company accepted deposit amount principal interest outstanding balance sheet date loan guarantee investment detail loan guarantee investment covered provision section company act form part note financial statement policy director appointment remuneration company current policy appropriate mix executive independent director maintain independence board separate function governance management march board consists director majority independent director besides chairperson managing director promoter board comprises vice chairman wholetime director ceo joint managing director non executive director independent director board periodically evaluates need change composition size policy company director appointment remuneration including criterion determining qualification positive attribute independence director matter required subsection section company act formulated nomination remuneration committee policy company director appointment remuneration appended herewith annexure board report board diversity diverse board enables efficient functioning difference perspective skill also foster differentiated thought process back varied industrial management expertise gender knowledge geographical background board recognises importance diverse composition adopted board diversity policy set approach diversity policy available weblink httpwwwbiocon comdocspolicydocument_boarddiversitypdf declaration independent director company received necessary declaration independent director section company act heshe meet criterion independence laid section company act regulation sebi lodr board evaluation pursuant provision company act regulation sebi lodr board carried annual performance evaluation performance director individually well evaluation working various committee structured questionnaire prepared taking consideration input received director covering various aspect board functioning adequacy composition board committee board culture execution performance specific duty obligation independence governance ethic value adherence corporate governance norm interpersonal relationship attendance contribution meeting etc separate exercise carried evaluate performance individual director including chairperson board evaluated parameter participation contribution commitment including guidance provided senior management outside board committee meeting effective deployment knowledge expertise effective management relationship various stakeholder independence behaviour judgment etc performance evaluation independent director carried entire board performance evaluation chairperson managing director carried independent director evaluation process explained corporate governance report board reviewed evaluation result collated nomination remuneration committee appointment director key managerial personnel member th agm held june appointed mr damodaran independent director period three consecutive year term upto conclusion st agm company calendar year member said agm also appointed dr arun chandavarkar ceo joint managing director director liable retire rotation thank member support confirming mentioned appointment board recommendation nomination remuneration committee appointed mr rajiv balakrishnan company secretary compliance officer effective january place mr kiran kumar g relinquished post company secretary company pursue interest within group board place record appreciation service rendered mr kiran kumar g tenure company secretary retirement reappointment per provision section company act prof ravi mazumdar retires rotation ensuing agm eligible seek appointment board recommends reappointment current term appointment mr russell wall mary harney mr daniel bradbury independent director company shall come end ensuing agm based outcome performance evaluation nomination remuneration committee recommended continue term appointment independent director nominated board reappointment mr russell wall mary harney mr daniel bradbury independent director additional term five consecutive year company received declaration three independent director confirming meet criterion independence prescribed subsection section company act regulation sebi lodr company also received requisite notice writing member proposing mr russell wall mary harney mr board report daniel bradbury independent director company board recommends appointment mr russell wall mary harney mr daniel bradbury independent director committee board currently board four committee audit risk committee nomination remuneration committee corporate social responsibility committee stakeholder relationship committee required provision section company act composition audit committee disclosed mr russell wall chairman mr daniel bradbury dr jeremy levin mr damodaran detailed note composition board committee provided corporate governance report section annual report meeting board meeting board scheduled regular interval decide discus business performance policy strategy matter significance schedule meeting circulated advance ensure proper planning effective participation meeting certain exigency decision board also accorded circulation board financial year met four time maximum interval two meeting exceed day prescribed company act detailed information regarding meeting board included report corporate governance form part board report related party contract arrangement transaction entered related party defined company act year ordinary course business arm length basis company formulated policy materiality related party transaction process dealing transaction line provision company act sebi lodr also available weblink httpwwwbioconcomdocs policydocument_relatedpartytransaction_pdf prior omnibus approval audit risk committee obtained transaction repetitive also normal nature disclosure related party contract arrangement made audit risk committee board quarterly basis year review material related party transaction regulation sebi lodr entered company necessitates approval shareholder particular contract arrangement related party referred section company act prescribed form aoc appended herewith annexure board report credit rating crisil icra continued reaffirm rating aa stable various banking facility throughout year enabling company avail facility bank attractive rate indicating strong degree safety timely payment financial obligation conservation energy technology absorption foreign exchange earnings outgo particular prescribed subsection section company act read company account rule appended herewith annexure board report auditor statutory auditor messrs b r co llp chartered accountant icai registration ww appointed statutory auditor company hold office conclusion th agm held june conclusion rd agm company held calendar year subject ratification appointment member every agm required provision section company act company received written consent b r co llp chartered accountant appointment certificate effect appointment made would accordance company act rule framed thereunder satisfy criterion provided section company act member requested ratify appointment statutory auditor ensuing agm auditor report financial statement company year ending march unmodified ie contain qualification reservation adverse remark auditor report enclosed financial statement forming part annual report cost auditor board director recommendation audit risk committee appointed messrs rao murthy cost accountant firm registration number cost auditor company fy section company act messrs rao murthy cost accountant confirmed appointment within limit section g company act also certified free disqualification specified section proviso section read section company act audit risk committee also received certificate cost auditor certifying independence arm length relationship company ahead curve annual report biocon limited per provision company act remuneration payable cost auditor required placed member general meeting ratification accordingly resolution seeking member ratification remuneration payable messrs rao murthy cost accountant included notice convening th agm secretarial auditor pursuant provision section company act rule thereunder sreedharan co practicing company secretary appointed conduct secretarial audit company fy secretarial audit report fy appended herewith annexure board report secretarial audit report contain qualification reservation adverse remark board appointed mr damodaran damodaran associate practising company secretary secretarial auditor company financial year risk management policy company put place enterprise wide risk management framework object timely identification risk assessment evaluation line overall business objective define adequate mitigation strategy quarterly basis audit risk committee review critical risk rotation basis line mitigation progress effectiveness impact overall risk exposure company critical risk area covered least year annually critical risk area identified reevaluated internal financial control company laid certain guideline process structure enable implementation appropriate internal financial control across organisation internal financial control encompasses policy procedure adopted company ensuring orderly efficient conduct business including adherence policy safeguarding asset prevention detection fraud error accuracy completeness accounting record timely preparation reliable financial information include control process manual application including erp application wherein transaction approved recorded appropriate review control mechanism built place ensure control system adequate operating effectively inherent limitation internal financial control including possibility collusion improper management override control material misstatement financial reporting due error fraud may occur detected also evaluation internal financial control subject risk internal financial control may become inadequate change condition compliance policy procedure may deteriorate company material respect adequate internal financial control system internal financial control operating effectively based internal control criterion established company considering essential component internal control stated guidance note audit internal control financial reporting issued institute chartered accountant india vigil mechanism vigil mechanism envisaged company act rule prescribed thereunder sebi lodr implemented company whistle blower policy enable director employee stakeholder company report genuine concern provide adequate safeguard victimisation person use mechanism make provision direct access chairman audit risk committee whistle blower policy company available company website accessed weblinkhttpwwwbioconcomdocsbiocon_ group_integrity_whistle_blower_policypdf director responsibility statement pursuant requirement section c company act director confirm preparation annual account applicable accounting standard followed along proper explanation relating material departure b selected accounting policy applied consistently made judgement estimate reasonable prudent give true fair view state affair company end financial year profit loss company period c taken proper sufficient care maintenance adequate accounting record accordance provision act safeguarding asset company preventing detecting fraud irregularity prepared annual account going concern basis e laid internal financial control based internal control framework established company adequate operating effectively f devised proper system ensure compliance provision applicable law system adequate operating effectively particular employee statement containing particular term section company act read rule company appointment remuneration managerial personnel rule form part report appended herewith annexure board report board report statement containing particular term section company act read rule company appointment remuneration managerial personnel rule form part report considering first proviso section company act annual report excluding aforesaid information sent member company others entitled thereto said information available inspection registered office company business hour working day company date ensuing annual general meeting shareholder interested obtaining copy thereof may write company secretary regard corporate social responsibility csr biocon csr integral part business since inception incorporation biocon foundation company formally structured csr activity today company span csr effort biocon foundation biocon academy partnership program like minded private organization government company promotes social economic inclusion marginalized community integrated system focussing largely following area health care service company firmly belief use technology make healthcare delivery rural area efficient therefore developed integrated holistic healthcare delivery service seek address critical gap delivery healthcare rural india effort targeted enabling last mile reach preventive primary health service rural area education company project address experiential learning basic math computer skill language skill underserved young people rural area also imparts advanced training necessary skill required gainful employment biopharma sector young graduate biocon academy promote art culture india rich heritage art culture across land need preserved promoted various form music dance style painting sculpture intrigued many across globe yet large pool artiste gained enough recognition biocon foundation belief creating platform promote art culture encourage artist share knowledge marginalized community various initiative help develop keen sense appreciating fine art safety woman child biocon belief safety woman child collective responsibility society company provides safe transport pregnant woman come primary health centre ante natal checkup child attending aata paata wadi also provides vehicle police support work managing safety citizen gender equality gender equality equity basic human right company work towards community company work towards gender equality providing vocational skill assisting employment opportunity company counsel mentor protect young woman risk sexual trafficking assist woman girl life skill coaching employment opportunity rural development company working build township school sanitation water supply system fulfil basic need underprivileged rural urban community company adopted township north karnataka also providing support infrastructure including school safe drinking water health centre community hall village company installed solar light rain water harvesting system household community toilet enable clean sanitation facility rural community compliance provision section company act board formed corporate social responsibility committee monitor oversees various csr initiative activity company csr committee comprises mary harney chairperson dr vijay kuchroo prof ravi mazumdar detailed report regarding corporate social responsibility appended herewith annexure board report sexual harassment woman workplace prevention prohibition redressal act company place antisexual harassment policy line requirement sexual harassment woman workplace prevention prohibition redressal act internal complaint committee icc set redress complaint received regarding sexual harassment employee permanent contractual temporary trainee covered policy policy gender neutral year review complaint allegation sexual harassment filed disposedoff per provision sexual harassment woman workplace prevention prohibition redressal act significant material order significant material order passed year regulator court tribunal impacting going concern status company operation future statutory disclosure none director company disqualified per provision section company act director made necessary disclosure required various provision act sebi lodr material change commitment material change commitment affecting financial position company occurred march date report ahead curve annual report biocon limited change nature business change nature business company company continues pioneer biopharmaceutical company engaged manufacturing active pharmaceutical ingredient formulation including biosimilar drug diabetic oncology autoimmune disease sale market across globe extract annual return accordance provision section company act extract annual return prescribed format appended herewith annexure board report acknowledgement place record appreciation committed service every member biocon family globally whose contribution significant growth success company would like thank client partner vendor investor banker business associate continued support encouragement year also thank government india malaysia government karnataka government telangana ministry information technology biotechnology ministry commerce industry ministry finance department scientific industrial research ministry corporate affair custom excise department income tax department csez ltu bengaluru regulatory agency assistance cooperation year look forward continued support future behalf board bengaluru kiran mazumdar shaw april chairperson managing director space intentionally left blank board report annexure statement containing salient feature financial statement subsidiary associate company joint venture pursuant first proviso subsection section company act read rule company account rule aoc million part subsidiary sl name subsidiary date since subsidiary reporting reporting share reserve total total liability investment turnover profit loss provision profit proposed acquired period currency capital surplus asset excl capital excluding year dividend shareholding incorporated equity reserve subsidiary taxation taxation company syngene international limited india november apr mar biocon research limited india may apr mar biocon academy india december apr mar biocon pharma limited india october apr mar biocon sa switzerland april apr mar usd biocon biologics limited uk march apr mar usd biocon sdn bhd malaysia january apr mar usd refer note biocon pharma inc u july jan dec usd refer note biocon fz llc uae june apr mar aed ahead curve annual report biocon biologics india limited india june apr mar refer note exchange rate considered case foreign subsidiary usd aed part b associate joint venture statement pursuant section company act related associate company joint venture sl name joint venture date latest share joint venture held description reason net worth attributable profit year joint venture audited company year end significant influence joint venture share holding per latest associatedacquired balance number amount extent consolidated audited balance sheet considered sheet date share investment considered joint venture holding consolidation consolidation neobiocon uae april march mn way control na mn mn twenty percent total share capital note none subsidiary proposed dividend march except syngene international limited biocon research limited hold equity stake syngene international limited biocon pharma limited biocon pharma inc yet commence commercial operation march biocon biologics limited uk hold equity stake biocon sdn bhd malaysia reporting currency biocon sdn bhd myr however usd disclosed since functional currency biocon pharma limited india hold equity stake biocon pharma inc u biocon biologics india limited india pending share application money biocon biologics limited uk behalf board kiran mazumdarshaw arun chandavarkar siddharth mittal rajiv balakrishnan chairperson managing director ceo joint managing director president finance chief financial officer company secretary bengaluru april biocon limited annexure dividend distribution policy pursuant regulation sebi listing obligation disclosure requirement regulation dividend distribution policy policy establishes principle ascertain amount distributed equity shareholder dividend company well enable company strike balance payout retained earnings order address future need company policy shall come force accounting period beginning april preamble profit earned company may either retained business used acquisition expansion diversification distributed shareholder dividend policy company would endeavor maintain consistent approach dividend payout plan reconciling need company currently one class share ordinary equity share therefore dividend declared distributed amongst shareholder based shareholding record date dividend generally recommended board year announcement full year result annual general meeting agm shareholder may permitted company act board may also declare interim dividend may permitted company act company consistent dividend policy balance objective appropriately rewarding shareholder dividend support future growth company would ensure strike right balance quantum dividend paid amount profit retained business various purpose past subject provision applicable law company dividend payout determined based available financial resource investment requirement taking account optimal shareholder return board director refer policy declaring recommending dividend behalf company company shall comply provision section company act pertaining recommendation declaration payment dividend category dividend company act provides two form dividend final interim final dividend final dividend paid financial year annual account prepared board director company power recommend payment final dividend shareholder general meeting b interim dividend interim dividend may declared board director one time financial year may deemed fit board board director company would declare interim dividend considered appropriate line policy normally board could consider declaring interim dividend finalization quarterly half yearly financial result board discretion may additionally recommend special dividend certain circumstance extraordinary profit sale investment etc factor considered declaring dividend determining nature quantum dividend payout board would take account following factor internal factor profitable growth company specifically profit earned financial year compared previous year b internal budget ii cash flow position company iii accumulated reserve iv earnings stability v future cash requirement organic growthexpansion andor inorganic growth vi brand acquisition vii current future leverage exceptional circumstance amount contingent liability viii deployment fund short term marketable investment ix long term investment x capital expenditure board report external factor business cycle ii economic environment iii cost external financing iv applicable tax including tax dividend v industry outlook future year vi inflation rate vii change government policy industry specific ruling regulatory provision apart board also considers past dividend history determining rate dividend board may consider declaring dividend may recommend lower payout given financial year analyzing prospective opportunity threat event challenging circumstance regulatory financial environment event board provide rationale annual report retained earnings company may used following way capital expenditure working capital ii organic inorganic growth iii investment new business e andor additional investment existing business e iv declaration dividend v capitalisation share vi buy back share vii general corporate purpose including contingency viii correcting capital structure ix permitted usage per company act policy review policy reviewed periodically board amended appropriate change revision policy communicated shareholder timely manner policy available company website disclosed company annual report space intentionally left blank ahead curve annual report biocon limited annexure disclosure respect employee stock option plan company summary status esop sl particular date shareholder approval september total number option approved esos vesting requirement exercise price pricing formula refer note standalone financial statement maximum term option granted source share primary secondary combination combination variation term option variation method used account esos intrinsic fair value refer note standalone financial statement impact profit eps company number option approved esop adjusted subdivision face value equity share fy fy issue bonus share fy fy b option movement year sl particular grant iv grant v grant vi grant vii grant viii grant ix grant x number option outstanding beginning period number option granted year number option forfeited lapsed year number option vested year number option exercised year number share arising result exercise option money realized exercise option inr scheme implemented directly company loan repaid trust year exercise price received number option outstanding end year number option exercisable end year weightedaverage exercise price option outstanding end year weightedaverage fair value option granted c option granted employee company year option granted senior managerial personnel year sl name employee designation grant option exercise price granted suresh subramanian senior vice president grant ix prasad deshpande vice president grant x paul vazhayil thomas vice president grant x sandeep nilkanth athalye senior vice president grant ix b employee received grant year option amounting option granted year nil c identified employee granted option year equal exceeding issued capital excluding outstanding warrant conversion company time grant nil board report description method significant assumption used year estimate fair value option including following information weightedaverage value share price exercise price expected volatility expected option life expected dividend riskfree interest rate input model method used assumption made incorporate effect refer note standalone financial statement expected early exercise expected volatility determined including explanation extent expected volatility based historical volatility whether feature option grant incorporated none measurement fair value market condition behalf board bengaluru kiran mazumdarshaw april chairperson managing director space intentionally left blank ahead curve annual report biocon limited annexure policy director appointment remuneration policy appointment remuneration director key management personnel provides underlying basis guide human resource management thereby aligning plan strategic growth company policy pursuant section company act regulation sebi listing obligation disclosure requirement regulation brief summary policy relation objective appointment criterion remuneration general matter administered nomination remuneration committee reproduced herewith background section key objective committee policy would guide board relation appointment retention removal director key managerial personnel senior management evaluate performance member board provide necessary report board evaluation board recommend board remuneration payable director key managerial personnel retain motivate promote talent ensure long term sustainability talented managerial person create competitive advantage devise policy board diversity develop succession plan board regularly review plan composition meeting board constituted nomination remuneration committee nrc line requirement company act oversees function related appointment remuneration director key managerial personnel senior management personnel term composition requirement meeting committee committee shall consist minimum nonexecutive director atleast one half composition shall independent minimum two member shall constitute quorum committee meeting nrc shall meet atleast twice year membership committee shall disclosed annual report definition act mean company act rule framed thereunder amended time time board mean board director company committee mean nomination remuneration committee director mean director company key managerial personnel mean chief executive officer managing director wholetime director chief financial officer company secretary officer may prescribed act senior management mean personnel company member core management team excluding board director including functional head section ii section cover duty committee relation various matter recommendation made committee board duty role committee matter dealt perused recommended board committee shall include formulating criterion determining qualification positive attribute independence director identifying person qualified become director person may appointed key managerial position accordance criterion laid policy recommending board appointment removal director key managerial personnel senior management personnel specifically duty include nomination matter determining appropriate size diversity composition board board report setting formal transparent procedure selecting new director appointment board ensuring appropriate induction place new director reviewing effectiveness identifying recommending director put forward retirement rotation developing succession plan board senior management regularly reviewing plan evaluating performance board member senior management context company performance industry benchmark compliance making recommendation board concerning matter relating continuation office director time including suspension termination service executive director employee company subject provision law service contract recommend necessary change board line board diversity policy considering matter may requested board b remuneration matter considering determining remuneration policy based performance reasonable sufficient need attract retain motivate member board approve remuneration key managerial personnel company maintaining balance fixed incentive pay reflecting short long term performance objective appropriate working company growth strategy manage administer employee stock option plan company consider matter may requested board section iii section cover policy appointment term retirement director key managerial personnel committee appointment criterion qualification committee shall identify ascertain integrity qualification expertise experience person appointment director key managerial personnel recommend board hisher appointment person possess adequate qualification expertise experience position heshe considered appointment committee discretion decide whether qualification expertise experience possessed person sufficientsatisfactory concerned position company shall appoint person wholetime director attained age seventy year provided term person holding position may extended beyond age seventy year approval shareholder passing special resolution based explanatory statement annexed notice motion indicating justification extension appointment beyond seventy year termtenure managing directorwholetime director company shall appoint reappoint person executive chairman managing director executive director term exceeding term may specified act reappointment shall made earlier one year expiry term shall done approval shareholder company independent director independent director shall hold office term five consecutive year board company eligible reappointment passing special resolution company disclosure appointment board report independent director shall hold office two consecutive term independent director shall eligible appointment expiry three year ceasing become independent director provided independent director shall said period three year appointed associated company capacity either directly indirectly evaluation committee shall carry evaluation performance every director regular interval least annual basis removal due reason disqualification mentioned act applicable act rule regulation thereunder committee may recommend board reason recorded writing removal director key managerial personnel subject provision compliance said act rule regulation retirement director key managerial personnel shall retire per applicable provision act prevailing policy company board discretion retain director key managerial personnel position remuneration otherwise even attaining retirement age benefit company ahead curve annual report biocon limited section iv section policy cover provision relating remuneration wholetime director key managerial personnel senior management personnel general remuneration wholetime director key managerial personnel determined committee recommended board approval wherever required remuneration compensation commission etc shall subject approval shareholder company central government remuneration commission including increment recommended paid wholetime director shall accordance percentage slab condition laid per provision act would subject approval shareholder company remuneration wholetime executive managing director key managerial personnel fixed pay wholetime director managing director shall eligible monthly remuneration may approved board recommendation committee breakup pay scale quantum perquisite including employer contribution provident fund pension scheme medical expense club fee etc shall decided approved board approved shareholder central government wherever required committee shall approve remuneration key managerial personnel b minimum remuneration financial year company profit profit inadequate company shall pay remuneration wholetime director accordance provision schedule v act able comply provision previous approval central government c longterm reward longterm reward linked contribution performance company based relative position personnel organisation reward could form nature stock option based level employee criticality provision excess remuneration wholetime director draw receives directly indirectly way remuneration sum excess limit prescribed act without prior sanction central government required shall refund sum company sum refunded hold trust company company shall waive recovery sum refundable unless permitted central government remuneration non executive independent director remuneration commission remuneration commission shall fixed per limit mentioned act subject approval shareholder applicable b sitting fee non executive independent director shall receive remuneration way fee attending meeting board committee thereof provided amount fee shall exceed amount may prescribed central government time time c stock option independent director shall entitled stock option company remuneration structure independent director per meeting board committee effective april follows particular currency amount board sitting fee inr board remuneration u travel allowance overseas directorsnon u u travel allowance overseas director u u chairperson audit risk committee u chairperson committee u member audit risk committee u member committee u revised u u effect january revised u u effect january amendment update nomination remuneration committee periodically shall review policy may recommend amendment policy time time deems appropriate shall accordance provision company act case modification amendment inconsistency act provision act rule made thereunder would prevail policy behalf board bengaluru kiran mazumdarshaw april chairperson managing director board report annexure particular contractsarrangements made related party pursuant clause h subsection section act rule company account rule aoc form disclosure particular contractsarrangements entered company related party referred subsection section company act including certain arm length transaction third proviso thereto detail contract arrangement transaction arm length basis sl particular detail name related party nature relationship b nature contractsarrangementstransactions c duration contractsarrangementstransactions applicable since contract salient term contract arrangement transaction including value arrangement transaction entered e justification entering contract arrangement transaction company year ended march f date approval board arm length basis g amount paid advance h date special resolution passed general meeting required first proviso section detail material contract arrangement transaction arm length basis sl particular detail name related party nature relationship b nature contractsarrangementstransactions applicable since material c duration contractsarrangementstransactions contract arrangement transaction salient term contract arrangement transaction including value entered company year e date approval board ended march f amount paid advance behalf board bengaluru kiran mazumdarshaw april chairperson managing director space intentionally left blank ahead curve annual report biocon limited annexure conservation energy technology absorption foreign exchange earnings outgo particular pursuant section company act read rule company account rule conservation energy step taken impact conservation power consumption fy mn unit mn unit fy account energy increased consumption yoy unit consumption increased total energy cost reduced mn fy mn fy reduction overall energy cost attributable procurement power alternate source ii step taken company company started procuring wind power october total wind power procured utilizing alternate source energy fy mn unit corresponding reduction c emission approx ton iii capital investment energy mn conservation equipment sl power fuel consumption detail fy fy electricity purchased million unit total amount mn rate unit b captive generation hsd quantity kl million unit unit litre cost litre generation cost rate unit steam furnace oil quantity kl total amount mn average rate sl energy conservation measure investment energy saved per annum mn unit amount mn conversion conventional motor energy efficient motor conversion cfl light energy efficient led light installation energy efficient brine chiller optimisation hvac system brc continuous monitoring high energy consumption areasequipment taking appropriate corrective measure required resulted energy saving maintained marginal increment power consumption production growth b technology absorption effort made towards technology absorption ii benefit derived like product improvement cost reduction product development import substitution iii case imported technology imported last three year reckoned beginning technology imported financial year company year detail technology imported b year import c whether technology fully absorbed fully absorbed area absorption taken place reason thereof iv expenditure incurred research development rd detailed disclosure rd provided board report research development specific area rd work carried company development synthetic fermentation based generic small molecule antiinfective oncology cardiovascular nephrology transplantation segment formulation development abbreviated new drug application andas generation intellectual property development process patent manufacture key generic small molecule biotherapeutics clinical development pertaining novel program benefit derived result rd activity global presence supply fermentation based small molecule generic industry regulated market rich pipeline generic small molecule catering varied therapeutic area internationally competitive price product quality established intellectual property patent pct application filed indian international market company granted patent various jurisdiction safe environment friendly process first anda molecule approval received future plan action strategic collaboration increased speed cost competitiveness drug discovery inhouse rd scale generic formulation collaborate global academia industry build value visibility portfolio expenditure incurred research development million fy fy capital b recurring total less recharge net rd expense c foreign exchange earnings outgo million foreign exchange earned used year fy fy gross earnings outflow net foreign exchange earnings behalf board bengaluru kiran mazumdarshaw april chairperson managing director ahead curve annual report biocon limited annexure secretarial audit report financial year ended march pursuant sub section section company act rule company appointment remuneration managerial personnel rule member biocon limited bengaluru conducted secretarial audit compliance applicable statutory provision adherence good corporate practice biocon limited hereinafter called company secretarial audit conducted manner provided u reasonable basis evaluating corporate conductsstatutory compliance expressing opinion thereon based verification company book paper minute book form return filed record maintained company also information provided company officer agent authorized representative conduct secretarial audit hereby report opinion company financial year ended march audit period complied statutory provision listed hereunder also company proper boardprocesses compliancemechanism place extent manner subject reporting made hereinafter examined book paper minute book form return filed record maintained company audit period according provision company act act rule made thereunder ii security contract regulation act scra rule made thereunder iii depository act regulation byelaws framed thereunder iv foreign exchange management act rule regulation made thereunder extent foreign direct investment overseas direct investment external commercial borrowing v following regulation guideline prescribed security exchange board india act sebi act security exchange board india substantial acquisition share takeover regulation b security exchange board india prohibition insider trading regulation c security exchange board india issue capital disclosure requirement regulation applicable company audit period security exchange board india share based employee benefit regulation e security exchange board india issue listing debt security regulation applicable company audit period f security exchange board india registrar issue share transfer agent regulation regarding company act dealing client g security exchange board india delisting equity share regulation applicable company audit period h security exchange board india buyback security regulation applicable company audit period security exchange board india listing obligation disclosure requirement regulation vi law applicable specifically company namely drug cosmetic act b bio medical waste management handling rule c ich guidelinesthis base u fda eu guideline etc created ucpmp currently voluntary however proposed made mandatory e national biodiversity act f drug magical remediesobjectionable advertisement rule g narcotic drug psychotropic substance act board report also examined compliance applicable clause following secretarial standard issued institute company secretary india meeting board director general meeting b listing agreement entered company bse limited national stock exchange india limited period review company complied provision act rule regulation guideline standard etc mentioned examined compliance applicable financial law like direct indirect tax law since subject review statutory financial audit designated professional report board director company duly constituted proper balance executive director nonexecutive director independent director change composition board director took place period review carried compliance provision act adequate notice given director schedule board meeting agenda detailed note agenda sent least seven day advance system exists seeking obtaining information clarification agenda item meeting meaningful participation meeting per minute meeting duly recorded signed chairman decision board unanimous dissenting view recorded report based review compliance report certificate chief executive officer ceo company taken record board director adequate system process company commensurate size operation company monitor ensure compliance applicable law rule regulation guideline report audit period event action major bearing company affair pursuance referred law rule regulation guideline etc v sreedharan associate company secretary pradeep b kulkarni bengaluru partner april fcs cp space intentionally left blank ahead curve annual report biocon limited annexure particular remuneration detail pertaining remuneration required section read rule company appointment remuneration managerial personnel rule sl name directorkey managerial personnel remuneration director percentage increase ratio remuneration designation key managerial personnel remuneration director year ended march directorcfocs fy median remuneration employee million kiran mazumdar shaw chairperson managing director mr john shaw vice chairman mr arun chandavarkar ceo joint managing director mary harney independent director mr russell wall independent director mr daniel bradbury independent director dr jeremy levin independent director dr vijay kumar kuchroo independent director mr damodaran na independent director mr siddharth mittal na chief financial officer mr rajiv balakrishnan na na company secretary mr kiran kumar na company secretary mr rajiv balakrishnan appointed company secretary effective january place mr kiran kumar g relinquished post december hence remuneration disclosed period holding title note remuneration independent director excluding sitting fee remuneration include perquisite value account stock option exercised year percentage increase decrease median median remuneration employee increased representing remuneration employee financial increase computing increase median remuneration employee considered year employee march march ii number permanent employee permanent employee march roll company iii average percentile increase salary average increase employee remuneration managerial personnel employee managerial personnel marginally higher managerial personnel increase managerial comparison percentile remuneration line measure attract retain best talent company also u increase managerial remuneration mix fixed variable esop based compensation midtolong term basis align middle justification thereof senior management compensation enhance shareholder value hereby affirmed remuneration paid financial year per policy remuneration director key managerial personnel employee behalf board bengaluru kiran mazumdarshaw april chairperson managing director board report annexure annual report corporate social responsibility activity financial year pursuant provision section company act biocon belief making difference life million people underprivileged promotes social economic inclusion ensuring marginalized community equal access health care service educational opportunity proper civic infrastructure company csr activity implemented biocon foundation work towards development implementation healthcare education infrastructure project marginalized section society biocon academy aim address skill deficit biotechnology space external partner partner reliable csr player work towards development society csr vision company promote social economic inclusion ensuring marginalized community equal access healthcare service educational opportunity proper civic infrastructure create globally competitive biotech ecosystem india skill development bridge gap gender disparity education healthcare employment create platform promoting rich art culture country sensitizing community appreciate fine art please refer httpwwwbioconcombiocon_csr_about_policyasp detail related company csr policy csr committee csr committee board provides oversight csr policy monitor execution various activity meet set csr objective member csr committee mary harney chairperson b dr vijay kumar kuchroo c prof ravi mazumdar financial detail provision pertaining corporate social responsibility prescribed section company act applicable company summary financial detail company follows particular million average net profit tax company last three financial year prescribed csr expenditure average net profit computed detail csr spent financial year total amount spent financial year total amount spent amount unspent nil ahead curve annual report biocon limited detail amount spent financial year detailed million sl csr project program sector location project program amount amount cumulative amount spent name district state outlay spent spend direct budget external agency project reporting program period expenditure project program ary primary healthcare medical karnataka nine arogya biocon foundation healthcare clinic facility raksha yojana primary healthcare outpatient clinic cancer screening healthcare medical various district karnataka biocon foundation program facility ehealth rajasthan healthcare medical rajasthan karnataka direct biocon karnataka facility foundation project one clean drinking water bengaluru huskur karnataka biocon foundation rain water harvesting lake development rural development hebbagudi bengaluru biocon foundation project karnataka rural development rural development karnataka biocon foundation project international school improving quality hyderabad telangana biocon foundation business education grant ngo healthcare medical karnataka telengana biocon foundation facility biotechnology training improving quality bengaluru karnataka biocon academy education contribution biocon funding activity bengaluru karnataka biocon foundation foundation approved csr programme ii administrative expense project excluding office expense bengaluru karnataka biocon foundation sl responsibility statement hereby confirm implementation policy monitoring csr project activity compliance csr objective csr policy company behalf board bengaluru kiran mazumdarshaw mary harney april chairperson managing director chairperson csr committee board report annexure extract annual return financial year ended march pursuant section company act rule company management administration rule form mgt registration detail cin lkaplc registration date november name company biocon limited category subcategory company category company limited share sub category indian non government company address registered office contact detail th km hosur road electronic city bengaluru contact tel email cosecretarybioconcom whether listed company yes name address contact detail registrar transfer agent karvy computershare private limited plot karvy selenium tower b gachibowli financial district nanakramguda hyderabad contact tel email einwardriskarvycom ii principal business activity company sl name description main product service nic code product service total turnover company manufacture pharmaceutical medicinal chemical botanical product iii particular holding subsidiary associate company sl name address company cingln holdingsubsidiary share held applicable section syngene international limited lkaplc subsidiary biocon research limited ukaplc subsidiary biocon pharma limited ukaplc subsidiary biocon biologics india limited ukaflc subsidiary biocon academy ukanpl subsidiary biocon sa na subsidiary biocon sdn bhd na subsidiary biocon biologics limited na subsidiary biocon pharma inc na subsidiary biocon fz llc na subsidiary neo biocon fz llc na associate including held biocon research limited iv share holding pattern equity share capital breakup percentage total equity categorywise shareholding category category shareholder share held beginning year share held end year code change demat physical total demat physical total total total share share year promoter promoter group indian individualhuf b central govtstate govts c body corporate financial institutionsbanks e others subtotal ahead curve annual report biocon limited category category shareholder share held beginning year share held end year code change demat physical total demat physical total total total share share year foreign individual nrisforeign individual b body corporate c institution qualified foreign investor e others subtotal total aaa b public shareholding institution mutual fundsuti b financial institutionsbanks c central governmentstate government venture capital fund e insurance company f foreign institutional investor g foreign venture capital investor h qualified foreign investor others subtotal b noninstitutions body corporate b individual individual holding nominal share capital upto lakh ii individual holding nominal share capital excess lakh c others clearing member foreign national non resident indian nri nonrepatriation employee esop trust trust qualified foreign investor subtotal b total bbb total ab c share held custodian gdrs adrs grand total abc board report shareholding promoter sl shareholder name shareholding beginning year shareholding end year change share total share share total share shareholding share pledged share pledged company encumbered encumbered year total share company total share kiran mazumdarshaw glentec international limited john shaw ravi rasandra mazumdar yamini r mazumdar dev mazumdar total change promoter shareholding sl particular shareholding beginning year cumulative shareholding year share total share share total share company company kiran mazumdarshaw beginning year increase decrease shareholding year end year glentec international beginning year increase decrease shareholding year end year john shaw beginning year increase decrease shareholding year end year ravi rasendra mazumdar beginning year increase decrease shareholding year end year yamini r mazumdar beginning year increase decrease shareholding year end year dev mazumdar beginning year increase decrease shareholding year end year ahead curve annual report biocon limited shareholding pattern top ten shareholder director promoter holder gdrs adrs franklin templeton investment fund increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold end year oppenheimer developing market fund increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year increasebought increasebought increasebought increasebought increasebought increasebought increasebought increasebought increasebought increasebought increasebought increasebought end year board report life insurance corporation india increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold end year templeton developing market trust increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold end year ahead curve annual report biocon limited reliance capital trustee co ltd ac reliancepharm increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year decreasesold decreasesold decreasesold decreasesold increasebought decreasesold decreasesold decreasesold decreasesold increasebought decreasesold decreasesold increasebought increasebought increasebought increasebought decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold increasebought decreasesold decreasesold decreasesold increasebought decreasesold increasebought increasebought decreasesold increasebought decreasesold decreasesold decreasesold end year murali krishnan k n increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year increasebought decreasesold decreasesold end year board report swiss finance corporation mauritius limited increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year increasebought increasebought increasebought increasebought decreasesold increasebought increasebought increasebought increasebought increasebought increasebought increasebought decreasesold decreasesold increasebought increasebought decreasesold increasebought increasebought increasebought decreasesold increasebought decreasesold decreasesold increasebought decreasesold decreasesold decreasesold decreasesold increasebought decreasesold decreasesold decreasesold decreasesold increasebought decreasesold decreasesold increasebought increasebought decreasesold decreasesold decreasesold decreasesold decreasesold increasebought increasebought increasebought increasebought end year ahead curve annual report biocon limited national westminster bank plc trustee jupiter india fund increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year increasebought increasebought increasebought increasebought increasebought increasebought increasebought end year icici prudential equity arbitrage fund increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year increasebought decreasesold decreasesold decreasesold decreasesold increasebought increasebought increasebought increasebought increasebought increasebought increasebought decreasesold increasebought increasebought increasebought decreasesold decreasesold increasebought decreasesold increasebought decreasesold decreasesold decreasesold decreasesold end year board report credit suisse singapore limited increase decrease shareholding beginning increase cumulative shareholding reason year decrease year share total shareholding share total share share company company beginning year decreasesold increasebought increasebought decreasesold increasebought increasebought increasebought increasebought increasebought increasebought increasebought increasebought decreasesold decreasesold increasebought increasebought increasebought increasebought increasebought increasebought decreasesold increasebought decreasesold decreasesold increasebought decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold decreasesold increasebought increasebought decreasesold decreasesold decreasesold increasebought increasebought decreasesold decreasesold increasebought decreasesold decreasesold increasebought increasebought end year ahead curve annual report biocon limited v shareholding director key managerial personnel sl director kmp shareholding beginning cumulative shareholding year year share total share share total share company company kiran mazumdarshaw beginning year increase decrease shareholding year end year john shaw beginning year increase decrease shareholding year end year arun suresh chandavarkar beginning year increase decrease shareholding year end year ravi rasendra mazumdar beginning year increase decrease shareholding year end year siddharth mittal beginning year increase decrease shareholding year end year rajiv balakrishnan beginning year increase decrease shareholding year end year kiran kumar g beginning year increase decrease shareholding year end year indebtedness indebtedness company including interest outstandingaccrued due payment million secured loan unsecured loan deposit total excluding indebtedness deposit indebtedness beginning financial year principal amount ii interest due paid iii interest accrued due total iiiiii change indebtedness financial year addition reduction net change indebtedness end financial year principal amount ii interest due paid iii interest accrued due total iiiiii board report remuneration director key managerial personnel remuneration managing director wholetime director andor manager million sl particular remuneration total amount name mdwtd manager gross salary kiran mazumdar john shaw arun shaw cmd wtd chandavarkar ceo jt md salary per provision contained section incometax act b value perquisite u incometax act c profit lieu salary section income tax act stock option sweat equity commission profit others specify others please specify total ceiling per act amount indicates perquisite value stock option exercised year b remuneration director million sl particular remuneration name director total amount independent director russell daniel jeremy mary harney vijay k damodaran wall bradbury levin kuchroo fee attending boardcommittee meeting commission others please specify total nonexecutive director ravi mazumdar fee attending board committee meeting commission others please specify total total b total managerial remuneration ab overall ceiling per act ahead curve annual report biocon limited c remuneration key managerial personnel mdmanagerwholetime director million sl particular key managerial personnel chief financial officer company secretary total gross salary salary per provision contained section incometax act b value perquisite u incometax act c profit lieu salary section incometax act stock option sweat equity commission profit others specify others please specify total amount indicates perquisite value stock option exercised year note remuneration ceo included since joint managing director detail already included section remuneration company secretary includes remuneration paid year mr kiran kumar g mr rajiv balakrishnan period holding title penalty punishment compounding offence material penaltiespunishmentcompounding offence year ended march behalf board bengaluru kiran mazumdarshaw april chairperson managing director space intentionally left blank board report management discussion analysis global life science industry fared well amidst past economic downturn light today volatile marketplace faced economic political social challenge industry faced reformdriven pricing pressure increased demand value innovation significant global unmet need aided favourable demographic trend make likely industry would enjoy long term growth driven recent wave innovative therapy approved regulator report suggest global drug spending could reach trillion globally spending healthcare correlate well general economic strength country given high contribution usa russia brazil china global growth healthcare spending coupled pricing pressure united state unstable economic condition large emerging market led slowdown global marketplace strict measure taken government regard health care budget reduction ofpocket expenditure country impacted spending aging population rise chronic disease introduction innovative frequently expensive treatment eg cancer hepatitis c main factor would continue drive growth health care spending however many country taken step contain health care cost includes price control valuebased pricing reimbursement along progeneric probiosimilar policy company responding current changing market dynamic trying position continued growth portfolio transformation merger acquisition costcutting sharpened focus highperforming therapeutic area ta key geographic market global biologics market continues grow growth pharmaceutical company driven specialty product focus personalized medicine includes biologic drug increased number biologics approved compared nonbiologics synthetic molecule recent time antibody drug become increasingly significant component therapeutic landscape antibody exhibit high specificity selectivity reducing risk offtarget toxicity typical synthetic molecule enabling personalized treatment top pharma drug sale drug biologics figure figure biologics comprised top drug revenue sl drug sponsor biologic yn sale humira adalimumab abbvie harvoni ledipasvir mgsofosbuvir mg gilead science n enbrel etanercept amgen pfizer rituxan rituximab mabthera roche genentech biogen remicade infliximab johnson johnson merck revlimid lenalidomide celgene n avastin bevacizumab roche genentech herceptin trastuzumab roche genentech lantus insulin glargine sanofi prevnar pneumococcal valent conjugate vaccine pfizer xarelto rivaroxaban bayer johnson johnson n eylea aflibercept bayerregeneron lyricapregabalin pfizer n neulasta pegfilgrastim amgen kyowa hakko kirin advairfluticasone salmeterol glaxosmithkline n source genetic engineering biotechnology news wwwgenengnewscom driven recent advance created much excitement industry eg nivolumab pembrolizumab atezolizumab ocrelizumab oncology remains sought therapeutic area followed immunotherapy expanding waistline across globe continue see growth segment antidiabetic drug attract research dollar past several year biologics made many new ground breaking treatment possible gained significant traction pharmaceutical industry novel biologic blockbuster continued enter market company increasingly focusing narrow patient population characterized large unmet need easier market access estimate evaluate pharma indicate sale biotechnology product stood billion revenue likely go billion comprise nearly pharmaceutical market mentioned growth trend expected offset increased demand generic drug biosimilars defines biosimilars biotherapeutic product similar term quality safety efficacy already licensed reference biotherapeutic product given high cost biologic treatment coming year lower cost biosimilars instrumental expanding access population need therapy unable afford access analyst expect worldwide biosimilars market reach billion billion access affordability biological drug cost access advanced biologic therapy paid different channel across globe reimbursed market welldefined insurance payment mechanism government funded healthcare cash based outofpocket market access patient biologic treatment defined accordingly ahead curve annual report biocon limited developed market success led united state reimbursement widely available private insurance medicare federal health insurance program people older certain others followed eu even developed market access biologics uniform often patient struggle cope cost continued therapy emerging market biologics penetration suboptimal given varied nature payment mechanism drug coverage government emerging market country trending towards adoption universal healthcare promote wellbeing citizen reduce outofpocket cost drug provided may include biologics like human insulin available competitive price seldom include expensive drug treat cancer chronic inflammatory condition hence access biologics patient might severely limited market government unable afford higher priced branded biologic therapy biosimilars landscape biologics development long complex expensive resulting patient payer buying drug high cost resulted large unmet need affordable alternative form biosimilars made available patient different part world negate effect high pricing drug seen increase biosimilar development activity globally developed market focus area biologics manufacturer emerging market may attracted level attention developed market incurred biosimilar environment market poised drive long term growth company would require specific strategy successful segment key success vary based market chosen although country environment unique similarity trend across developed emerging market given need significant investment capital time required biosimilar development company need build right condition success able get fair return investment figure biosimilar landscape summary crosscountry analysis access regulatory payer assessment prescriber patient biosimilars affordable environment access acceptance acceptance presence variable biologics presence engagement willingness patient attitude number ranked importance physical financial abbreviated advocacy prescribe biosimilar towards biosimilars approved ability receive dedicated pathway payer favour v reference biosimilars biologics biosimilars molecule market u large access development low low low developed eu large access established high medium medium japan large access established medium low low brazil poor access established high medium medium russia fragmented development low low medium brics india poor access established low medium medium china poor access development medium medium low south africa poor access established high high medium mexico fragmented established high low medium indonesia poor access medium medium low mist south korea fragmented established high medium medium turkey fragmented established low medium medium source deloitte winning biosimilars opportunity global market developed market per deloitte greatest biosimilar presence today figure seen developed market led adoption seen eu country market u eu japan provide growth opportunity biosimilars aided availability better defined regulatory requirement registration biosimilar product payer pushing contain cost witnessed eu market adoption biosimilars largely payerdriven figure given need contain public health expenditure market uptake product varied across eu early physician scepticism low patient awareness certain market especially southern europe payer include government many instance proactively promoting use biosimilars education patient encouraging doctor use lower cost alternative branded biologics biosimilar manufacturer tasted success recent success infliximab eu specifically penetration level seen nordic country good example pricing discount varied based level penetration achieved various market discount seen eu country discount may higher eastern europe given higher unmet need due lack sophisticated reimbursement mechanism nordic country government promoted use biosimilars witnessed much steeper discount compared either eu eastern europe outcome government tender guaranteed volume physician willingness switch patient branded biologics biosimilars japan government pushing doctor incentivising pharmacy increase use generic biosimilars treat aging population thereby helping control spiralling drug cost japan traditionally branded market process adoption slow encouraging long term perspective united state market behind rest world adoption biosimilars still area regulatory policy evolving point include standard interchangeability pharmaceutical substitution extrapolation indication traceability pharmacovigilance report naming convention permit differentiation product recent commentary action payer regulatory level increased political noise around drug pricing encouraging towards acceptance biosimilars currently two biosimilars one generic insulin glargine commercially available u biosimilar filgrastim achieved success launched market sep biosimilar management discussion analysis infliximab launched nov initial report suggest generic insulin glargine launched dec also well accepted price discount launched product suggested range given providing rebate secure formulary access common u one would expect net discount higher given high cost development long developmental time inherent risk developer face includes change standard care delay due potential intellectual property lawsuit commercial challenge establish mainstream use drug therefore commercial strategy formulary placement physician education increased patient awareness coupled smart navigation intellectual property landscape needed company successful developed market notably u coming year analyst report suggest pace adoption may surprise industry advanced biosimilars current wave approved marketed united state emerging market company would want presence developed market considerable opportunity exists emerging market biosimilars market characterized poor physical financial access current highpriced branded biologics provide favourable long term growth opportunity biosimilar company figure addition favourable macroeconomic factor improving gross domestic product gdp growth rate coupled growing middle class increasing healthcare spending strong focus containing cost increasing treatment access physician would increase prescription rate lower priced biosimilar alternative available many country biosimilar approval pathway place finalizing guideline many case intellectual property landscape market less troublesome biosimilar sponsor compared developed market historically emerging market seen high penetration generic drug similar trend could apply biosimilars well signalling strong growth attainable biosimilar manufacturer course next year market would require tailored approach due regional country local complexity key success would involve choosing right market right therapeutic area provide greatest impact local population keeping price competitive secure broad access partnering local company overcome local resource knowledge gap getting access local commercial capability distribution network distinctive understanding local stakeholder including prescribing physician figure therefore biosimilar player would grow sale albeit lower margin developed market among increasing affluent health conscious population figure key theme emerging market government pushing development patient cannot domestic pharmaceutical afford industry access high priced biologics shifting disease profile infectious disease physcians key chronic condition influencers deciders better treated large patient therapy often make molecule therapy decision brand v generic biosimilars based perceived ability pay source deloitte winning biosimilars opportunity global market conclusion regulatory framework governing requirement biosimilar development continues evolve globally requirement large expensive phase trial currently mandated many geography could waived biosimilar sponsor able demonstrate biosimilarity address regulatory concern around residual risk using bioassay limited population pharmacokineticpharmacodynamics pkpd phase trial technologically sophisticated analytical tool characterization seen eu guidance future development insulin product globally process becomes mainstream includes complex drug like monoclonal antibody would help reduce cost time associated biosimilar development benefitting patient healthcare system macro favourable ignore support requirement biosimilars effective tool bring healthcare cost provide increased access biologic therapy however risk cannot ignored highly fluid environment would require utmost focus dedication perseverance access large pool capital make opportunity would play next five year current set molecule development indian pharmaceutical industry indian pharmaceutical industry seen steady growth last decade backed increased export expanding indian pharma market ipm indian company revenue coming sale intermediate active pharmaceutical ingredient api formulation various global market include developed market like u europe japan semi developed market across world major indian pharma company global player generic vaccine biosimilars generating half sale outside country ipm highly ahead curve annual report biocon limited fragmented player sale dominated branded generic top player include indian well multinational firm accounting market value past year indian company grown tremendously capitalizing major blockbuster losing patent protection paving way generic especially u market volume indian company supply global generic however every passing year left fewer patented drug opportunity indian company launch new product market moving plain vanilla drug complex formulation delivery system thus indian pharma company stepped rd effort newer area company spending establish niche product portfolio future growth respiratory dermatology biosimilars sterile injectable product development major area focus regulatory challenge especially u fda impacted many player including major player u market resulting lower growth last two year complicated debate drug pricing impacted sentiment around industry economic growth increase disposable income india resulted greater affordability consumption healthcare service general particularly generic medicine growing burden account noncommunicable disease infectious disease india lifestyle disease diabetes cardiovascular disease stroke india become public health challenge estimate disease mostly preventable risk factor account death significant morbidity india continue increase per caput consumption medicine country however access quality healthcare service equal country resulting inequitable outcome instance led catastrophic expenditure family one major contributor family discontinuing treatment thrust poverty central state government india taking step address problem recent national health policy nhp lay plan towards achieving universal health coverage india policy aim achieving universal health coverage delivering quality health care service affordable cost recommends prioritizing role government shaping health system dimension roadmap nhp predicated public spending gdp phased manner provisioning public healthcare system comprehensive integrated accessible seek promote quality care focus emerging disease investment promotive preventive healthcare policy patient centric quality driven address health security promotes make india drug device private player strategic partner cro space contract research organization cro provide support pharmaceutical biotechnology related industry outsourced research development service span drug discovery preclinical research clinical research clinical trial management commercialization pharmacovigilance life science industry evolved matured company dedicating resource effort particular area value chain developed outsourcing relationship perform function incremental outsourcing additional process qualified contract research organization cro brought cost efficiency process improved quality control speed market increased spending drug development industry outsourcing increasing quantum service competitive vendor strong underlying pharmaceutical demand coupled increasing complexity regulatory burden created favourable environment cro helped change dynamic pharmaceutical biotechnology industry cro purely client vendor relationship strategic partnership company trying consolidate simplify supply chain concentrating sourcing among select number multiservice vendor increased outsourcing manufacturing service cro moderate manufacturing cost outsourcing lowcost global destination like india india emerged one leading economical quality pharmaceutical manufacturing hub number global player outsourcing india offer significant benefit mature pharmaceutical hub north america europe india become increasingly important global pharmaceutical supply chain hence incentivising engagement indian pharmaceutical player research related manufacture resulted contract research manufacturing service crams emerging one fastest growing segment country opportunity prospect outsourcing cro discovery service estimated usd bn estimate exclude clinical research contract manufacturing outsourcing number estimated grow usd bn source iqi report increased outsourcing efficient low cost cro hub especially india china compared european american counterpart asiapacific therefore expected fastest growing region drug discovery outsourcing market time period space intentionally left blank management discussion analysis company review biocon utilises core capability fermentation technology high end rd skill manufacturing biopharmaceuticals across small molecule apis large molecule biologics company currently front end presence india uae sell novel branded small molecule biologic product field force also address customer rd requirement various service provided publically listed research service arm syngene international company organized following reporting segment small molecule apis generic formulation b biologics biosimilars insulin mabs biologics novel biologics c branded formulation currently india uae research service syngene detailed analysis business segment indicated hereunder small molecule segment apis generic formulation small molecule segment comprises apis well generic formulation revenue segment currently derived sale api third party segment successful track record regulatory audit developed well emerging market regulator segment leverage strength manufacturing product high degree complexity case using fermentation preferred route include production various statin api various immunosuppressant api api contract manufacturing innovator fermentation space working towards entering oncology space near future investment towards enhancing development manufacturing capability key api product portfolio statin basket simvastatin pravastatin atorvastatin rosuvastatin fluvastatin b immunosuppressant basket tacrolimus sirolimus everolimus mycophenolate mofetil mmf mycophenolate sodium mpa c key product orlistat fidaxomicin leading supplier product leading company estimate global market share range high top molecule api portfolio product manufactured via fermentation process core strength biocon supplying customer high quality product many year resulted multiyear association client enabling high global market share biocon api space diversify address need changing landscape given limited number fermentation based api available generic opportunity decided move value chain ventured generic formulation focusing following disease segment metabolics oncology immunology auto immune indication strategy vertically integrated business model currently nascent pipeline product couple approved dossier u eu market working niche portfolio product complex expected limited competition aim leverage strength acquired characterization manufacturing complex protein business hence would targeting select opportunity would fit selection criterion vertically integrated believe could add value api business help sustain long term growth segment work greenfield generic oral solid dosage facility would key component vertical integration effort full swing facility expected commissioned fy propose use facility primarily potent product currently segment business contributes significant revenue fy profit company cash generated business helped fund early biosimilar foray global market operationally fy good year small molecule segment growth compared fy growth driven large extent supply rosuvastatin api customer targeting u generic market generic formulation side received approval rosuvastatin calcium anda usfda eu approval received fy biologics segment biosimilars novel biologics biocon ahead curve india focussing early innovation especially area biologic drug made significant investment building capability science technology courtesy highly talented team scientist novel process engineering drug substance drug product predictive toxicology adaptive clinical trial design data analytics outcome effort innovative product include antibody like biomabegfr nimotuzumab treatment head neck cancer alzumab itolizumab treating psoriasis addition capability also enabled approval canmab affordable trastuzumab biosimilar treating breast cancer large scale development insulin insugen insulin analog basalog device system insupen made available global patient population biocons biologics segment comprises pipeline biosimilar molecule includes human insulininsulin analogue monoclonal antibody biologics apart pipeline novel biologic product focus segment drug help patient fight diabetes cancer auto immune disease inflammation future segment identified management significant growth driver company early starter among peer india experience developing manufacturing selling product many market globally company confident making mark global scene enters developed market portfolio product year review built upon success fy multiple clinical regulatory milestone met business segment segment revenue grew fy mn ahead curve annual report biocon limited biosimilars biocon possesses one largest global biosimilars portfolio spanning human insulininsulin analogue monoclonal antibody biologics addressable market size usd bn disclosed molecule pipeline nine molecule developed partnership mylan global generic major strategic partnership biocon mylan represents biocons strength biologics development manufacturing well mylans regulatory commercial strength globally received first developed market approval insulin glargine product japan partnership fujifilm pharma fy partner fujifilm pharma ffp launched product japan th july feedback product positive device appreciated ease use market insulin glargine japan small compared percentage insulin glargine sale globally however success getting product approved first pa selling product japanese market reinforces internal belief well positioned address insulin glargine opportunity developed market partnership mylan proposed biosimilar trastuzumab pegfilgrastim accepted review united state food drug administration usfda european medicine agency ema ema also reviewing proposed biosimilar insulin glargine targeted eu market expect receive marketing approval decision molecule second half fy filing generic insulin glargine usfda expected early fy proposed biosimilar adalimumab global clinical trial complete completed emerging market targeted indian clinical trial proposed biosimilar bevacizumab filed marketing authorization indian health regulator fy global phase trial bevacizumab also initiated late fy work recombinant human insulin rhi product targeted u market two global program insulin analog insulin aspart insulin lispro continues table summarizes status global biosimilar portfolio march table status biocons global biosimilar portfolio category molecule status regular acting insulin recombinant human insulin preclinical u market marketed emerging market long acting insulin insulin glargine filed eu australia canada u filing h fy marketed japan since jul emerging market rapid acting insulin analog insulin aspart preclinical rapid acting insulin analog insulin lispro preclinical cancer trastuzumab filed u eu marketed emerging market neutropenia pegfilgrastim filed u eu canada australia emerging market autoimmune adalimumab global phase completed cancer bevacizumab indiaemerging market phase complete global phase commenced neutropenia filgrastim early development autoimmune etanercept early development biocon achieved significant commercialization milestone first overseas facility malaysia subsidiary biocon sdn bhd malaysia awarded myr million million three year contract supplying rhi cartridge reusable insulin pen malaysian government offtake agreement ota initiative large scale biopharmaceutical facility johor malaysia ota seek encourage local manufacturing new pharmaceutical product thus lowering country reliance import also enhancing export potential biocons rhi malaysia first locally manufactured biosimilar biologic product approved national pharmaceutical regulatory authority npra malaysia commercial sale country apart japanese malaysia milestone insulin portfolio saw increase licensing income fy income great extent result successful partnership outcome trastuzumab several large emerging market local partner receive regulatory approval market expect would result meaningfully contribution trastuzumab sale segment fy beyond larger emerging market given high unmet need drug see biosimilar trastuzumab meaningful opportunity developed market also emerging market developed market stand point partner mylan entered settlement agreement genentech la hoffman roche related intellectual property around trastuzumab remove legal uncertainty related timing launch product various market around world ability address market demand creating capacity reducing cost increasing operational efficiency key differentiator success biosimilar foray developed well emerging market biocon building manufacturing capacity phased manner fulfil market demand portfolio product malaysia insulin plant started commercial operation fy plan augment biologics manufacturing capacity monoclonal antibody line launch ramp supply product across globe expect break ground new monoclonal antibody facility bengaluru fy facility built two phase period three four year expansion malaysian insulin plant malaysia phase also considered due course line movement portfolio molecule insulin lispro insulin aspart clinic regulatory commercial outcome insulin glargine product eu u market company continues work towards augmenting portfolio biosimilar candidate development name undisclosed market formation expected next decade current effort focused executing partnered pipeline expected commercialized next year novel biologics biocons novel biologics portfolio comprised therapeutic aim treating diabetes immunooncology autoimmune inflammatory disease therapeutic span across broad range platform including recombinant protein monoclonal antibody mabs novel fusion mabs small interfering rna sirna management discussion analysis field diabetes biocons lead program insulin tregopil phase ready firstinclass oral prandial insulin molecule postprandial glycaemic control january biocon announced successful result phase study concluded fy study established target product profile molecule includes food effect drugdrug interaction pkpd profile data provide basis rd group continue development program type type diabetes patient population type diabetes patient india pivotal phase study expected start fy likewise type diabetes patient population multiple ascending dose study planned fy combined study different diabetic population form foundation broad global program envisioned insulin tregopil autoimmuneinflammatory disease itolizumab humanized monoclonal cd antibody approved india psorasis fy bridging phase pk safety study normal healthy volunteer initiated australia evaluate pharmacokinetics subcutaneous route administration itolizumab comparison intravenous route company marketing approval india stage dosing completed subcutaneous route administration show good bioavailability drug plan initiate stage dosing shortly biocon first global company biologically clinically validate cd target autoimmune disease qpi novel sirna molecule treat nonarteritic ischemic optic neuropathy naion based quark pharma sirna technology platform licensed india related market qpi continues make good progress following initiation pivotal global phase study partner quark pharma study initiated fy u includes patient randomized india immunooncology biocons lead program fmab preclinical development fusion protein efgr mab tgfβ rii ecd fusion antibody work concept preferentially delivering immune modulators tumour site enhancing efficacy delivering larger tgfβ tumour micro environment ind molecule planned fy currently ready pharmacology mechanism action moa established invitro invivo tumour model provides u potentially broad clinical opportunity multiple tumour type also nd generation humanized antibody targeting cd path ind mapped plan advance asset neuroinflammatory disease eg multiple sclerosis biocons focus innovation global market continues strengthened via increasing depth emphasis inhouse research capability including access novel ip therapeutic modality invivo invitro model toxicology study early regulatory filing academic collaboration etc development broader global advancement novel program asset likely driven via external collaboration fund larger study required bring market realize full value innovation branded formulation biocon branded formulation business focus regional market currently operational india uae clear strategy focused around leveraging strength biologics differentiated product chronic therapeutic area metabolics diabetes cardiovascular oncotherapeutics immunotherapy inflammation autoimmune nephrology dialysis transplant specialty provide worldclass quality product thousand patient india uae performance india business continued sluggish fy increased competition low priced biosimilar mabs introduction price cap key brand government loss key inlicensed oncology brand abraxane withdrawn licensor india uae market impacted growth working overcome challenge modernising tomarket approach focussed execution expanding reach adjacent market like sri lanka making organizational change year review company worked portfolio consolidation focused targeting segmenting operating market targeted licensing strategy focus therapy area repurposing resource high growth segment market anticipated drive growth fy idea increase reach key opinion leader kol augmented method digital strategy communicate detail also flattened organization structure brought outside talent rolled attractive reward recognition career path branded formulation india key area objective quicker decision making aim taking current execution notch higher ultimately deliver superior result company change hope deliver higher growth segment fy beyond fy branded formulation segment grew mn compared previous year attributable growth uae business biocon one strongest company india insulin space prescription share human insulin glargine market respectively source cmarc oncology product novel biosimilars command high market share respective category top brand contribute sale india business grew fy previous year primarily due impact price control key brand like insugen tacrograf insulin franchise grew fy mn uae branded business supported brand sale well diversified across portfolio product top brand contribute sale grew fy compared fy biocon brand ranked top respective therapy segment uae market research service syngene subsidiary syngene biocon shareholding one leading india based cro offering suite integrated endtoend drug discovery development service novel molecular entity nmes hundred client including startup company large pharma biotech agrochemical chemical nutrition animal health company u europe asia pacific including japan includes held biocon research limited syngene amongst one listed drug discovery development company globally offer onestop solution organisation looking optimize rd expenditure right foundation conducting discovery hit candidate selection development including preclinical clinical study analytical bioanalytical evaluation formulation development stability study pilot manufacturing scaleup preclinical clinical supply one roof service offering discovery development cover multiple domain across small molecule large molecule ahead curve annual report biocon limited antibodydrugs conjugate adc oligonucleotides unlike traditional business model service offered flexible time engagement model customized client requirement engagement range fulltime equivalent fte feeforservice ffs model combination based client requirement scientist laboratory base million square foot currently service client ranging multinational corporation startup including eight top ten global pharma company based rd spend besides number multiyear contract syngene five longduration multidisciplinary partnership dedicated research centre bristolmeyers squibb co bm amgen research development center sarc abbott laboratory singapore pte ltd abbott herbalife nutrition company baxter international inc baxter year review syngenes revenue grew mn driven business momentum across three vertical discovery service dedicated centre development manufacturing service notable achievement year includes commissioning first phase syngene research centre set stateofthe art viral testing facility commissioning integrated multidisciplinary drug discovery development centre amgen syngene amgen research development centre capacity staff highly qualified scientist acquisition strand life science asset related system biology heptox pharma bioinformatics service signing strategic partnership herbalife nutrition global nutrition company set first dedicated nutrition research development lab india commissioning phase new formulation facility capable manufacturing clinical commercial supply small volume niche technology product complies regulatory requirement usfda emea authority december fire accident one syngenes research facility bangalore facility includes office lab space made approximately total revenue fire caused due chemical reaction conducted facility injury loss life part business continuity plan client related project redeployed lab enhanced shift working introduced minimize impact revenue long term structural story business robust syngene continues investment expand service offering building capacity near term investment include forward integration commercialscale manufacturing nmes proven track record effective combination scientific talent global accredited system rd infrastructure continued focus protection client intellectual property syngene remains well positioned benefit expected growth cro industry operational performance year eventful one company made lot clinical progress diverse pipeline product also delivered better financial performance group overview financial performance company given next page form part mda resource review employee employee represent cornerstone success believe good employee culture translates individual performance success shareholder light steady growth ambitious plan attracting grooming retaining talent utmost importance detailed discussion human capital provided human resource section annual report group employ people including individual outside india ipr one key focus area creation intellectual property ip generates competitive advantage also creates potential exponential enduring value patent ip portfolio biocon group company comprises patent application patent granted various jurisdiction trade mark biocon limited ip portfolio comprises trade mark application registered trademark different class various jurisdiction across world design biocon limited ip portfolio consists four design application three design registered management discussion analysis financial performance overview april company adopted new indian accounting standard commonly referred ind based ifrs principle displayed financials classified based new accounting standard previous year number fy restated reflect change consolidated balance sheet following table highlight consolidated balance sheet march fy march fy table figure million particular fy fy change asset noncurrent asset tangible intangible asset investment associate joint venture financial asset asset current tax net deferred tax asset net noncurrent asset current asset inventory financial asset current asset total equity liability equity equity share capital equity noncontrolling interest noncurrent liability financial liability provision noncurrent liability current liability financial liability income tax liability net provision current liability total noncurrent asset noncurrent asset grew primarily due investment tangible asset malaysian facility research service syngene intangible capitalisation pertaining product development expense also continued invest research service business facility investment long term security mat credit also contributed increase noncurrent financial asset equity share capital equity share capital comprises equity share face value change equity capital company year equity equity majorly comprises share premium treasury share retained earnings reserve total equity company increased fy compared fy due profit accumulation year net dividend distribution noncontrolling interest profit attributable minority shareholder increased fy attributable accumulation profit current year ahead curve annual report biocon limited noncurrent liability major movement noncurrent liability fy compared fy increase termloan obtained biocon sdn bhd offset reduction derivative liability release deferred revenue working capital current asset less current liability working capital march stood mn compared fy line volume operation consolidated statement profit loss following table highlight key component statement profit loss fiscal year ended march fy march fy table figure million particular fy fy change total revenue expense cost material consumed excise duty employee benefit expense depreciation amortisation expense finance cost expense subtotal less recovery product development cost codevelopment partner net total expense share profit joint venture profit tax exceptional item exceptional item profit tax tax expense tax exceptional item profit tax noncontrolling interest profit year comprehensive income attributable shareholder total comprehensive income attributable shareholder revenue year review revenue grew consolidated basis mn mn small molecule segment grew driven strong sale rosuvastatin immunosuppressant biologics segment achieved annual growth year year major contributor growth insulin sale malaysia trastuzumab sale emerging market including strong outlicencing opportunity also branded formulation segment showed growth resulting total revenue mn mn previous fiscal due deconsolidation joint venture uae likeforlike basis however segment marginally contract research segment syngene reported turnover mn reflecting annual growth total revenue composition fy fy detailed table fy fy fy fy particular mn mn small molecule biologics branded formulation research service revenue operation income total revenue cost material consumed material cost comprised raw material packing material traded good change inventory fy material cost percentage overall revenue operation remained consistent fy management discussion analysis employee benefit expense employee benefit expense comprise following item salary wage allowance bonus contribution provident fund contribution towards gratuity provision amortisation employee stock compensation expense welfare expense including employee insurance scheme expense increased fy driven largely increased employee strength annual increment research development expense net rd expenditure fy reduced mn mn fy amount profit loss account represented revenue exsyngene compared previous year capitalized mn taking gross rd spend mn year compared mn fy decrease rd expense account reduced spends anda development program whereas expenditure inhouse novel program increased fy estimate rd spends remain range revenue exsyngene coming year depreciation amortization fiscal depreciation amortization increased mn mn fy new facility research arm resulted additional depreciation current year finance cost finance cost fy mn contributed use foreign currency borrowing address routine operation total finance cost fy reduced mn increase interest cost term loan new term obtained fy however fy exchange difference considered borrowing cost remained nil mn fy exceptional item net year ended march biocon sa bsa biocon sdn bhd biocon malaysia entered assignment license agreement pursuant bsa transferred right interest obligation insulin analog ipr biocon malaysia consequent transfer bsa recorded net gain standalone book offered tax swiss tax law restructuring impact consolidated financial statement except tax cost mn representing tax payable bsa locally included within income tax expense year ended march exceptional item previous year comprised following consequent agreement customer resulted change nature group future obligation rhinsulin program deferred revenue mn relating program recognized income consolidated financial result year ended march disclosed exceptional item b pursuant uncertainty respect ability group license product development commercialization certain territory biocon sa recorded impairment carrying value intangible asset amounting mn impairment recognized exceptional item consolidated financial result year ended march c gain arising sale equity share respect syngene net related expense cost equity share amounting mn accounted exceptional gain standalone financial result year ended march year ended march company sold investment equity share biocon malaysia wholly owned subsidiary biocon biologics limited uk another wholly owned subsidiary company sum mn gain arising sale equity share net cost equity share amounting mn recorded exceptional item standalone financial result consequential tax mn recorded gain tax expense tax expense fiscal stood mn comparison mn fy increase account higher profit comparison previous year comprehensive income comprehensive income includes remeasurement gainslosses defined benefit plan gainlosses hedging instrument cash flow hedge increase current year primarily account gain hedging instrument amounting mn net tax arising research business group ahead curve annual report biocon limited risk threat concern risk potential event nonevent occurrence nonoccurrence adversely affect objective strategy company global pharma industry bear striking resemblance financial service industry decade ago industry landscape affected product safety quality issue intellectual property tangle inappropriate marketing practice corruption thereby leading penalty product recall brand loss revenue loss regulatory landscape international pharma industry complex dynamic primary industry driver patient health safety even regulatory approach patient protection vary market market besides factor rapid change increased scrutiny sophisticated riskmonitoring technique coordination across agency region context imperative respond holistic risk mitigation framework company carved niche back steadfastness conducting business accordance applicable law regulation well manner consistent core organizational value established risk management framework address strategic operational legal financial compliance risk inherent pharma business impact strategic goal risk management coupled robust internal control framework help company emphasize qualitative consistency employee safety longterm sustainability global pharma business marked variety risk pharmaceutical company struggle globally enforce ip protection particularly emerging market enhanced regulatory scrutiny set backdrop increasing patient advocacy social medium affiliate marketing programme digitisation proliferation electronic medical record networked medical device mobile health application cloudbased technology datasharing among industry stakeholder increased complexity managing information asset particularly protected health information intellectual property success new product global pharmaceutical industry offset global pricing pressure supporting outlook change stable positive industry although comprehensive eradication risk associated business company unfeasible constant effort made mitigate adverse impact company implemented precise methodology entailing timely identification analysis assessment risk potential consequence formulation specific mitigation strategy seamless execution enterprisewide risk evaluation validation process conducted regularly reviewed risk management committee board director government investor public demand transparency life science company covering aspect like product commercialisation executive pay financial information accuracy manufacturing process clinical trial quality several highprofile incident particularly emerging market enhanced need transparency key development comprise indian government plan involve private sector rd across vaccine drug pharmaceutical brighter side drug approval process simplified authority approval time new facility drastically reduced onus company capitalise opportunity protecting risk addition key risk relating current operation include human capital risk loss key personnel timely non replenishment critical vacant role concentration reliance third party sole supplier service provider including regional supplier reliance risk arising codevelopment arrangement disruption operation natural disaster risk arising strategic project foreign exchange fluctuation changing global political regulatory landscape change company strategy etc internal control company responsible establishing maintaining adequate effective internal control preparation presentation financial statement including assertion internal financial control accordance broader criterion established company robust comprehensive internal control system prerequisite organisation function ethically commensuration ability objective established strong internal control system company comprised policy guideline procedure adopted company ensure orderly efficient business conduct including adherence policy asset safeguarding fraud cum error prevention detection accounting record accuracy completeness timely preparation presentation reliable financial information internal control system aimed providing assurance operational effectiveness efficiency compliance law regulation asset safeguarding reliability financial management reporting company staffed experienced qualified professional play important role designing implementing maintaining monitoring internal control environment independent firm chartered accountant perform periodic internal audit provide reasonable assurance internal control effectiveness advice industrywide best practice audit committee consisting independent director review important issue raised internal statutory auditor regular basis status rectification measure ensure risk mitigated appropriately timely basis outlook fiscal exciting year biocon marked beginning new growth journey company led biologics segment coupled commencement insulin glargine product sale japan followed initiation commercial supply recombinant human insulin malaysian insulin facility progress global biosimilar pipeline continued multiple filing across various developed market syngene continued make investment expand capacity service offering taking everything consideration beginning new growth journey provided good visibility u deliver long term growth shareholder management discussion analysis corporate governance report company philosophy code governance biocon belief good corporate governance emerges application best management practice compliance law coupled highest standard integrity transparency accountability ethic business matter biocon also belief sound corporate governance critical enhance retain investor trust hence biocons business policy based ethical conduct health safety commitment building long term sustainable relationship relevant stakeholder company continues strengthen governance principle generate long term value stakeholder sustainable basis thus ensuring ethical responsible leadership board management level biocon also consider inherent responsibility disclose timely accurate information regarding financials performance well leadership governance company bioconites committed balanced corporate governance system provides framework attaining company objective encompassing practically every sphere management action plan internal control corporate disclosure company compliance requirement stipulated sebi listing obligation disclosure requirement regulation sebi lodr regard corporate governance also committed sound corporate governance principle practice constantly strives adopt emerging best corporate governance practice followed worldwide report compliance corporate governance provision prescribed sebi lodr given ii board director composition board company conformity regulation sebi lodr chairperson managing director company though professional director individual capacity promoter number independent director onehalf total number director board company kiran mazumdar shaw chairperson managing director mr john shaw vice chairman dr arun chandavarkar chief executive officer joint managing director executive director company prof ravi mazumdar non executive non independent director remaining director board company comprises six independent director march renowned professional drawn diverse field possessing requisite qualification experience general corporate management finance banking insurance economics science technology allied field enable contribute effectively company enhance quality board decision making process board aware fiduciary responsibility recognizes responsibility towards stakeholder uphold highest standard matter concerning company empowered responsible person implement broad policy guideline set adequate review process board provides strategic guidance affair company independent director provide independent objective judgement matter placed company day day affair managed chairperson vice chairman ceo assisted competent management team overall supervision board company commitment ethical lawful business conduct fundamental shared value board senior management employee board committed representing long term interest stakeholder providing effective governance company affair exercise reasonable business judgment affair company director elected based qualification experience varied field time induction director formal invitation join board sent director handbook comprising compendium role power duty performed given new director independent director annually provide certificate independence accordance applicable law taken record board board member encouraged meet interact management board member invited key meeting senior management strategic guidance advice composition board board company comprises ten director march name category director number directorship committee position held company given none director director public limited company specified section company act act act independent director listed company listed company case heshe serf wholetime director listed company specified regulation sebi lodr none director board member committee chairman committee specified regulation sebi lodr across indian public limited company heshe director ahead curve annual report biocon limited name director category director total number directorship committee chairmanship identification membership public limited company number march directorship committee committee chairmanship membership kiran mazumdarshaw promoter executive mr john shaw promoter executive dr arun chandavarkar executive prof ravi mazumdar promoter nonexecutive mr russell wall independent mary harney independent mr daniel bradbury independent dr vijay k kuchroo independent dr jeremy levin independent mr damodaran independent excludes private limited company foreign company company registered section act government body includes additional directorship directorship biocon limited committee considered audit committee stakeholder relationship committee including biocon limited kiran mazumdar shaw chairperson managing director spouse mr john shaw vice chairman wholetime director sister prof ravi mazumdar non executive director b board procedure detailed agenda sent director least day advance board committee meeting material information incorporated agenda facilitating meaningful focused discussion meeting practicable attach document agenda tabled meeting specific reference effect agenda special exceptional circumstance additional supplementary item agenda permitted enable board discharge responsibility effectively chairperson present every board meeting overall performance company board review strategy business plan annual operating capital expenditure budget investment exposure limit compliance report law applicable company well step taken company rectify instance noncompliance board also review major legal issue minute meeting various committee board subsidiary company significant transaction arrangement entered subsidiary company adoption financial result transaction pertaining purchase disposal property major accounting provision writeoffs corporate restructuring detail joint venture collaboration agreement material default financial obligation fatal serious accident material effluent pollution problem transaction involve substantial payment towards goodwill brand equity intellectual property issue involves possible public product liability claim substantial nature including judgement order may passed stricture conduct company quarterly detail foreign exchange exposure step taken management limit risk adverse exchange rate movement information recruitment senior officer board level key managerial personnel company secretary record minute proceeding board committee meeting draft minute circulated board committee member within day meeting comment director communicate comment writing draft minute within seven day date circulation minute entered minute book within day conclusion meeting signed chairperson subsequent meeting guideline board committee meeting facilitate effective post meeting followup review reporting process decision taken board committee thereof important decision taken board committee meeting communicated promptly concerned department division actiontaken report decisionsminutes previous meeting placed succeeding meeting board committee noting apart board member company secretary board committee meeting also attended chief financial officer wherever required head various corporate function c number board meeting attendance director meeting board annual general meeting agm year april march four board meeting held following date april july october january board met least every calendar quarter gap two meeting exceed one hundred twenty day meeting well attended th agm company held june corporate governance report attendance director meeting director board meeting held board meeting attendance th agm fy attended kiran mazumdarshaw yes mr john shaw yes dr arun chandavarkar yes prof ravi mazumdar mr russell wall yes mary harney mr daniel bradbury dr vijay k kuchroo dr jeremy levin mr damodaran yes shareholding nonexecutive director detail company share held non executive director march director share held march prof ravi mazumdar mr russell wall nil mary harney nil mr daniel bradbury nil dr vijay k kuchroo nil dr jeremy levin nil mr damodaran nil joint holding spouse e meeting independent director independent director company met year without presence nonindependent director member management meeting conducted informal flexible manner enable independent director inter alia discus matter pertaining review performance non independent director board whole review performance chairperson company taking account view executive nonexecutive director assess quality quantity timeliness flow information company management board necessary board effectively reasonably perform duty f detail familiarisation programme imparted independent director year independent director apprised frequent interval industry trend business model overview company operation senior management team various business unit head made presentation independent director periodic interval performance future strategy respective business unit independent director also regularly appraised regulatory policy change including role right responsibility presentation internal control financial reporting operational control financial reporting prevention insider trading regulation sebi lodr framework related party transaction etc made board member year company familiarisation policy detail programme attended hour spent independent director financial year available company website httpwwwbioconcomdocsfamiliarisation_programme_fypdf iii committee board board constituted various committee focus specific area make informed decision within authority committee directed charter outline scope role responsibility power decision recommendation committee placed board approval company guideline relating board meeting applicable committee meeting far practicable committee authority engage outside expert advisor counsel extent considers appropriate assist function senior officer functional head company invited present various detail called committee meeting various committee board audit risk committee nomination remuneration committee stakeholder relationship committee corporate social responsibility committee ahead curve annual report biocon limited audit risk committee brief description term reference power role term reference audit risk committee line provision section act part c schedule ii sebi lodr audit risk committee discharge duty function generally indicated regulation sebi lodr company act function may specifically assigned board time time company put place enterprise wide risk management framework overseen audit risk committee holistic approach provides assurance best capability company business unit identify assess mitigate risk could materially impact performance achieving stated objective committee ensures company taking appropriate measure achieve prudent balance risk reward ongoing new business activity review strategic decision company regular basis review company portfolio risk considering company risk appetite committee also recommend change appropriate risk management technique andor associated framework process practice company ii composition following director member committee mr russell wall chairman mr daniel bradbury dr jeremy levin mr damodaran member committee independent director committee member possess sound knowledge account finance audit governance legal matter senior staff account finance department representative statutory internal auditor attend audit risk committee meeting company secretary act secretary committee chairman audit risk committee mr russell wall present last annual general meeting held june iii meeting attendance year year committee met time april july october january attendance meeting member meeting held attended mr russell wall mr daniel bradbury dr jeremy levin mr damodaran mr damodaran appointed member audit risk committee board meeting held april committee good governance practice also meet external auditor internal auditor chief financial officer company private know independent opinion performance company b stakeholder relationship committee brief description term reference term reference stakeholder relationship committee line provision section act part schedule ii sebi lodr stakeholder relationship committee primarily responsible redressal shareholder investor security holder grievance including complaint related transfer share nonreceipt declared dividend annual report etc ii composition following director member committee mr daniel bradbury chairman mr russell wall prof ravi mazumdar member committee nonexecutive director majority independent mr rajiv balakrishnan company secretary compliance officer company corporate governance report iii meeting attendance year year committee met time april july october january attendance meeting member meeting held attended mr daniel bradbury mr russell wall prof ravi mazumdar year complaint received resolved satisfaction investor march outstanding complaint investor quarterly statement investor complaint received disposed filed stock exchange within day end quarter statement filed also placed subsequent meeting board director c corporate social responsibility committee brief description term reference term reference committee line provision section act committee prime responsibility assist board discharging social responsibility way formulating monitoring implementing framework line corporate social responsibility policy company ii composition following director member committee mary harney chairperson dr vijay k kuchroo prof ravi mazumdar member committee nonexecutive director majority independent iii meeting attendance year year committee met twice april october attendance meeting member meeting held attended mary harney dr vijay k kuchroo prof ravi mazumdar nomination remuneration committee brief description term reference term reference nomination remuneration committee line provision section act part schedule ii sebi lodr nomination remuneration committee vested authority inter alia recommend nomination board membership develop recommend policy respect composition board commensurate size nature business operation company establish criterion selection board member respect competency qualification experience track record integrity devise appropriate succession plan determine overall compensation policy company scope committee also includes review market practice decide remuneration package executive director lay performance parameter chairperson managing director executive director senior management key managerial personnel etc review addition committee role includes identifying person may appointed senior management accordance criterion laid recommending board appointment removal committee also formulates criterion determining qualification positive attribute independence director recommends board periodically policy relating remuneration director key managerial personnel employee committee also carry separate exercise evaluate performance individual director feedback sought way structured questionnaire covering various aspect board functioning adequacy composition board committee board culture execution performance specific duty obligation governance performance evaluation carried based response received director ahead curve annual report biocon limited performance evaluation independent director based various criterion including experience expertise independent judgment ethic value adherence corporate governance norm interpersonal relationship attendance contribution meeting etc ii composition following director member committee mary harney chairperson dr vijay k kuchroo prof ravi mazumdar kiran mazumdar shaw majority member committee nonexecutive director half committee composition consist independent director iii meeting attendance year year committee met thrice april october january attendance meeting member meeting held attended mary harney dr vijay k kuchroo prof ravi mazumdar kiran mazumdar shaw kiran mazumdar shaw appointed member nomination remuneration committee board meeting held april attended invitee iv remuneration director remuneration policy company welldefined policy remuneration director key managerial personnel employee policy furnished annexure iii board report element remuneration package executive director includes fixed variable salary performance bonus contribution provident fund superannuation gratuity perquisite allowance reimbursement expense etc applicable employee company executive director employee company subject service condition per company policy two month notice period period mutually agreed separate provision payment severance fee executive director non executive director independent director paid remuneration form commission apart sitting fee subject notice period severance fee b remuneration nonexecutive director pursuant approval granted shareholder company th agm held th july independent director paid commission upto maximum net profit company financial year computed manner laid act subject limit independent director eligible commission outlined participation various meeting meeting various performance parameterscriteria including restricted participation contribution director commitment guidance provided senior management outside board committee meeting effective deployment knowledge expertise effective management relationship various stakeholder independence behaviour judgment etc set nomination remuneration committee sl particular amount usd commission attending board meeting commission attending audit risk committee meeting chairman member commission attending nomination remuneration committee meeting chairman member commission attending corporate social responsibility committee meeting chairman member besides commission foreign independent director paid travel allowance usd case travel united state usd case travel country attending meeting non executive director paid consolidated sitting fee attending board committee meeting company also reimburses outofpocket expense incurred director attending meeting non executive director bring significant professional expertise rich experience across wide spectrum functional area marketing technology corporate strategy legal finance corporate function company seek expert advice various matter science corporate governance report technology legal governance matter pecuniary relationship transaction nonexecutive director vi avis company financial year c remuneration executive director shareholder th agm appointed kiran mazumdar shaw chairman managing director period five year effective april certain term condition including remuneration subject limit net profit company remuneration includes fixed variable salary performance bonus contribution provident fund superannuation gratuity perquisite allowance reimbursement expense etc applicable employee company mr john shaw appointed whole time director designated vice chairman company shareholder nd agm certain term condition including remuneration comprising fixed variable salary performance bonus contribution provident fund superannuation gratuity perquisite allowance reimbursement expense etc applicable employee company shareholder th agm increased remuneration mr john shaw subject limit net profit company dr arun chandavarkar appointed ceo joint managing director period five year effective april shareholder th agm certain term condition including remuneration comprising fixed variable salary performance bonus contribution provident fund superannuation gratuity perquisite allowance reimbursement expense etc applicable employee company detail remuneration paid director year ended march given amount million director salary perquisite others fixed pay bonus perquisite retiral benefit commission sitting fee total kiran mazumdar shaw mr john shaw dr arun chandavarkar prof ravi mazumdar mr russell wall mary harney mr daniel bradbury dr vijay k kuchroo dr jeremy levin mr damodaran perquisite valued per income tax act dr arun chandavarkar granted restricted stock unit rsus company subsidiary syngene international limited april nil exercise price doesnt form part remuneration shown rsus shall vest period year date grant year rsus exercised dr arun chandavarkar option company esop plan granted executive nonexecutive director financial year v general body meeting annual general meeting date time location annual general meeting held last three year special resolution passed follows year date time venue special resolution passed july tyler jack auditorium biocon research centre approval enhancement borrowing limit creation pm plot biocon sez bommasandra jigani link road charge bengaluru july tyler jack auditorium biocon research centre amendment article association company pm plot biocon sez bommasandra jigani link road implementation esop plan esop trust bengaluru acquisition share esop trust secondary market june tyler jack auditorium biocon research centre appointment statutory auditor pm plot biocon sez bommasandra jigani link road approval new grant company esop plan bengaluru special resolution passed postal ballot special resolution passed postal ballot fy board meeting held april proposes seek approval shareholder special resolution increasing authorised share capital company consequent amendment memorandum association way postal ballot none business proposed transacted ensuing agm requires passing special resolution postal ballot ahead curve annual report biocon limited ii procedure postal ballot compliance provision section act read applicable rule company provides electronic voting evoting facility member company engages service karvy computershare private limited karvy purpose providing evoting facility member member option vote either physical ballot evoting company dispatch postal ballot notice form along postage prepaid business reply envelope member whose name appear register member list beneficiary cutoff date postal ballot notice sent member electronic form email address registered depository participant case electronic shareholding registered address member case physical shareholding company also publishes notice newspaper declaring detail completion dispatch requirement mandated act applicable rule voting right reckoned paidup value share registered name member cutoff date member desiring exercise vote physical postal ballot form requested return form duly completed signed scrutinizer close voting period member desiring exercise vote electronic mode requested vote close business hour last date evoting scrutinizer submits report chairman completion scrutiny consolidated result voting postal ballot announced chairman director company company secretary result also displayed company website wwwbioconcom besides communicated stock exchange depository registrar share transfer agent date declaration postal ballot result shall date resolution would deemed passed approved requisite majority b mean communication quarterly result quarterly financial result published financial express vijayavani kannada edition also displayed company website www bioconcom ii news release presentation official news press release sent stock exchange displayed company website wwwbioconcom iii presentation institutional investor analyst presentation made institutional investor financial analyst quarterly financial result company presentation also uploaded company website wwwbioconcom sent stock exchange schedule meeting institutional investor financial analyst intimated advance stock exchange disclosed company website iv website company website wwwbioconcom contains separate dedicated section investor shareholder information available information press release notice board meeting outcome board meeting revision credit rating clipping newspaper publication etc uploaded website company annual report also uploaded website userfriendly downloadable form v nse electronic application processing system neap neap webbased application designed nse corporates periodical compliance filing like shareholding pattern corporate governance report medium release etc filed electronically neap vi bse corporate compliance listing centre listing centre b listing centre webbased application designed corporates periodical compliance filing like shareholding pattern corporate governance report medium release etc filed electronically listing centre vii sebi complaint redress system score investor complaint processed centralized webbased complaint redressal system centralized database complaint received online upload action taken report atrs company online viewing investor action taken complaint current status updated resolved electronically sebi score system vi general shareholder information company registration detail company registered state karnataka india corporate identity number cin allotted company ministry corporate affair mca lkaplc corporate governance report b annual general meeting date time friday july pm venue tyler jack auditorium biocon research centre plot biocon sez bommasandra jigani link road bengaluru financial year april march dividend payment date creditdispatch dividend warrant approved member meeting would made july august date book closure saturday july friday july day inclusive financial result calendar q fy july q fy october q fy january q fy april date tentative listed stock exchange national stock exchange india limited exchange plaza bandrakurla complex bandra e mumbai bse limited p j tower dalal street mumbai stock codesymbol nse biocon bse international security identification number ine g payment annual listing fee stock exchange paid market price data monthly high low closing price volume share company april march given month bse nse high price low price volume equity high price low price volume equity share share apr may jun jul aug sep oct nov dec jan feb mar ii performance comparison broad based index chart show performance company share price comparison broad based index bse sensex nse nifty biocon management caution stock price movement shown graph considered indicative potential future stock price performance ahead curve annual report biocon limited biocon bse sensex share price movement april march r v c p ay g ar b n n l ap oc de ju au se fe ju ja biocon bse sensex close note share price biocon limited bse sensex indexed april biocon p nifty share price movement april march r l v c p n n ay g ar b ap oc de ju au se fe ju ja biocon nse nifty close note share price biocon limited nse nifty indexed april iii share transfer system share transfer processed share certificate duly endorsed returned within period fifteen day date receipt subject document valid complete respect stakeholder relationship committee delegated authority approving transfer transmission etc company security share transfer committee consisting kiran mazumdar shaw chairperson managing director mr john shaw vice chairman wholetime director company summary transfertransmission security company approved share transfer committee placed every stakeholder relationship committee meeting company obtains company secretary practice halfyearly certificate compliance share transfer formality required sebi lodr file copy said certificate stock exchange iv dematerialization share liquidity equity share company electronic form march trading equity share company permitted dematerialized form company equity share actively traded nse bse substantial increase daily trading activity company equity share witnessed fy compared fy corporate governance report v distribution shareholding category wise march category share equity promoter indian foreign foreign institutional investor mutual fund bank ifis nris foreign national corporate body trust indian public others total vi distribution shareholding number share march category holder holder share equity total vii outstanding adrsgdrswarrants convertible instrument conversion date likely impact equity company issued adrsgdrs warrant convertible instrument viii commodity price risk foreign exchange risk hedging activity input pricing risk managed appropriate long term rate contract constant evaluation alternate support source key raw material company approved foreign exchange risk management policy accordingly year ended march company managed foreign exchange risk hedged extent considered necessary detail foreign currency exposure hedging disclosed note standalone financial statement ix plant location th km hosur road biocon park plot plot electronics city po plot ida phaseii pashamylaram road jn pharma city ida bengaluru bommasandra jigani link road medak district parvada vishakapatnam bengaluru andhra pradesh india x address correspondence financial disclosure medium corporate communication mr siddharth mittal seema ahuja president finance chief financial officer head corporate communication tel tel email id siddharthmittalbioconcom email id seemaahujabioconcom investor relation institutional investor research analyst registrar share transfer agent mr saurabh paliwal karvy computershare private limited head investor relation unit biocon limited tel plot karvy selenium tower b gachibowli financial district email id investorrelationsbioconcom nanakramguda hyderabad email id einwardriskarvycom corporate governance compliance registered office mr rajiv balakrishnan biocon limited company secretary compliance officer th k hosur road tel electronics city po bengaluru email id cosecretarybioconcom ahead curve annual report biocon limited company also designated cosecretarybioconcom exclusive email id purpose investor servicing registering complaint displayed company website c disclosure materially significant related party transaction financial year materially significant transaction arrangement entered company promoter management director relative subsidiary etc may potential conflict interest company large company formulated policy dealing related party transaction specify manner entering related party transaction policy also posted website company accessed web link httpwwwbioconcomdocspolicydocument_relatedpartytransaction_ pdf ii detail noncompliance last three year instance noncompliance company related capital market penalty stricture imposed company stock exchange sebi statutory authority company also complied requirement corporate governance report para mentioned part c schedule v sebi lodr disclosed necessary information specified regulation regulation b appropriately annual report iii vigil mechanism whistle blower policy vigil mechanism envisaged act rule prescribed thereunder sebi lodr implemented company whistle blower policy provide adequate safeguard victimisation person use mechanism make provision direct access chairperson audit committee address chairman audit risk committee given policy employee director vendor supplier stakeholder associated company report matter concern whistle blower policy company available website company accessed web link httpwwwbioconcomdocsbiocon_group_integrity_whistle_blower_policypdf iv compliance nonmandatory requirement apart complying mandatory requirement prescribed sebi listing obligation disclosure requirement regulation company complied nonmandatory requirement year review audit qualification company financial statement company continues adopt best practice ensure regime unqualified financial statement post chairperson managing director chief executive officer separately held internal auditor report directly audit risk committee v material subsidiary company subsidiary board managed respective board right obligation manage company best interest stakeholder audit risk committee review financial statement particular investment made unlisted subsidiary company minute board meeting unlisted subsidiary company placed reviewed periodically company board statement containing significant transaction arrangement entered unlisted subsidiary company placed company board periodically company formulated policy determining material subsidiary defined regulation sebi lodr policy also posted website company accessed web link httpwwwbioconcomdocspolicydocument_materialsubsidiarypdf vi disclosure respect demat suspense account unclaimed suspense account company security demat suspense accountunclaimed suspense account vii code conduct code conduct code board member senior management personnel adopted board comprehensive code applicable director senior management personnel code lay detail standard business conduct ethic strict governance norm board senior management personnel copy code put company website wwwbioconcomthe code circulated director senior management personnel compliance affirmed annually declaration signed company chief executive officer effect published report viii code prevention insider trading practice company formulated comprehensive code conduct prevention insider trading designated person compliance security exchange board india prohibition insider trading regulation amended time time director officer designated person connected person company governed code ix disclosure senior management personnel senior management company made disclosure board confirming material financial commercial transaction personal interest may potential conflict interest company large corporate governance report x ceocfo certification chief executive officer ceo chief financial officer cfo company furnished board requisite compliance certificate regulation sebi lodr financial year ended march declaration code conduct biocon group committed conducting business accordance applicable law rule regulation highest standard business ethic company adopted code ethic business conduct applicable director officer employee hereby certify board member senior management personnel company affirmed compliance code ethic business conduct year biocon limited sd bengaluru dr arun chandavarkar april chief executive officer space intentionally left blank ahead curve annual report biocon limited auditor certificate corporate governance member biocon limited examined compliance condition corporate governance biocon limited year ended march per regulation clause b regulation paragraph c e schedule v security exchange board india listing obligation disclosure requirement regulation listing regulation management responsibility company management responsible compliance condition corporate governance requirement stipulated listing regulation responsibility includes design implementation maintenance corporate governance process relevant compliance condition responsibility also includes collecting collating validating data designing implementing monitoring corporate governance process suitable ensuring compliance mentioned listing regulation auditor responsibility pursuant requirement mentioned listing regulation examination limited procedure implementation thereof adopted company ensuring compliance condition corporate governance neither audit expression opinion financial statement company conducted examination corporate governance compliance company per guidance note report certificate special purpose revised issued institute chartered accountant india icai guidance note requires comply ethical requirement code ethic issued icai complied relevant applicable requirement standard quality control sqc quality control firm perform audit review historical financial information assurance related service engagement opinion opinion best information according explanation given u certify company complied condition corporate governance per regulation clause b regulation paragraph c e schedule v listing regulation applicable state compliance neither assurance future viability company efficiency effectiveness management conducted affair company restriction use certificate solely issued purpose complying aforesaid regulation may suitable purpose accordingly accept assume liability duty care purpose person report shown whose hand may come save expressly agreed prior consent writing b r co llp chartered accountant firm registration number ww sethuraman partner membership number place bengaluru date april corporate governance report business responsibility report pursuant regulation f security exchange board india listing obligation disclosure requirement regulation section general information company corporate identity number cin company lkaplc name company biocon limited registered address th km hosur road electronic city bangalore website wwwbioconcom email id cosecretarybioconcom financial year reported sector company engaged industrial activity codewise industrial group description manufacture pharmaceutical medicinal chemical botanical product per national industrial classification ministry statistic programme implementation list three key productsservices company manufacturesprovides balance sheet statin ii immunosuppressant iii insulin total number location business activity undertaken company number international location united state america switzerland united kingdom malaysia dubai b number national location manufacturing location bengaluru hyderabad vishakhapatnam marketing office india market served company localstatenationalinternational addition serving indian market company global footprint serf market country section b financial detail company paid capital million total turnover million total profit tax million total spending corporate social responsibility csr percentage profit tax list activity expenditure incurred refer annexure board report csr activity section c detail company subsidiary company company yes company subsidiary march subsidiary companycompanies participate br initiative parent company yes indicate number subsidiary company yes company subsidiary biocon academy participates br initiative company entityentities eg supplier distributor etc company business participate br initiative company yes indicate percentage entityentities less per corporate risk governance process supplier distributor work closely supply chain several risk mitigation program including business continuity plan geographic risk mitigation reducing environmental burden using recycled solvent training user team inside company manage product functioning related hazard product specific product handling usage procedure set supplier required followed ahead curve annual report biocon limited section br information detail directordirectors responsible br detail directordirectors responsible implementation br policypolicies din number ii name dr arun chandavarkar iii designation ceo joint managing director b detail br head particular detail din number applicable name dr arun chandavarkar designation ceo joint managing director telephone number email id arunchandavarkarbioconcom principlewise per nvgs br policypolicies p business conduct govern ethic transparency accountability p business provide good service safe contribute sustainability throughout life cycle p business promote wellbeing employee p business respect interest responsive towards stakeholder especially disadvantaged vulnerable marginalized p business respect promote human right p business respect protect make effort restore environment p business engaged influencing public regulatory policy responsible manner p business support inclusive growth equitable development p business engage provide value customer consumer responsible manner space intentionally left blank business responsibility report detail compliance reply yn question p p p p p p p p p ethic product wellbeing responsiveness respect environmental public support inclusive engagement transparency responsibility stakeholder human responsibility policy growth customer employee right advocacy policy policy n policy formulated n consultation relevant stakeholder policy conform n n national international standard yes specify word policy approved n board yes signed md owner ceo appropriate board director company n n specified committee board ahead curve annual report director official oversee implementation policy indicate link policy refer refer refer httpwwwbiocon n httpwwwbiocon httpwwwbioconcom viewed online table table table combiocon_aboutus_ combiocon_csr_ biocon_invrelation_cor_ ehspolicyasp about_policyasp codeaspsublinkgover policy formally n communicated relevant internal external stakeholder company inhouse n structure implement policy policy policy uploaded local intranet company n grievance redressal mechanism related policy policy address stakeholder grievance related policy policy company carried n n n independent audit evaluation working policy internal external agency note company doesnt formal stakeholder responsiveness policy however specific stakeholder engagement policy exist like biocon communication policy social medium policy internal external stakeholder also outline issue management crisis communication sop company practice upload policy biospace intranet site information implementation internal stakeholder note public policy advocacy yet formulated however company play strong role public policy advocacy regular engagement specific external stakeholder including industry association government body regulatory department biocon limited principle business conduct principle business promote principle business respect govern ethic transparency wellbeing employee promote human right accountability code conduct code conduct code conduct standing order employment policy standing order company practice upload policy intranet site information implementation internal stakeholder however code conduct integrity policy applicable internal external stakeholder available company website wwwbioconcom governance related br indicate frequency board director committee board ceo meet assess br performance company within month month annually year corporate social responsibility committee board meet interval six month assess br performance company ii company publish br sustainability report hyperlink viewing report frequently published maiden br report published annually part company annual report compliance provision sebi listing obligation disclosure requirement regulation hyperlink viewing report httpwwwbioconcombiocon_invrelation_annualreportsaspsublinkfinance section e principle wise performance principle business conduct govern ethic transparency accountability policy relating ethic bribery corruption cover company yes extend groupjoint venture supplier contractorsngos others extends groupjoint venturescontractors etc many stakeholder complaint received past financial year percentage satisfactorily resolved management provide detail thereof word closed pending management review yet commence investigation total received end march company hotline whistle blowing concern voiced complaint received addressed accordingly authorized official principle business provide good service safe contribute sustainability throughout life cycle list product service whose design incorporated social environmental concern risk andor opportunity anticholesterol agent human insulin immunosuppresants product provide following detail respect resource use energy water raw material etc per unit productoptional reduction sourcingproduction distribution achieved since previous year throughout value chain biocon belief behaviour practice throughout value chain contribute sustainability company prefers enter long term commitment supplier fulfil responsibility towards society well environment initiative taken improve awareness legal compliance enhance ecofriendly efficiency packaginglogistics improvement supplier end supplier transporter meet held periodical basis company engages encourages undertake sustainable practice across supply chain company drive distribution plan using erp enterprise resource planning system optimize freight cost approach add value manner product affordable accessible practice also sustainable equitable along spreading wellness product also work welfare neighbourhood economy sourcing local material labour wherever possible local sourcing also environmentally sustainable option decrease logistics significantly reduces carbon footprint business responsibility report b reduction usage consumer energy water achieved since previous year company manufacture distributes world class manufacturing facility wide range small molecule biosimilars fermentation based product diverse product portfolio complex production process calculating environmental performance per product pose unique challenge however company taken several measure reduce consumption energy water biocon adopted principle natural resource conservation reuse reduce recycle waste minimization renewable energy manufacturing unit certified ohsas iso standard waste generated company operation either recycled disposed responsible way line legal requirement manufacturing facility zero discharge facility wastewater recycled reused back process utility water consumption form important part agenda manufacturing unit across india effort continuously underway reduce fresh water consumption company procedure place sustainable sourcing including transportation yes percentage input sourced sustainably also provide detail thereof word yes company formulated operating procedure approve vendor material procured approved vendor local international quality assurance team company conduct periodic audit vendor especially supply key material various parameter towards evaluating business sustainability integrated scm function encompasses multiple product vertical manufacturing location revolves around meticulous planning smart sourcing disciplined monitoring initiative place sustainable sourcing sourcing vendor consolidation believe strategic supplier interest business best minimum touchpoints multiple level help driving common corporate message across without fly multiple channel towards sourcing strategy consolidated plant bengaluru headquarters strive achieve balance benefit centralization decentralization ii consolidating vendor also help u keeping transaction minimum thereby minimizing operational load consolidating requirement also help better planning effective negotiation b green supply chain biocon made tremendous stride moving animalorigin recombinant supply base key product portfolio includes insulin believe contributed significantly environment friendly initiative apart social cause ii sourcing team biocon focus use green solvent nonpetrochemicals based eg ethanol majority business unit thereby reducing dependency nonrenewable form energy iii deployment professional regulatory compliant logistics provider help consolidating solvent delivery help achieving reduction fuel cost per unit solvent consumed biocon c periodic vendor evaluation supplier small medium large periodically evaluated basis supply performance matrix used evaluate include otif ontime infull delivery number quality complaint ii conduct monthly review supply chain function address issue supplier iii also entrusted vendor evaluation rd party international agency like dun bradstreet company taken step procure good service local small producer including community surrounding place work yes step taken improve capacity capability local small vendor yes biocon always strived work develop small medium enterprise around area operation company procures considerable part good avail service local small vendor particularly located around manufacturing location total supplier base small medium enterprise also strong corporate directive develop sourcing capability locally enables u achieving multiple benefit like shorter turnaround time delivery b quicker resolution issue pertaining material quality c contribute local economy thereby enhancing sustainability operation besides also help long term capacity planning vendor sharing forecast upto month ahead curve annual report biocon limited company mechanism recycle product waste yes percentage recycling product waste separately also provide detail thereof word yes mechanism recycling product well waste place company since company zero liquid discharge facility wastewater recycled reused back process utility stp treated water used gardening company premise thereby reducing usage fresh water hyderabad unit managed reduce water consumption around used solvent recovered part reused internally reduce usage fresh solvent rest sent recycling authorized recyclers effort made strengthen recovery process biologics b small molecule c cross functional project drive reduction utility solvent novel technology platform help making significant progress towards long term reduction consumption fresh solvent principle business promote wellbeing employee company committed promote diversity work place recognize right heard provide equal opportunity employee regardless race colour religion age gender sexual orientation national origin disability factor may covered local labour law child labour unpaid form involuntary labour encouraged employee right work environment free form discrimination considered harassing coercive disruptive particularly behaviour tantamount sexual harassment company ensures providing safe healthy clean working environment employee employee provided transport canteen facility subsidised price employee engagement activity conducted regularly maintain healthy work environment comprehensive health checkup mandatory employee annually company ensures timely fair payment wage accordance applicable law standard wellbeing employee priority company necessary step taken ensure please indicate total number employee ii please indicate total number employee hired temporarycontractualcasual basis iii please indicate number permanent woman employee iv please indicate number permanent employee disability employee association recognized management percentage permanent employee member recognized employee association na please indicate number complaint relating child labour forced labour involuntary labour sexual child labour nil harassment last financial year pending end financial year forced labour nil involuntary labour nil sexual harassmentsh sh pending closure received mar percentage mentioned employee given safety skill upgradation training last year skill upgradation safety permanent employee permanent woman employee casualtemporarycontractual employee employee disability principle business respect interest responsive towards stakeholder especially disadvantaged vulnerable marginalized company mapped internal external stakeholder yesno yes stakeholder mapped key category government regulatory authority ii employee iii customer iv local community v investor shareholder vi supplier business responsibility report company identified disadvantaged vulnerable marginalized stakeholder yes company identified disadvantaged marginalized stakeholder biocon foundation csr arm work marginalized underserved community promote social economic inclusion ensuring marginalized community equal access healthcare service educational opportunity special initiative taken company engage disadvantaged vulnerable marginalized stakeholder provide detail thereof word biocons csr initiative vision promote social economic inclusion ensuring marginalised community equal access healthcare service educational opportunity healthcare focused primary healthcare establishing e laj smart clinic ensure rural poor access efficient health management via competent clinical care generic medicine standard diagnostic test also provide service early detection prevention non communicable disease like cancer diabetes hypertension primary objective program eliminate health disparity among poor address social determinant health develop care pathway educate disseminate information health wellbeing education since education hold key progress biocon made concentrated effort empower rural indian youth aiming provide computer aided learning extracurricular activity life skill education english language skill rural child foundation spearheaded several education program chinnara ganitha seek strengthen learning basic math concept aata paata wadi afterschool resource center child local government school kelsa initiative try inexpensively reach lowincome staff biocons campus community development foundation also provides support infrastructure village like community centre primary health clinic proper sanitation safe drinking water rain water harvesting facility water purification system etc importantly biocon built new village resettle villager mangalgudda north karnataka washed away flood year ago company effort directed constructing new house equipped toilet solar light house principle business respect promote human right policy company human right cover company extend groupjoint venture supplier contractor ngo others extends groupjoint venture contractor etc many stakeholder complaint received past financial year percent satisfactorily resolved management received financial year resolved financial year percentage satisfactorily resolved principle business respect protect make effort restore environment policy related principle cover company extends groupjoint venture supplier contractorsngosothers yes biocon well defined environment health safety policy place motivate employee minimize environmental impact prevent injury ill health workplace cover internal external stakeholder extends group joint venture supplier contractor stakeholder like ngo work u policy communicated stakeholder ensure compliance policy adherence ehs policy emphasized stake holder top management well appropriate communication within company company strategy initiative address global environmental issue climate change global warming etc yn yes please give hyperlink webpage etc yes commitment pertaining global warming climate change biodiversity clearly stressed company ehs policy relevant project initiative place hyperlink webpage httpwwwbioconcombiocon_aboutus_ehspolicyasp company identify assess potential environmental risk yn yes aspect impact identification methodology place assess identify environmental risk activity new project modification ahead curve annual report biocon limited company project related clean development mechanism provide detail thereof word also yes whether environmental compliance report filed date company project registered clean development mechanism cdm company various project related clean technology strive identify cdm potential project project line cdm methodology company switching piped natural gas fuel boiler instead conventional fossil fuel thus reducing ghg emission usage biogas generated effluent treatment unit anaerobic digester cofuel boiler usage solar energy water heating lighting purpose power requirement sourced wind energy currently exploring opportunity registering cdm project near future company undertaken initiative clean technology energy efficiency renewable energy etc yn yes please give hyperlink web page etc yes energy efficiency clean technology renewable energy project implemented site installation energy efficient centrifugal air compressor ii installation led lighting replace fluorescent lamp iii power trading indian energy exchange iv installation energy efficient air blower motor v reduction co emission using png piped natural gas steam generation vi power requirement sourced wind energy vii installation solar powered lighting viii installation waste steam recovery system intranetlink httpsbionetinbioconcomceehsirbp_layoutswopiframeaspxsourcedocceehsirbpmanagement_review_report mrm reportmrmmrmpdfpdfactiondefault emissionswaste generated company within permissible limit given cpcbspcb financial year reported yes air emission waste generated company well within permissible limit prescribed environmental regulator reported last financial year number show causelegal notice received cpcbspcb pending ie resolved satisfaction end financial year show causelegal notice received cpcbspcb pending end financial year principle business engaged influencing public regulatory policy responsible manner company member trade chamber association yes name major one business deal cii idma kdpma karnataka chamber commerce advocatedlobbied association advancement improvement public good yesno yes specify broad area drop box governance administration economic reform inclusive development policy energy security water food security sustainable business principle others pioneering biotechnology company biocon engages various stakeholder including various government department facilitate progressive pragmatic policy address daunting healthcare challenge country biocons cmd kiran mazumdar shaw biotech pioneer well regarded globally passionate enabling affordable healthcare therefore contributes selflessly towards creating enabling ecosystem promotes science encourages startup enables access affordable universal healthcare biocons ceo also chairperson national cii committee biotechnology engages government enable creation optimal biotech ecosystem principle business support inclusive growth equitable development company specified programmesinitiativesprojects pursuit policy related principle yes detail thereof biocon belief corporate social responsibility lie creating comprehensive integrated ecosystem deliver affordable effective healthcare less privileged among india rural urban population also support education initiative impart better learning underprivileged student rural school empower community providing proper infrastructure self sustained village health centre community centre school sanitation water source light business responsibility report understand csr effort must collaborative concentrated comprehensive must integrate private public sector participation permeate social stratum expand radius reach grassroots level poorest underserved citizen primary healthcare service elaj based core principle integrated healthcare service biocon foundation introduced elaj smart clinic across karnataka rajasthan clinic state art diagnostic equipment clinic patient management software along doctor technician eclinics provide access preventive primary healthcare supported robust screening early detection program digital record patient case file elaj electronic medical record system multi parameter monitor mpm clinic collect following vitals blood pressure temperature random blood sugar spo pulse rate height weight preventive healthcare biocon foundation primary healthcare program well supported population based screening programme specialist clinic early detection prevention oral cancer mhealth program eighty percent burden oral cancer occurs lowresource setting due delayed presentation community approach ensure last mile reach critical making program impactful biocon foundation introduced mhealth approach mobile health connect specialist remote rural population implemented since program reached around people individually obtained risk profile image lesion electronically program empowered community health worker capable identifying oral lesion monitoring high risk group biocon running several pilot government karnataka gok facilitate integration government screening program detection prevention cervical cancer screening high incidence cervical cancer among indian woman growing public health concern biocon foundation addressed since may developing comprehensive program look towards preventive mechanism also provides support service free screening subsidized treatment program focus community information education b conducting monthly screening service includes pap smear pelvic breast bimanual examination c effective followup referral diagnosis andor treatment service tertiary care centre breast cancer screening biocon foundation introduced hand held device called intelligent breast exam ibe order conduct breast screening field practice area designed geography cancer case detected later stage limited access early detection breast cancer device accuracy detect clinically relevant breast lesion higher device easily used healthworker doctor pain free process without radiation device helped health worker conduct house house breast cancer screening diabetes hypertension built successfully executed multipronged holistic strategy manage non communicable disease focus diabetes hypertension health promotion prevention strategy conducted community encourage healthy life style reduce incidence integrated risk factor addition incorporated psychosocial counselling meet emotional social mental health need patient conduct early diagnosis combination periodic opportunistic screening community provide handholding referral required balaspandana management malnutrition program support government anganwadis ensuring child severe acute malnutrition sam child receive regular health check ups prescribed medicine nutritional supplement program reached malnourished child age year bagalkot district karnataka education company spearheaded several education program chinnara ganitha seek strengthen learning basic math concept aata paata wadi afterschool resource centre child local government school kelsa initiative provides access internet connected computer encourages informal selfpaced learning program run support staff company community development community school sanitation line swachh bharat mission swachh vidyalaya program constructed toilet government primary school anekal taluk near bangalore badami bagalkot district also built plus household toilet anekal bagalkot district karnataka ahead curve annual report biocon limited project one project one community drinking water initiative program installed water purification system ro uv technology provide potable drinking water community serve system capacity purifying litre water one hour provide drinking water community member installed community water point location biocon nagar biocon nagar village consists house built biocon foundation mangalgudda community displaced flood house solar light independent toilet foundation built clinic community provides medical consultation medicine diagnostic test school community centre also built girl hostel biocon foundation collaboration shri vr deshpande memorial trust established lady hostel economically weaker section society haliyal north karnataka hostel dormitory provision woman young girl surrounding distant village come haliyal learn vocational skill hostel provides safe free accommodation biocon academy established biocon academy centre excellence advanced learning applied bio science platform provides industry oriented training program make student industry ready programmesprojects undertaken inhouse teamown foundationexternal ngogovernment structuresany organization csr initiative primarily implemented house grant provided ngo impactful work foundation carried program domain healthcare education community development past year also support ngo small grant implement project done impact assessment initiative impact assessment conducted continuously program interval program primary healthcare program monitored assessed continuous basis live dashboard snapshot information dashboard annual patient footfall recorded across clinic biocon foundation clinic government rajasthan primary health centre government karnataka primary health centre disease profile community populated dashboard help public health planning developing better public health policy listing patient suffering disease also made available facilitate follow control rate non communicable disease ncds compliance medication progress illness monitored patient counselled frequently effective follow referral patient visiting clinic possible clinic created complete care pathway address health concern community accuracy elaj data data presentation elaj dashboard project evaluation also impact indicator project company direct contribution community development project amount inr detail project undertaken refer annexure board report corporate social responsibility taken step ensure community development initiative successfully adopted community please explain word yes step taken ensure program successfully adopted community illustrated example increase patient footfall clinic show community using service tried strengthen preventive primary health service reduce burden larger tertiary centre reduce number patient regular awareness sensitization program conducted beneficiary dedicated team health worker last mile reach community use iec material train educate health worker create awareness amongst beneficiary disease screening program doctor consultation lab test medicine provided subsidized cost noncommunicable disease health promotion prevention strategy conducted community encourage healthy life style reduce incidence integrated risk factor introduced diabetes educator counsellor help patient key selfcare point diet exercise drug compliance optimal management blood sugar behaviour change education given care giver malnourished child health camp regular growth monitoring nourished child facilitated upward growth trend child business responsibility report rigorous training care giver malnourished child providing nutritional supplement growth monitoring nourished child health camp reduced outlier cancer screening low resource setting quality care referral encouraged individual participate screening process follow referral required increased patient footfall clinic training operation maintenance school sanitation unit helped maintaining toilet facility introducing subscription mechanism drinking water project one helped community maintain water purification system principle business engage provide value customer consumer responsible manner percentage customer complaintsconsumer case pending end financial year customer complaintsconsumer case pending end financial year company display product information product label mandated per local law yesnonaremarks additional information since company product biopharmaceuticals product information approved regulatory authority displayed product label case filed stakeholder company regarding unfair trade practice irresponsible advertising andor anticompetitive behaviour last five year pending end financial year provide detail thereof word nil company carry consumer survey consumer satisfaction trend however company process conducting formal survey financial year space intentionally left blank ahead curve annual report biocon limited independent auditor report member biocon limited report standalone indian accounting standard ind financial statement audited accompanying standalone ind financial statement biocon limited company comprise balance sheet march statement profit loss including comprehensive income statement cash flow statement change equity year ended summary significant accounting policy explanatory information herein referred standalone ind financial statement management responsibility standalone ind financial statement company board director responsible matter stated section company act act respect preparation standalone ind financial statement give true fair view financial position financial performance including comprehensive income cash flow change equity company accordance accounting principle generally accepted india including ind prescribed section act read relevant rule issued thereunder responsibility also includes maintenance adequate accounting record accordance provision act safeguarding asset company preventing detecting fraud irregularity selection application appropriate accounting policy making judgment estimate reasonable prudent design implementation maintenance adequate internal financial control operating effectively ensuring accuracy completeness accounting record relevant preparation presentation standalone ind financial statement give true fair view free material misstatement whether due fraud error auditor responsibility responsibility express opinion standalone ind financial statement based audit taken account provision act accounting auditing standard matter required included audit report provision act rule made thereunder conducted audit accordance standard auditing specified section act standard require comply ethical requirement plan perform audit obtain reasonable assurance whether standalone ind financial statement free material misstatement audit involves performing procedure obtain audit evidence amount disclosure standalone ind financial statement procedure selected depend auditor judgment including assessment risk material misstatement standalone ind financial statement whether due fraud error making risk assessment auditor considers internal financial control relevant company preparation standalone ind financial statement give true fair view order design audit procedure appropriate circumstance audit also includes evaluating appropriateness accounting policy used reasonableness accounting estimate made company director well evaluating overall presentation standalone ind financial statement believe audit evidence obtained sufficient appropriate provide basis audit opinion standalone ind financial statement opinion opinion best information according explanation given u aforesaid standalone ind financial statement give information required act manner required give true fair view conformity accounting principle generally accepted india including ind financial position company march financial performance including comprehensive income cash flow change equity year ended date matter comparative financial information company year ended march transition date opening balance sheet april included standalone ind financial statement based previously issued statutory financial statement prepared accordance company accounting standard rule audited predecessor auditor whose report year ended march march dated april april respectively expressed unmodified opinion standalone financial statement adjusted difference accounting principle adopted company transition ind audited u opinion modified respect matter report legal regulatory requirement required company auditor report order order issued central government india term section act give annexure statement matter specified paragraph order required section act report sought obtained information explanation best knowledge belief necessary purpose audit financial report b opinion proper book account required law kept company far appears examination book c balance sheet statement profit loss statement cash flow statement change equity dealt report agreement book account opinion aforesaid standalone ind financial statement comply indian accounting standard specified section act read relevant rule issued thereunder e basis written representation received director march taken record board director none director disqualified march appointed director term section act f respect adequacy internal financial control financial reporting company operating effectiveness control refer separate report annexure b g respect matter included auditor report accordance rule company audit auditor rule opinion best information according explanation given u company disclosed impact pending litigation financial position standalone ind financial statement refer note standalone ind financial statement ii provision made financial statement required applicable law accounting standard material foreseeable loss longterm contract including derivative contract refer note standalone ind financial statement iii delay transferring amount required transferred investor education protection fund company iv company provided requisite disclosure standalone ind financial statement holding well dealing specified bank note period november december based audit procedure relying management representation report disclosure accordance book account maintained company produced u management refer note standalone ind financial statement b r co llp chartered accountant firm registration number ww sethuraman partner membership number place bengaluru date april ahead curve annual report biocon limited annexure independent auditor report annexure referred independent auditor report member company standalone ind financial statement biocon limited year ended march report company maintained proper record showing full particular including quantitative detail situation property plant equipment b company regular programme physical verification property plant equipment property plant equipment verified phased manner period three year opinion periodicity physical verification reasonable regard size company nature asset accordance programme certain property plant equipment verified year material discrepancy noticed verification c according information explanation given u basis examination record company title deed immovable property held name company except one immovable property amounting million march company process obtaining registration ii inventory apart good transit inventory lying outside party physically verified management year discrepancy noticed verification physical stock book record material opinion frequency verification reasonable inventory lying outside party substantially confirmed yearend material discrepancy noticed respect confirmation iii company granted loan company covered register maintained section company act act opinion rate interest term condition loan granted company listed register maintained section act prima facie prejudicial interest company b case loan granted covered register maintained section act borrower regular payment principal interest stipulated c overdue amount respect loan granted company covered register maintained section act iv opinion according information explanation given u company complied provision section act respect loan given investment made guarantee security given v company accepted deposit public vi broadly reviewed book account maintained company pursuant company cost record audit rule amended prescribed central government section act opinion prima facie prescribed account record made maintained however made detailed examination record vii according information explanation given u basis examination record company amount deducted accrued book account respect undisputed statutory due including provident fund employee state insurance incometax sale tax value added tax duty custom excise duty service tax cess material statutory due regularly deposited year appropriate authority according information explanation given u undisputed amount payable respect provident fund employee state insurance income tax sale tax value added tax duty custom excise duty service tax cess material statutory due arrears march period six month date became payable b according information explanation given u due income tax sale tax value added tax service tax duty custom duty excise deposited appropriate authority account dispute following due name statute nature due amount amount paid period amount forum dispute disputed protest relates pending million million incometax act income tax supreme court incometax act income tax commissioner appeal incometax act income tax income tax appellate tribunal itat incometax act income tax high court finance act service tax march commissioner appeal april march march december july march finance act service tax may september custom excise october march service tax appellate march march tribunal cestat financial report name statute nature due amount amount paid period amount forum dispute disputed protest relates pending million million finance act service tax january may additional commissioner june june finance act service tax april march principal commissioner ltu value added tax act value added tax commissioner appeal central excise act excise duty april march cestat central excise act excise duty commissioner appeal central excise act excise duty commissioner appeal september october custom act custom duty till cestat custom act custom duty till commissioner appeal viii opinion according information explanation given u company defaulted repayment due bank financial institution government company borrowing year way debenture ix according information explanation given u company raised money way public issue public offer including debt instrument year term loan raised company applied purpose raised x according information explanation given u fraud company company officer employee noticed reported year xi according information explanation given u based examination record company company paid provided managerial remuneration accordance requisite approval per provision section read schedule v act xii opinion according information explanation given u company nidhi company xiii according information explanation given u based examination record company transaction related party compliance section act applicable detail transaction disclosed standalone ind financial statement required applicable accounting standard xiv according information explanation given u based examination record company company made preferential allotment private placement share fully partly convertible debenture year accordingly para xiv order applicable xv according information explanation given u based examination record company company entered noncash transaction director person connected xvi according information explanation given u company required registered section ia reserve bank india act b r co llp chartered accountant firm registration number ww sethuraman partner membership number place bengaluru date april ahead curve annual report biocon limited annexure b independent auditor report even date standalone financial statement biocon limited report internal financial control clause subsection section company act act audited internal financial control financial reporting biocon limited company march conjunction audit standalone ind financial statement company year ended date management responsibility internal financial control company management responsible establishing maintaining internal financial control based internal control financial reporting criterion established company considering essential component internal control stated guidance note audit internal financial control financial reporting guidance note issued institute chartered accountant india icai responsibility include design implementation maintenance adequate internal financial control operating effectively ensuring orderly efficient conduct business including adherence company policy safeguarding asset prevention detection fraud error accuracy completeness accounting record timely preparation reliable financial information required company act auditor responsibility responsibility express opinion company internal financial control financial reporting based audit conducted audit accordance guidance note audit internal financial control financial reporting guidance note standard auditing issued icai deemed prescribed section company act extent applicable audit internal financial control applicable audit internal financial control issued institute chartered accountant india standard guidance note require comply ethical requirement plan perform audit obtain reasonable assurance whether adequate internal financial control financial reporting established maintained control operated effectively material respect audit involves performing procedure obtain audit evidence adequacy internal financial control system financial reporting operating effectiveness audit internal financial control financial reporting included obtaining understanding internal financial control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk procedure selected depend auditor judgment including assessment risk material misstatement financial statement whether due fraud error believe audit evidence obtained sufficient appropriate provide basis audit opinion company internal financial control system financial reporting meaning internal financial control financial reporting company internal financial control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statement external purpose accordance generally accepted accounting principle company internal financial control financial reporting includes policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction recorded necessary permit preparation financial statement accordance generally accepted accounting principle receipt expenditure company made accordance authorisation management director company provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition company asset could material effect ind financial statement inherent limitation internal financial control financial reporting inherent limitation internal financial control financial reporting including possibility collusion improper management override control material misstatement due error fraud may occur detected also projection evaluation internal financial control financial reporting future period subject risk internal financial control financial reporting may become inadequate change condition degree compliance policy procedure may deteriorate opinion opinion company material respect adequate internal financial control system financial reporting internal financial control financial reporting operating effectively march based internal control financial reporting criterion established company considering essential component internal control stated guidance note audit internal financial control financial reporting issued institute chartered accountant india b r co llp chartered accountant firm registration number ww sethuraman partner membership number place bengaluru date april financial report balance sheet march amount indian rupee million except share data per share data unless otherwise stated note march march april asset noncurrent asset property plant equipment capital workinprogress investment property intangible asset financial asset investment ii loan iii financial asset incometax asset net deferred tax asset net noncurrent asset total noncurrent asset current asset inventory financial asset investment ii trade receivables iii cash cash equivalent iv bank balance iii v financial asset b current asset b total current asset total equity liability equity equity share capital equity total equity noncurrent liability financial liability borrowing ii financial liability provision deferred tax liability net noncurrent liability total noncurrent liability current liability financial liability borrowing ii trade payable iii financial liability b provision b incometax liability net current liability b total current liability total accompanying note integral part standalone financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april ahead curve annual report biocon limited statement profit loss year ended march amount indian rupee million except share data per share data unless otherwise stated note year ended year ended march march income revenue operation income total income expense cost raw material packing material consumed purchase traded good change inventory traded good finished good workinprogress excise duty employee benefit expense finance cost depreciation amortisation expense expense less recovery product development cost codevelopment partner net total expense profit tax exceptional item exceptional item net profit tax tax expense current tax less mat credit entitlement deferred tax total tax expense profit year comprehensive income expense item reclassified subsequently profit loss remeasurement defined benefit plan income tax effect ii item reclassified subsequently profit loss effective portion gainslosses hedging instrument cash flow hedge income tax effect comprehensive income expense year net tax total comprehensive income year earnings per share basic diluted accompanying note integral part standalone financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april financial report statement change equity year ended march amount indian rupee million except share data per share data unless otherwise stated equity share capital march march opening balance change equity share capital closing balance b equity particular security revaluation general retained sez share treasury cash flow item total premium reserve reserve earnings investment based share hedging reserve reserve payment reserve comprehensive equity reserve income balance april profit year comprehensive income net tax transaction recorded directly equity dividend including dividend distribution tax purchase treasury share share based payment exercise share option balance march profit year comprehensive income net tax transaction recorded directly equity share based payment purchase treasury share transfer special economic zone sez reinvestment reserve transfer sez reinvestment reserve utilization exercise share option balance march accompanying note integral part standalone financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april ahead curve annual report biocon limited statement cash flow year ended march amount indian rupee million except share data per share data unless otherwise stated march march cash flow operating activity profit year adjustment reconcile profit year net cash flow depreciation amortisation expense unrealised foreign exchange gainloss sharebased compensation expense provisionreversal provision doubtful debt bad debt written interest expense interest income net gain financial asset measured fair value profit loss dividend income net gain sale investment tax expense operating profit working capital change movement working capital decreaseincrease inventory decreaseincrease trade receivables decreaseincrease asset increasedecrease trade payable liability provision cash generated operation direct tax paid net refund net cash flow generated operating activity ii cash flow investing activity purchase tangible asset acquisition intangible asset proceeds sale fixed asset loan given subsidiary recovery loan subsidiary purchase investment proceeds sale investment investment bank deposit inter corporate deposit redemptionmaturity bank deposit inter corporate deposit interest received dividend received net cash flow generated fromused investing activity iii cash flow financing activity purchase treasury share proceeds exercise share option proceeds longterm borrowing repayment longterm borrowing proceedsrepayment shortterm borrowing net dividend paid equity share including tax thereon interest paid net cash flow generated fromused financing activity financial report statement cash flow year ended march contd amount indian rupee million except share data per share data unless otherwise stated march march iv net increasedecrease cash cash equivalent ii iii v effect exchange difference cash cash equivalent held foreign currency vi cash cash equivalent beginning year vii cash cash equivalent end year iv v vi reconciliation cash cash equivalent per statement cash flow cash cash equivalent note balance bank current account unpaid dividend account deposit original maturity less month bank overdraftscash credit note balance per statement cash flow company utilize balance towards settlement respective unpaid dividend liability accompanying note integral part standalone financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april space intentionally left blank ahead curve annual report biocon limited note standalone financial statement year ended march amount indian rupee million except share data per share data unless otherwise stated company overview reporting entity biocon limited biocon company engaged manufacture biotechnology product research service company public limited company incorporated domiciled india registered office bengaluru karnataka india company share listed bombay stock exchange bse national stock exchange nse india basis preparation financial statement statement compliance standalone financial statement prepared accordance indian accounting standard ind per company indian accounting standard rule notified section company act act relevant provision act company standalone financial statement year ended march prepared accordance company accounting standard rule notified section act read together paragraph company account rule previous gaap company first standalone financial statement prepared accordance indian accounting standard ind ind firsttime adoption indian accounting standard applied explanation transition ind affected previously reported financial position financial performance cash flow company provided note standalone financial statement prepared company going concern basis relevant ind effective company annual reporting date march standalone financial statement authorised issuance company board director april detail company accounting policy included note b functional presentation currency standalone financial statement presented indian rupee inr also functional currency company amount roundedoff nearest million unless otherwise indicated c basis measurement standalone financial statement prepared historical cost basis except following item certain financial asset liability including derivative instrument measured fair value net defined benefit assetsliability measured fair value plan asset less present value defined benefit obligation use estimate judgement preparation financial statement conformity ind requires management make estimate judgement assumption estimate judgement assumption affect application accounting policy reported amount asset liability disclosure contingent asset liability date financial statement reported amount revenue expense period accounting estimate could change period period actual result could differ estimate appropriate change estimate made management becomes aware change circumstance surrounding estimate change estimate reflected financial statement period change made material effect disclosed note standalone financial statement judgement information judgement made applying accounting policy significant effect amount recognised financial statement included following note note b assessment functional currency note financial instrument note b c useful life property plant equipment intangible asset investment property note asset obligation relating employee benefit note share based payment note l provision income tax related tax contingency evaluation recoverability deferred tax asset assumption estimation uncertainty information assumption estimation uncertainty significant risk resulting material adjustment year ending march included following note note recognition deferred tax asset availability future taxable profit tax loss carried forward used note impairment financial asset note recognition measurement provision contingency key assumption likelihood magnitude outflow resource financial report measurement fair value number company accounting policy disclosure require measurement fair value financial nonfinancial asset liability fair value categorised different level fair value hierarchy based input used valuation technique follows level quoted price unadjusted active market identical asset liability level input quoted price included level observable asset liability either directly ie price indirectly ie derived price level input asset liability based observable market data unobservable input measuring fair value asset liability company u observable market data far possible input used measure fair value asset liability fall different level fair value hierarchy fair value measurement categorised entirety level fair value hierarchy lowest level input significant entire measurement company recognises transfer level fair value hierarchy end reporting period change occurred information assumption made measuring fair value included following note note share based payment arrangement note investment property note financial instrument significant accounting policy financial instrument recognition initial measurement trade receivables debt security issued initially recognised originated financial asset financial liability initially recognised company becomes party contractual provision instrument financial asset financial liability initially measured fair value plus item fair value profit loss fvtpl transaction cost directly attributable acquisition issue ii classification subsequent measurement financial asset initial recognition financial asset classified measured amortised cost fvoci debt investment fvoci equity investment fvtpl financial asset reclassified subsequent initial recognition except period company change business model managing financial asset financial asset measured amortised cost meet following condition designated fvtpl asset held within business model whose objective hold asset collect contractual cash flow contractual term financial asset give rise specified date cash flow solely payment principal interest principal amount outstanding debt investment measured fvoci meet following condition designated fvtpl asset held within business model whose objective achieved collecting contractual cash flow selling financial asset contractual term financial asset give rise specified date cash flow solely payment principal interest principal amount outstanding initial recognition equity investment held trading company may irrevocably elect present subsequent change investment fair value oci designated fvoci equity investment election made investment investment basis financial asset classified measured amortised cost fvoci described measured fvtpl includes derivative financial asset initial recognition company may irrevocably designate financial asset otherwise meet requirement measured amortised cost fvoci fvtpl eliminates significantly reduces accounting mismatch would otherwise arise ahead curve annual report biocon limited financial asset subsequent measurement gain loss financial asset fvtpl asset subsequently measured fair value net gain loss including interest dividend income recognised statement profit loss however see note derivative designated hedging instrument financial asset amortised cost asset subsequently measured amortised cost using effective interest method amortised cost reduced impairment loss interest income foreign exchange gain loss impairment recognised statement profit loss gain loss derecognition recognised statement profit loss debt investment fvoci asset subsequently measured fair value interest income effective interest method foreign exchange gain loss impairment recognised statement profit loss net gain loss recognised oci derecognition gain loss accumulated oci reclassified statement profit loss equity investment fvoci asset subsequently measured fair value dividend recognised income statement profit loss unless dividend clearly represents recovery part cost investment net gain loss recognised oci reclassified statement profit loss financial liability classification subsequent measurement gain loss financial liability classified measured amortised cost fvtpl financial liability classified fvtpl classified held trading derivative designated initial recognition financial liability fvtpl measured fair value net gain loss including interest expense recognised statement profit loss financial liability subsequently measured amortised cost using effective interest method interest expense foreign exchange gain loss recognised statement profit loss gain loss derecognition also recognised statement profit loss iii derecognition financial asset company derecognises financial asset contractual right cash flow financial asset expire transfer right receive contractual cash flow transaction substantially risk reward ownership financial asset transferred company neither transfer retains substantially risk reward ownership retain control financial asset company enters transaction whereby transfer asset recognised balance sheet retains either substantially risk reward transferred asset transferred asset derecognised financial liability company derecognises financial liability contractual obligation discharged cancelled expire company also derecognises financial liability term modified cash flow modified term substantially different case new financial liability based modified term recognised fair value difference carrying amount financial liability extinguished new financial liability modified term recognised statement profit loss iv offsetting financial asset financial liability offset net amount presented balance sheet company currently legally enforceable right set amount intends either settle net basis realise asset settle liability simultaneously v derivative financial instrument hedge accounting company hold derivative financial instrument hedge foreign currency interest rate risk exposure embedded derivative separated host contract accounted separately host contract financial asset certain criterion met derivative initially measured fair value subsequent initial recognition derivative measured fair value change therein generally recognised statement profit loss company designates certain derivative hedging instrument hedge variability cash flow associated highly probable forecast transaction arising change foreign exchange rate interest rate inception designated hedging relationship company document risk management objective strategy undertaking hedge company also document economic relationship hedged item hedging instrument including whether change cash flow hedged item hedging instrument expected offset cash flow hedge derivative designated cash flow hedging instrument effective portion change fair value derivative recognised oci accumulated equity effective portion cash flow hedge effective portion change fair value derivative recognised oci limited cumulative change fair value hedged item determined present value basis inception hedge ineffective portion change fair value derivative recognised immediately statement profit loss hedge longer meet criterion hedge accounting hedging instrument sold expires terminated exercised hedge accounting discontinued prospectively hedge accounting cash flow hedge discontinued amount accumulated financial report equity remains hedge transaction resulting recognition nonfinancial item included nonfinancial item cost initial recognition cash flow hedge reclassified profit loss period period hedged expected future cash flow affect profit loss hedged future cash flow longer expected occur amount accumulated equity immediately reclassified statement profit loss vi treasury share company created employee welfare trust ewt providing sharebased payment employee equity instrument reacquired treasury share recognised cost deducted equity treasury share issued employee ewt amount received recognised increase equity resultant gain loss transferred security premium vii cash cash equivalent cash cash equivalent balance sheet comprise cash bank hand shortterm deposit original maturity three month less subject insignificant risk change value purpose statement cash flow cash cash equivalent consist cash shortterm deposit defined net outstanding bank overdraft considered integral part company cash management cash dividend equity holder company recognises liability make cash equity holder distribution authorised distribution longer discretion company per corporate law india distribution authorised approved shareholder corresponding amount recognised directly equity interim dividend recorded liability date declaration company board director b property plant equipment recognition measurement item property plant equipment measured cost less accumulated depreciation accumulated impairment loss cost selfconstructed item property plant equipment comprises cost material direct labor cost directly attributable bringing item working condition intended use estimated cost dismantling removing item restoring site located significant part item property plant equipment different useful life accounted separate item major component property plant equipment gain loss disposal item property plant equipment recognised statement profit loss subsequent expenditure capitalised probable future economic benefit associated expenditure flow company ii depreciation depreciation calculated cost item property plant equipment less estimated residual value estimated useful life using straightline method asset acquired finance lease depreciated shorter lease term useful life unless reasonably certain company obtain ownership end lease term freehold land depreciated estimated useful life item property plant equipment current comparative period follows asset management estimate useful life per schedule ii useful life building year year road year year plant equipment including electrical installation lab equipment year year computer server year year office equipment year year research development equipment year year furniture fixture year year vehicle year year leasehold improvement year lease period whichever lower depreciation method useful life residual value reviewed financial yearend adjusted appropriate based technical evaluation consequent advice management belief estimate useful life given best represent period management expects use asset depreciation addition disposal provided prorata basis ie upto date asset ready use disposed c intangible asset internally generated research development expenditure research activity recognised statement profit loss incurred development expenditure capitalised part cost resulting intangible asset expenditure measured reliably product process technically commercially feasible future economic benefit probable company intends sufficient ahead curve annual report biocon limited resource complete development use sell asset otherwise recognised statement profit loss incurred subsequent initial recognition asset measured cost less accumulated amortisation accumulated impairment loss others intangible asset initially measured cost subsequently intangible asset measured cost less accumulated amortization accumulated impairment loss subsequent expenditure subsequent expenditure capitalised increase future economic benefit embodied specific asset relates expenditure including expenditure internally generated goodwill brand recognised statement profit loss incurred ii amortisation goodwill amortised tested impairment annually intangible asset amortised straight line basis estimated useful life follows computer software year marketing manufacturing right year customer related intangible year amortisation method useful life residual value reviewed end financial year adjusted appropriate investment property investment property property held either earn rental income capital appreciation sale ordinary course business use production supply good service administrative purpose upon initial recognition investment property measured cost subsequent initial recognition investment property measured cost less accumulated depreciation accumulated impairment loss based technical evaluation consequent advice management belief period year representing best estimate period investment property quite similar expected used accordingly company depreciates investment property period year straightline basis useful life estimate year different indicative useful life relevant type building mentioned part c schedule ii act ie year gain loss disposal investment property recognised statement profit loss e business combination accordance ind business combination company account business combination acquisition date using acquisition method control transferred company see note cost acquisition measured fair value asset given equity instrument issued liability incurred assumed date exchange cost acquisition also includes fair value contingent consideration deferred consideration goodwill arises tested annually impairment gain bargain purchase recognised oci accumulated equity capital reserve exists clear evidence underlying reason classifying business combination resulting bargain purchase otherwise gain recognised directly equity capital reserve transaction cost expensed incurred f inventory inventory measured lower cost net realisable value cost inventory based firstin firstout formula includes expenditure incurred acquiring inventory production conversion cost cost incurred bringing present location condition case manufactured inventory workinprogress cost includes appropriate share fixed production overhead based normal operating capacity net realisable value estimated selling price ordinary course business less estimated cost completion selling expense net realisable value workinprogress determined reference selling price related finished product raw material component supply held use production finished product written cost except case material price declined estimated cost finished product exceed net realisable value comparison cost net realisable value made itembyitem basis g impairment impairment financial asset accordance ind company applies expected credit loss ecl model measurement recognition impairment loss following financial asset measured amortised cost financial asset measured fvoci debt investment loss allowance trade receivables significant financing component measured amount equal lifetime expected credit loss financial asset ecl measured amount equal month ecl unless significant increase credit risk initial recognition case measured lifetime ecl loss allowance financial asset measured amortised cost deducted gross carrying amount asset debt security fvoci loss allowance charged statement profit loss recognised oci financial report ii impairment nonfinancial asset company assess reporting date whether indication carrying amount may recoverable indication exists asset recoverable amount estimated impairment loss recognised carrying amount asset cgu exceeds estimated recoverable amount statement profit loss goodwill tested annually impairment purpose impairment testing goodwill arising business combination allocated cgus group cgus expected benefit synergy combination company nonfinancial asset inventory deferred tax asset reviewed reporting date determine whether indication impairment indication exists asset recoverable amount estimated impairment testing asset generate independent cash inflow grouped together cashgenerating unit cgus cgu represents smallest group asset generates cash inflow largely independent cash inflow asset cgus impairment loss recognised respect cgu allocated first reduce carrying amount goodwill allocated cgu reduce carrying amount asset cgu group cgus pro rata basis impairment loss respect goodwill subsequently reversed respect asset impairment loss recognised prior period company review reporting date whether indication loss decreased longer exists impairment loss reversed change estimate used determine recoverable amount reversal made extent asset carrying amount exceed carrying amount would determined net depreciation amortisation impairment loss recognised h employee benefit gratuity company provides gratuity defined benefit plan gratuity plan covering eligible employee company gratuity plan provides lumpsum payment vested employee retirement death incapacitation termination employment amount based respective employee salary tenure employment company liability regard gratuity plan determined actuarial valuation performed independent actuary balance sheet date using projected unit credit method defined benefit plan administered trust formed purpose company gratuity scheme company recognises net obligation defined benefit plan liability balance sheet gain loss remeasurement net defined benefit liability recognised comprehensive income reclassified profit loss subsequent period actual return portfolio plan asset excess yield computed applying discount rate used measure defined benefit obligation recognised comprehensive income effect plan amendment recognised statement profit loss ii provident fund eligible employee company receive benefit provident fund defined contribution plan eligible employee company make monthly contribution government administered provident fund scheme equal specified percentage eligible employee salary amount collected provident fund plan deposited government administered provident fund company obligation plan beyond monthly contribution iii compensated absence company policy compensated absence accumulating nonaccumulating nature expected cost accumulating compensated absence determined actuarial valuation performed independent actuary balance sheet date using projected unit credit method additional amount expected paidavailed result unused entitlement accumulated balance sheet date expense nonaccumulating compensated absence recognised period absence occur iv sharebased compensation grant date fair value equity settled sharebased payment award granted employee recognised employee expense corresponding increase equity period employee unconditionally become entitled award amount recognised expense based estimate number award related service nonmarket vesting condition expected met amount ultimately recognised expense based number award meet related service nonmarket vesting condition vesting date provision employee benefit provision recognised result past event company present legal constructive obligation estimated reliably probable outflow economic benefit required settle obligation provision determined discounting expected future cash flow representing best estimate expenditure required settle present obligation balance sheet date pre tax rate reflects current market assessment time value money risk specific liability unwinding discount recognised finance cost expected future operating loss provided onerous contract contract considered onerous expected economic benefit derived company contract lower unavoidable cost meeting obligation contract provision onerous contract measured present value lower expected cost terminating contract expected net cost continuing contract provision made company recognises impairment loss asset associated contract j revenue sale good revenue recognised significant risk reward ownership transferred buyer recovery consideration probable associated cost possible return good estimate reliably continuing management involvement ahead curve annual report biocon limited good amount revenue measured reliably timing transfer risk reward varies depending individual term sale revenue sale good includes excise duty measured fair value consideration received receivable net return sale tax applicable trade discount allowance ii milestone payment licensing arrangement company enters certain dossier sale licensing supply arrangement certain instance include certain performance obligation based evaluation whether obligation inconsequential perfunctory recognise defer upfront payment received arrangement deferred revenue recognised standalone statement operation period complete remaining performance obligation arrangement typically also consist subsequent payment dependent achieving certain milestone accordance term prescribed agreement milestone payment contingent achieving certain clinical milestone recognised revenue either achievement milestone milestone considered substantive period continuing performance obligation milestone considered substantive milestone payment creditable future royalty payment milestone deferred released period royalty anticipated paid iii sale return allowance company account sale return recording allowance sale return concurrent recognition revenue time product sale allowance based company estimate expected sale return estimate sale return determined primarily company historical experience market company operates iv dividend dividend recognised company right receive payment established generally shareholder approve dividend v rental income rental income investment property recognised statement profit loss straightline basis term lease except rental structured increase line expected general inflation lease incentive granted recognised integral part total rental income term lease vi contribution received customerscodevelopment partner towards plant equipment contribution received customerscodevelopment partner towards item property plant equipment require obligation supply good customer future recognised credit deferred revenue contribution received recognised revenue operation useful life asset company capitalises gross cost asset company control asset k government grant company recognises government grant reasonable assurance condition attached complied grant received government grant received relation asset presented reduction carrying amount related asset grant related income deducted reporting related expense l income tax income tax comprises current deferred income tax income tax expense recognised statement profit loss except extent relates item recognised directly equity case recognised comprehensive income current income tax current year prior period recognised amount expected paid recovered tax authority using tax rate law enacted substantively enacted balance sheet date deferred income tax asset liability recognised temporary difference arising tax base asset liability carrying amount financial statement except taxable temporary difference arising initial recognition goodwill temporary difference arising initial recognition asset liability transaction business combination affect neither accounting taxable profit loss time transaction temporary difference related investment subsidiary associate joint arrangement extent company able control timing reversal temporary difference probable reverse foreseeable future deferred tax asset reviewed reporting date reduced extent longer probable related tax benefit realised deferred income tax asset liability measured using tax rate law enacted substantively enacted balance sheet date expected apply taxable income year temporary difference expected recovered settled effect change tax rate deferred income tax asset liability recognised income expense period includes enactment substantive enactment date deferred income tax asset recognised extent probable future taxable income available deductible temporary timing difference tax loss utilised company offset incometax asset liability legally enforceable right set recognised amount intends either settle net basis realise asset settle liability simultaneously borrowing cost borrowing cost interest cost including exchange difference relating foreign currency borrowing extent regarded adjustment interest cost incurred connection borrowing fund borrowing cost directly attributable acquisition construction asset necessarily take substantial period time get ready intended use capitalised part cost asset borrowing cost recognised expense period incurred n earnings per share basic earnings per share computed using weighted average number equity share outstanding period adjusted treasury share held diluted earnings per share computed using weightedaverage number equity dilutive equivalent share outstanding period using treasury stock method option warrant except result would antidilutive financial report property plant equipment capital workinprogress land building leasehold plant research furniture vehicle total capital improvement equipment development workin equipment fixture progress refer note refer note refer note b e gross carrying amount april addition disposal march addition disposal march accumulated depreciation april depreciation year disposal march depreciation year disposal march net carrying amount april march march land includes land held leasehold basis gross carrying amount nil march net carrying amount nil march b plant equipment include computer office equipment c addition property plant equipment includes addition related research development amounting march year ended march company acquired business pharmaceutical manufacturing unit acacia lifesciences private limited located vishakhapatnam effect october also refer note e capital workinprogress mainly comprises new biopharmaceutical manufacturing unit constructed india f detail security certain property plant equipment refer note b space intentionally left blank ahead curve annual report biocon limited investment property gross carrying amount april addition march addition march accumulated depreciation april depreciation year march depreciation year march net carrying amount april march march year company recognised rental income march depreciation charge march statement profit loss investment property fair value investment property march march april intangible asset intellectual computer marketing customer total property right software manufacturing related right intangible refer note refer note b gross carrying amount april addition march addition march accumulated amortisation april amortisation year march amortisation year march net carrying amount april march march pursuant asset purchase agreement customer executed year ended march company acquired marketing manufacturing right product sum b also refer note acquisition customer related intangible part business acquired acacia lifesciences private limited financial report march march april noncurrent investment quoted equity instrument subsidiary company cost syngene international limited march april nil equity share refer note total quoted noncurrent investment ii unquoted equity instrument subsidiary company cost syngene international limited nil march nil april equity share refer note biocon research limited march april equity share biocon sa switzerland march april equity share chf biocon sdn bhd malaysia nil march nil april equity share rm refer note biocon fz llc uae march april nil equity share aed biocon pharma limited march april equity share biocon biologics limited uk march april nil equity share gbp biocon academy march april equity share joint venture company neobiocon fz llc uae march april equity share aed others energon kn wind power private limited march nil april nil equity share less provision decline temporary value non current investment total unquoted investment equity instrument iii unquoted preference share associate company iatrica inc usa march april series preferred stock u par value u less provision decline temporary value noncurrent investment total unquoted investment preference share associate company others vaccinex inc usa march april series b preferred convertible stock u par value u vaccinex inc usa march april series b preferred convertible stock u par value u less provision decline temporary value noncurrent investment energon kn wind power private limited march nil april nil compulsorily convertible preference share par value less provision decline temporary value non current investment total unquoted investment preference share iv unquoted debenture bond others lic housing finance co ltd march nil april nil bond par value hdfc ltd march nil april nil bond par value total unquoted investment debenture bond total noncurrent investment aggregate book value quoted investment aggregate market value quoted investment aggregate value unquoted investment aggregate amount impairment value investment company invested national saving certificate unquoted disclosed since amount rounded rupee million ahead curve annual report biocon limited march march april loan unsecured considered good loan subsidiary refer note loan related party comprise loan following subsidiary biocon research limited maximum amount outstanding year ii biocon pharma limited maximum amount outstanding year financial asset noncurrent fair value hedging instrument interest accrued due deposit receivables related party refer note b current fair value hedging instrument interest accrued due unbilled revenue receivables related party refer note others asset noncurrent capital advance duty drawback receivable balance statutorygovernment authority prepayment b current prepayment inventory raw material including goodsinbond packing material workinprogress finished good traded good includes good intransit nil march april nil writedown inventory net realisable value amounted march recognised expense year included change inventory traded good finished good workinprogress statement profit loss space intentionally left blank financial report march march april current investment unquoted investment mutual fund birla sun life short term fund growth unit march nil unit april nil unit dhfl pramerica banking psu debt fund gr unit march nil unit april nil unit axis liquid fund daily dividend reinvestment nil unit march nil unit april unit dws banking psu debt fund weekly dividend reinvestment nil unit march unit april nil unit edelweiss banking psu debt fund regular plan growth unit march nil unit april nil unit hdfc liquid fund daily dividend reinvestment nil unit march nil unit april unit hdfc medium term opportunity fund regular plan growth unit march nil unit april nil unit hdfc short term opportunity fund regular plan growth unit march nil unit april nil unit idfc cash fund daily dividend regular plan nil unit march nil unit april unit jp morgan banking psu debt fund weekly dividend reinvestment option nil unit march unit april nil unit reliance banking psu debt fund weekly dividend plan nil unit march unit april nil unit reliance banking psu debt fund growth unit march nil unit april nil unit reliance liquidity fund daily dividend reinvestment option nil unit march nil unit april unit sbi premier liquid fund regular plan daily dividend nil unit march unit april nil unit tata fixed maturity plan series scheme c plan growth nil unit march nil unit april unit tata liquid fund plan daily dividend nil unit march nil unit april unit uti treasury advantage fund institutional plan daily dividend reinvestment unit march unit april unit others inter corporate deposit financial institution aggregate value unquoted investment space intentionally left blank ahead curve annual report biocon limited march march april trade receivables unsecured considered good also refer note doubtful allowance credit loss includes due narayana hrudayalaya limited nhl formerly known narayana hrudayalaya private limited director company member board director nhl company exposure credit currency risk loss allowance disclosed note cash bank balance cash cash equivalent balance bank current account unpaid dividend account deposit original maturity less month total cash cash equivalent bank balance deposit maturity less month margin money deposit refer note total bank balance margin money deposit carrying amount march april subject first charge bank guarantee obtained b company cash hand disclosed since amount rounded rupee million space intentionally left blank financial report march march april equity share capital authorised march april equity share march april issued subscribed fully paidup march april equity share march april reconciliation share outstanding beginning end reporting year equity share march march million million beginning year issued year outstanding end year ii termsrights attached equity share company one class equity share par value per share holder equity share entitled one vote per share company declares pay dividend indian rupee dividend proposed board director subject approval shareholder ensuing annual general meeting event liquidation company holder equity share entitled receive remaining asset company distribution preferential amount distribution proportion number equity share held shareholder iii detail shareholder holding share company march march holding holding equity share fully paid dr kiran mazumdarshaw glentec international limited per record company including register shareholdersmembers shareholding represents legal beneficial ownership share iv share reserved issue option detail share reserved issue employee stock option plan esop company refer note b equity security premium reserve security premium used record premium received issue share utilised accordance provision company act general reserve general reserve used time time transfer profit retained earnings appropriation purpose retained earnings amount distributed company dividend equity shareholder sez reinvestment reserve sez reinvestment reserve created profit eligible sez unit term provision section aaii incometax act reserve utilised acquiring new plant machinery purpose business term section aa incometax act share based payment reserve company established various equity settled share based payment plan certain category employee company also refer note detail plan treasury share equity instrument reacquired treasury share recognised cost deducted equity cash flow hedging reserve cash flow hedging reserve represents cumulative effective portion gain loss net tax arising change fair value designated portion hedging instrument entered cash flow hedge ahead curve annual report biocon limited march march april longterm borrowing deferred sale tax liability unsecured refer note loan bank secured term loan refer note b loan advance unsecured nmitli csir loan refer note c financial assistance dsir refer note financial assistance dst refer note e less amount disclosed head current financial liability refer note b amount includes secured borrowing unsecured borrowing amount disclosed head current financial liability refer note b net amount february company obtained order karnataka sale tax authority allowing interest free deferment sale tax including turnover tax period upto year respect sale hebbagodi manufacturing facility amount exceeding interest free liability amount repayable equal half yearly instalment starting february loan repaid year b year ended march company obtained external commercial borrowing facility usd million bank term loan facility secured first priority paripassu charge plant machinery proposed expanded facility line existing facility carrying amount longterm loan repayable equal quarterly instalment usd million commencing december carry interest rate libor pa year ended march company entered interest rate swap convert floating rate fixed rate c march company entered agreement council scientific industrial research csir unsecured loan carrying part research development project new millennium indian technology leadership initiative nmitli scheme loan repayable equal annual instalment starting april carry interest rate pa march department scientific industrial research dsir sanctioned financial assistance sum company part financing one research project assistance repayable form royalty payment three year post commercialisation project five equal annual instalment starting april e august department science technology dst drug pharmaceutical research programme dprp sanctioned financial assistance sum company financing one research project loan repayable annual instalment starting july carry interest rate pa f respect financial assistance received aforesaid programme refer note c e company required utilise fund specified project required obtain prior approval said authority disposal assetsintellectual property right acquired developed programme company exposure liquidity interest rate currency risk disclosed note space intentionally left blank financial report march march april financial liability noncurrent fair value hedging instrument interest accrued due b current current maturity longterm borrowing refer note unpaid dividend payable capital good interim dividend equity share fair value hedging instrument provision noncurrent provision employee benefit gratuity refer note b current provision employee benefit gratuity refer note compensated absence provision sale return movement provision gratuity compensated sale return absence opening balance provision recognisedreversed year closing balance march march april deferred tax liabilityassets net deferred tax liability property plant equipment investment property intangible asset derivative asset gross deferred tax liability deferred tax asset employee benefit obligation allowance doubtful debt disallowable expense deferred revenue mat credit entitlement derivative liability others gross deferred tax asset net deferred tax liabilityassets liability noncurrent deferred revenue b current deferred revenue advance customer book overdraft statutory tax due payable ahead curve annual report biocon limited march march april shortterm borrowing banksfinancial institution packing credit foreign currency loan unsecured refer note ii iii cash credit secured refer note iv amount includes secured borrowing unsecured borrowing year ended march company obtained unsecured foreign currency denominated loan usd million april nil usd nil carrying interest rate libor pa bank facility repayable within day date origination repaid current year ii year ended march company obtained unsecured foreign currency denominated loan usd million april nil usd nil carrying interest rate libor pa bank facility repayable within day date origination repaid current year iii year ended march company obtained foreign currency denominated loan usd million carrying interest rate libor pa bank facility repayable within day date origination repaid year ended march iv company working capital facility various bank carrying interest rate ranging pa facility repayable demand secured paripassu first charge inventory trade receivables march march april trade payable trade payable refer note note disclosure required clause micro small medium enterprise development msmed act principal amount interest due thereon remaining unpaid supplier end year principal amount due micro small enterprise interest due ii amount interest paid buyer term section msmed act along amount payment made supplier beyond appointed day accounting year iii amount interest due payable period delay making payment paid beyond appointed day year without adding interest specified msmed act iv amount interest accrued remaining unpaid end accounting year v amount interest remaining due payable even succeeding year date interest due actually paid small enterprise purpose disallowance deductible expenditure section msmed act disclosure provided company based information available company respect registration status vendorssuppliers b trade payable current company exposure currency liquidity risk related trade payable disclosed note space intentionally left blank financial report march march revenue operation sale product finished good traded good sale service licensing development fee operating revenue sale process waste others refer note revenue operation others include processing charge rental cross charge power facility sez developer sez unit company income interest income deposit bank financial institution others dividend income subsidiary current investment net gain sale current investment net gain financial asset measured fair value profit loss foreign exchange gain net nonoperating income cost raw material packing material consumed inventory beginning year add purchase less inventory end year cost raw material packing material consumed change inventory traded good finished good workinprogress inventory beginning year traded good finished good workinprogress inventory end year traded good finished good workinprogress employee benefit expense salary wage bonus contribution provident fund gratuity refer note share based compensation expense refer note staff welfare expense finance cost interest expense financial liability measured amortised cost fair value change interest rate swap ahead curve annual report biocon limited march march depreciation amortisation expense depreciation tangible asset refer note amortisation intangible asset refer note expense royalty technical fee rent communication expense travelling conveyance professional charge payment auditor refer note director fee including commission power fuel insurance rate tax fee lab consumables repair maintenance plant machinery building others selling expense freight outwards clearing charge sale promotion expense commission brokerage sole selling agent bad debt written provisionreversal doubtful debt net foreign exchange fluctuation net printing stationery research development expense refer note csr expenditure refer note miscellaneous expense payment auditor auditor statutory audit fee tax audit fee limited review capacity service certification fee refer note b reimbursement outofpocket expense refer note b payment year ended march represents fee reimbursement paid predecessor auditor b amount presented since amount rounded rupee million research development expense research development expense research development expense included head account salary wage bonus contribution provident fund staff welfare expense lab consumables travelling conveyance professional charge b ab less recovery product development cost codevelopment partner net financial report employee stock compensation biocon esop plan september biocons board director approved biocon employee stock option plan esop plan grant stock option employee company subsidiariesjoint venture company nomination remuneration committee remuneration committee administers plan trust established specifically purpose called biocon india limited employee welfare trust esop trust esop trust shall make additional purchase equity share company using proceeds loan obtained company cash inflow allotment share employee esop plan shall subscribe allotted number share necessary transferring employee esop trust may also receive share promoter purpose issuance employee esop plan remuneration committee shall determine exercise price less face value share grant iv july company approved grant option face value share employee existing esop plan option grant would vest employee total grant end first second third year date grant existing employee end rd th th year date grant new employee exercise period year grant condition number option granted include service term performance grade employee option exercisable discount market price company share date grant detail grant iv particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year range exercise price outstanding option end year grant v april company approved grant employee existing esop plan option grant would vest employee total grant end first second third year date grant existing employee end rd th th year date grant new employee exercise period year grant condition number option granted include service term performance grade employee option exercisable market price company share date grant detail grant v particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year range exercise price outstanding option end year ahead curve annual report biocon limited grant vi july company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing market price company share existing date preceding date grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year grant vii july company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing market price company share existing date preceding date grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year grant viii july company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing price per national stock exchange last day month preceding month first grant space intentionally left blank financial report particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year grant ix june company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing price per national stock exchange preceding day date grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year grant x june company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing price per national stock exchange preceding day date grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year assumption used determination fair value stock option black scholes model follows ahead curve annual report biocon limited particular march march weighted average exercise price expected volatility life option granted vesting exercise period year average riskfree interest rate expected dividend rate expected volatility based historical volatility market price company publicly traded equity share expected term option grant b rsu plan march biocons remuneration committee approved biocon restricted stock unit rsus syngene rsu plan grant rsus employee company subsidiary syngene remuneration committee administers plan trust established specifically purpose called biocon limited employee welfare trust rsu trust purpose march company transferred equity share syngene rsu trust april company approved grant employee rsu plan rsus grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee exercise price rsus nil particular march march number weighted number weighted unit average unit average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted assumption used determination fair value stock option black scholes model follows particular march march weighted average exercise price expected volatility life option granted vesting exercise period year average riskfree interest rate expected dividend rate summary movement respect share held esop trust follows march march opening balance add share purchased esop trust less share exercised employee closing balance option granted eligible exercise end year option granted eligible exercise end year summary movement respect equity share syngene held rsu trust follows opening balance less share exercised employee closing balance financial report earnings per share eps march march earnings profit year share basic outstanding share less weighted average share held esop trust weighted average share used computing basic eps add effect dilutive option granted yet exercisednot yet eligible exercise weighted average share used computing diluted eps earnings per share basic diluted exceptional item net march march gain sale share subsidiary net refer note b year ended march company sold investment equity share biocon sdn bhd wholly owned subsidiary biocon biologics limited uk sum gain arising sale equity share amounting net cost equity share recorded exceptional gain standalone financial statement consequential tax recorded gain b year ended march syngene international limited syngene completed initial public offering ipo offer sale equity share company gain arising sale equity share net related expense cost equity share amounting recorded exceptional gain standalone financial statement consequential tax recorded gain included within income tax expense mat credit transaction recorded previous year due uncertainty utilization current year pursuant change income tax law business restructuring company belief able utilize mat credit entitlement accordingly year ended march company recorded mat credit entitlement included within income tax expense current year space intentionally left blank ahead curve annual report related party transaction related party control exists related party transaction taken place year listed sl name related party relationship description transaction april balance april balance balance march march march march april income payable income payable payable expense receivable expense receivable receivable transaction transaction remuneration paid key management personnel refer note g kiran mazumdarshaw chairperson managing director salary perquisite john shaw vicechairman director salary perquisite arun chandavarkar joint managing director ceo salary perquisite siddharth mittal president finance chief salary perquisite financial officer kiran kumar company secretary salary perquisite upto dec rajiv balakrishnan company secretary salary perquisite wef jan b others syngene international limited subsidiary power facility charge recovered refer note b rent income refer note b dividend income expense incurred behalf related party refer note sale goodsother product research service received ipo expense incurred behalf company receivables trade payable guarantee given behalf related party custom excise department ced guarantee given related party ced behalf company biocon research limited whollyowned subsidiary rent income refer note b power facility charge recovered refer note b cross charge towards lab consumables expense research service received sale good receivables royalty expense interest loan related party expense incurred behalf related party financial report refer note trade payable loan related party net biocon limited sl name related party relationship description transaction april balance april balance balance march march march march april income payable income payable payable expense receivable expense receivable receivable transaction transaction biocon sa whollyowned subsidiary cross charge towards facility expense expense incurred related party behalf company trade receivable receivable biocon sdnbhd whollyowned subsidiary expense incurred behalf related party refer biocon biologics limited note sale good purchase good operating income guarantee income trade payable ahead curve annual report trade receivables receivables guarantee given company bank behalf related party loan facility neobiocon fz llc jointventure sale good dividend income receivables trade receivables glentec international enterprise owned key rent expense limited management personnel biocon pharma limited whollyowned subsidiary investment equity share expense incurred behalf related party refer note interest loan related party loan related party net receivables guarantee given company bank behalf related party loan facility biocon biologics limited whollyowned subsidiary investment equity share sale noncurrent investment share biocon sdn bhd refer note sale good cross charge towards expense royalty expense trade receivables trade payable sl name related party relationship description transaction april balance april balance balance march march march march april income payable income payable payable expense receivable expense receivable receivable transaction transaction biocon fz llc whollyowned subsidiary investment equity share sale good trade receivables biocon pharma inc whollyowned subsidiary expense incurred behalf related party biocon pharma limited receivables biocon academy whollyowned subsidiary csr expenditure biocon foundation trust key management csr expenditure personnel board trustee narayana hrudayalaya enterprise director sale good limited formerly known company member trade receivables narayana hrudayalaya private board director limited expense incurred behalf related party include recharge software license fee amount paid behalf vendor b company sez developer division entered agreement lease land provide certain facility power utility etc sez unit biocon research limited syngene international limited respect company recovers rent facility usage charge c company purchased consumables mazumdar farm proprietary firm relative director disclosed since amount rounded rupee million year transaction biocon india limited employee welfare trust trust key management personnel board trustee e disclosure include related party per ind related party disclosure company act f remuneration key management personnel doesnt include provision made gratuity compensated absence obtained actuarial basis company whole g share based compensation expense allocable key management personnel march included remuneration disclosed h transaction related party priced arm length basis none balance secured space intentionally left blank financial report biocon limited tax expense march march amount recognised statement profit loss current tax mat credit entitlement deferred tax expenseincome related origination reversal temporary difference tax expense year b reconciliation effective tax rate profit tax less exceptional item net profit tax exceptional item tax statutory income tax rate march tax effect amount deductibletaxable calculating taxable income weighted deduction research development expenditure exempt income deduction nondeductible expense tax exceptional item basis difference reverse tax holiday period others income tax expense c tax loss unused tax loss deferred tax asset recognised potential tax impact expiry date financial year recognised deferred tax asset liability following movement deferred tax assetsliabilities presented balance sheet year ended opening recognised recognised closing march balance profit loss oci balance deferred tax liability property plant equipment investment property intangible asset derivative asset gross deferred tax liability deferred tax asset defined benefit obligation allowance doubtful debt disallowable expense deferred revenue mat credit entitlement derivative liability others gross deferred tax asset year ended opening recognised recognised closing march balance profit loss oci balance deferred tax liability property plant equipment investment property intangible asset derivative asset gross deferred tax liability deferred tax asset defined benefit obligation allowance doubtful debt disallowable expense deferred revenue mat credit entitlement derivative liability others gross deferred tax asset ahead curve annual report biocon limited contingent liability commitment extent provided march march april contingent liability claim company acknowledged debt includes direct taxation ii indirect taxation includes matter pertaining dispute central excise custom duty service tax iii litigation company involved taxation dispute lawsuit proceeding etc including patent commercial matter arise time time ordinary course business management view claim tenable material adverse effect company financial position result operation march march april b guarantee corporate guarantee given favour central excise department respect certain performance obligation subsidiary syngene international limited ii corporate guarantee given favour bank towards loan obtained subsidiary stepdown subsidiary biocon research limited biocon sdn bhd biocon pharma limited iii guarantee given bank behalf company contractual obligation company necessary term condition complied liability arisen ii commitment estimated amount contract remaining executed capital account provided net advance b operating lease commitment company lessee vehicle company taken vehicle certain employee operating lease expire period upto january gross rental expense year aggregate march committed lease rental future follows march march april later one year later one year later five year c march company committed provide financial support biocon research limited regard operation company disclosure specified bank note sbns year company specified bank note denomination note defined mca notification gsr e dated march detail specified bank note sbn held transacted period november december denomination wise sbns note per notification given amount particular sbns total denomination note closing cash hand november permitted receipt permitted payment amount deposited bank closing cash hand december purpose clause term specified bank note shall meaning provided notification government india ministry finance department economic affair number e dated november financial report employee benefit plan company defined benefit gratuity plan per payment gratuity act legislation employee completed five year service entitled specific benefit level benefit provided depends employee length service salary retirement termination age gratuity plan funded plan company make contribution recognised fund india based actuarial valuation obtained respect following table set status gratuity plan amount recognised company financial statement balance sheet date defined benefit fair value net defined obligation plan asset benefit assetliability balance april current service cost interest expenseincome amount recognised statement profit loss remeasurements return plan asset excluding amount included interest expenseincome actuarial gainloss arising demographic assumption financial assumption experience adjustment amount recognised comprehensive income employer contribution benefit paid balance march balance april current service cost interest expenseincome amount recognised statement profit loss remeasurements return plan asset excluding amount included interest expenseincome actuarial gainloss arising demographic assumption financial assumption experience adjustment amount recognised comprehensive income employer contribution benefit paid balance march march march april noncurrent current ii assumption used gratuity valuation march march april interest rate discount rate expected return plan asset salary increase attrition rate retirement age year assumption regarding future mortality experience set accordance published statistic mortality table weighted average duration defined benefit obligation year march year defined benefit plan expose company actuarial risk longevity interest rate risk iii sensitivity analysis sensitivity defined benefit obligation change weighted principal assumption particular march march increase decrease increase decrease discount rate salary increase attrition rate sensitivity significant actuarial assumption computed varying one actuarial assumption used valuation defined benefit obligation one percentage keeping actuarial assumption constant although analysis take account full distribution cash flow expected plan provide approximation sensitivity assumption shown ahead curve annual report biocon limited march march plan asset invested insurer managed fund expected contribution fund year ending march approximately march maturity profile defined benefit obligation particular million st following year nd following year rd following year th following year th following year year financial instrument fair value risk management accounting classification fair value carrying amount fair value march fvtpl fvtoci amortised total level level level total cost financial asset noncurrent investment loan current investment trade receivables cash bank balance financial asset financial liability borrowing trade payable financial liability march fvtpl fvtoci amortised total level level level total cost financial asset loan current investment trade receivables cash bank balance financial asset financial liability borrowing trade payable financial liability april fvtpl fvtoci amortised total level level level total cost financial asset loan current investment trade receivables cash bank balance financial asset financial liability borrowing trade payable financial liability financial report b measurement fair value fair value liquid mutual fund based quoted price derivative financial instrument valued based quoted price similar asset liability active market input directly indirectly observable market place sensitivity analysis fair value forward contract foreign currency reasonably possible change reporting date one significant observable input holding input constant would following effect significant observable input march march profit loss profit loss increase decrease increase decrease spot rate foreign currency movement interest rate bps movement c financial risk management company exposure following risk arising financial instrument credit risk liquidity risk market risk risk management framework company risk management carried treasury department policy approved board director board provides written principle overall risk management well policy covering specific area foreign exchange risk interest rate risk credit risk use derivative nonderivative financial instrument investment excess liquidity credit risk credit risk risk counterparty meet obligation financial instrument customer contract leading financial loss credit risk arises principally operating activity primarily trade receivables financing activity including deposit bank financial institution financial instrument customer credit risk managed business unit subject company established policy procedure control relating customer credit risk management audit risk management committee established credit policy new customer analysed individually creditworthiness company standard payment delivery term condition offered company review includes external rating available publicly available financial information outstanding customer receivables regularly monitored shipment major customer generally covered letter credit form credit insurance company establishes allowance impairment represents estimate expected loss respect trade receivables maximum exposure credit risk reporting date primarily trade receivables amounting march april movement allowance impairment respect trade receivables year follows allowance impairment march march opening balance impairment loss recognisedreversed closing balance single customer accounted trade receivable march significant concentration credit risk credit risk cash cash equivalent derivative limited company generally transacts bank financial institution high credit rating assigned international domestic credit rating agency investment primarily include investment liquid mutual fund unit bond non convertible debenture ii liquidity risk liquidity risk risk company encounter difficulty meeting obligation associated financial liability settled delivering cash another financial asset company approach managing liquidity ensure far possible sufficient liquidity meet liability due normal stressed condition without incurring unacceptable loss risking damage company reputation company belief working capital sufficient meet current requirement accordingly liquidity risk perceived addition company maintains following line credit cash credit facility bank carrying interest rate ranging pa facility repayable demand secured paripassu charge inventory trade receivables b unsecured foreign currency denominated loan bank amounting nil march carrying interest ranging nil march libor pa facility repayable within day origination ahead curve annual report biocon limited table provides detail regarding undiscounted contractual maturity significant financial liability march particular less year year year year total longterm borrowing shortterm borrowing trade payable financial liability total table provides detail regarding undiscounted contractual maturity significant financial liability march particular less year year year year total longterm borrowing shortterm borrowing trade payable financial liability total table provides detail regarding undiscounted contractual maturity significant financial liability april particular less year year year year total longterm borrowing shortterm borrowing trade payable financial liability total iii market risk market risk risk fair value future cash flow financial instrument fluctuate change market price foreign exchange rate interest rate equity price foreign currency risk company operates internationally major portion business transacted several currency consequently company exposed foreign exchange risk operating borrowing activity foreign currency company hold derivative instrument foreign exchange forward interest rate swap option contract mitigate risk change exchange rate foreign currency exposure currency profile financial asset financial liability march march march usd eur others total financial asset loan trade receivables cash cash equivalent noncurrent financial asset current financial asset financial liability longterm borrowing shortterm borrowing trade payable current financial liability net assetsliabilities march usd eur others total financial asset loan trade receivables cash cash equivalent noncurrent financial asset current financial asset financial liability longterm borrowing shortterm borrowing trade payable current financial liability net assetsliabilities financial report sensitivity analysis sensitivity profit loss change exchange rate arises mainly foreign currency denominated financial instrument impact component equity arises foreign exchange forwardoption contract designated cash flow hedge particular impact profit loss impact component equity march march march march usd sensitivity inrusd increase inrusd decrease eur sensitivity inreur increase inreur decrease derivative financial instrument following table give detail respect outstanding foreign exchange forward option contract particular march march million foreign exchange forward contract buy usd inr european style option contract periodical maturity date usd usd inr inr european style option contract periodical maturity date eur eur inr inr cash flow fair value interest rate risk company main interest rate risk arises longterm borrowing variable rate expose company cash flow interest rate risk year ended march march company borrowing variable rate mainly denominated usd interest rate risk exposure exposure company borrowing interest rate change end reporting period follows particular march march april variable rate borrowing fixed rate borrowing total borrowing b sensitivity company policy maintain borrowing fixed rate using interest rate swap achieve necessary therefore subject interest rate risk defined ind since neither carrying amount future cash flow fluctuate change market interest rate capital management key objective company capital management ensure maintains stable capital structure focus total equity uphold investor creditor customer confidence ensure future development business company focused keeping strong total equity base ensure independence security well high financial flexibility potential future borrowing required without impacting risk profile company company goal continue able return excess liquidity shareholder continuing distribute annual dividend future period amount future dividend equity share balanced effort continue maintain adequate liquidity status capital structure march follows particular march march total equity attributable equity shareholder company percentage total capital longterm borrowing shortterm borrowing total borrowing percentage total capital total capital equity borrowing ahead curve annual report biocon limited firsttime adoption ind standalone financial statement prepared accordance ind purpose transition previous gaap ind company followed guidance prescribed ind first time adoption indian accounting standard ind effect april transition date preparing ind balance sheet april presenting comparative information year ended march group adjusted amount reported previously financial statement prepared accordance previous gaap note explains transition previous gaap ind affected company balance sheet financial performance optional exemption availed mandatory exception preparing standalone financial statement company applied mentioned optional exemption mandatory exception optional exemption availed deemed cost investment subsidiary per ind entity may elect use fair value investment subsidiary date transition deemed cost accordingly company recognised fair value subsidiary deemed cost date transition business combination ind provides option apply ind business combination prospectively transition date specific date prior transition date company elected apply ind prospectively business combination occurring transition date business combination occurring prior transition date restated share based payment ind share based payment applied equity instrument share based payment transaction vested april cash settled share based payment transaction company applied ind liability settled april mandatory exemption availed estimate per ind entity estimate accordance ind date transition ind shall consistent estimate made date accordance previous gaap unless objective evidence estimate error company estimate ind consistent requirement key estimate considered preparation financial statement required previous gaap listed fair valuation financial instrument carried fvtpl fvoci impairment financial asset based expected credit loss model determination discounted value financial instrument carried amortised cost classification measurement financial asset ind requires entity assess classification financial asset basis fact circumstance existing date transition standard permit measurement financial asset accounted amortised cost based fact circumstance existing date transition retrospective application impracticable accordingly company determined classification financial asset based fact circumstance exist date transition measurement financial asset accounted amortised cost done retrospectively except impracticable hedge accounting hedge accounting applied prospectively transition date transaction satisfy hedge accounting criterion ind financial instrument date transition hedging relationship cannot designated retrospectively supporting documentation cannot created retrospectively result hedging relationship satisfied hedge accounting criterion date transition reflected hedge consolidated financial statement ind space intentionally left blank financial report b reconciliation following reconciliation provides effect transition ind previous gaap accordance ind firsttime adoption ind reconciliation equity april previous gaap adjustment ind asset noncurrent asset property plant equipment capital workinprogress investment property intangible asset financial asset investment ii loan iii financial asset incometax asset net noncurrent asset total noncurrent asset current asset inventory financial asset investment ii trade receivables iii cash cash equivalent iv bank balance iii v financial asset current asset total current asset total equity liability equity equity share capital equity total equity noncurrent liability financial liability borrowing ii financial liability provision deferred tax liability net noncurrent liability total noncurrent liability current liability financial liability borrowing ii trade payable iii financial liability provision incometax liability net current liability total current liability total space intentionally left blank ahead curve annual report biocon limited ii reconciliation equity march previous gaap adjustment ind asset noncurrent asset property plant equipment capital workinprogress investment property intangible asset financial asset investment ii loan iii financial asset incometax asset net noncurrent asset total noncurrent asset current asset inventory financial asset investment ii trade receivables iii cash cash equivalent iv bank balance iii v financial asset current asset total current asset total equity liability equity equity share capital equity total equity noncurrent liability financial liability borrowing ii financial liability provision deferred tax liability net noncurrent liability total noncurrent liability current liability financial liability borrowing ii trade payable iii financial liability provision incometax liability net current liability total current liability total space intentionally left blank financial report iii reconciliation statement profit loss year ended march previous gaap adjustment ind income revenue operation income total income expense cost raw material packing material consumed purchase traded good change inventory traded good finished good workinprogress excise duty employee benefit expense finance cost expense depreciation amortisation expense less recovery product development cost codevelopment partner net total expense profit tax exceptional item exceptional item net profit tax tax expense current tax deferred tax total tax expense profit year comprehensive incomeexpense item reclassified subsequently profit loss remeasurement defined benefit plan income tax effect ii item reclassified subsequently profit loss effective portion gainslosses hedging instrument cash flow hedge income tax effect comprehensive incomeexpense year net tax total comprehensive income year space intentionally left blank ahead curve annual report biocon limited iv reconciliation total equity note march april equity previous gaap attributable shareholder company adjustment difference account revenue recognition net related cost impact derivative accounting ii consolidation esop trust vii fair valuation investment subsidiary transition date adjustment iii income tax adjustment correction earlier year iv total adjustment equity ind attributable shareholder company v reconciliation net profit net profit reconciliation note march net profit attributable shareholder company per previous gaap adjustment difference account revenue recognition net related cost impact derivative accounting ii adjustment iii income tax impact adjustment correction earlier year iv impact profit sale syngene share net tax v total adjustment b profit year c ab comprehensive income oci actuarial loss defined benefit obligation gratuity vi subtotal total comprehensive income year c note reconciliation difference account revenue recognition net related cost primarily due difference timing revenue recognition ind compared previous gaap deferral licensing income account continuing obligation ii impact due derivative accounting accordance ind iii adjustment account employee benefit expense share based payment actuarial gainslosses mark market adjustment mutual fund guarantee income iv represents income tax impact ind adjustment including correction earlier year v reduction profit sale syngene share primarily account fair valuation investment syngene subsidiary ind transition date deemed cost vi actuarial loss defined benefit obligation gratuity taken comprehensive income ind compared statement profit loss previous gaap vii impact consolidation esop trust business combination year ended march company acquired business pharmaceutical manufacturing unit acacia lifesciences private limited located vishakhapatnam effect october going concern basis consideration paid cash transaction accounted ind business combination business combination purchase price allocated identifiable asset liability fair value following table present allocation purchase price particular amount net tangible asset customer related intangible total purchase price financial report segmental information accordance ind operating segment segment information provided consolidated financial statement company therefore separate disclosure segment information given standalone financial statement note company entered transaction sale product private company year ended march amounting respectively required prior approval central government section company act transaction entered prevailing market price approved board director company year ended march company filed application central government approval transaction compounding noncompliance pending central government march b company paid dividend distribution tax nil march interim dividend reducing amount dividend received company subsidiary corporate social responsibility per section company act company meeting applicability threshold need spend least average net profit immediately preceding three financial year corporate social responsibility csr activity gross amount required spent company year b amount spent year sl particular cash yet paid total cash constructionacquisition asset ii purpose event reporting period april board director company approved issue bonus share proportion ie two bonus equity share every one fully paidup equity share held record date subject approval shareholder company postal ballot b april board director company proposed final dividend per equity share prebonus share basis proposed dividend subject approval shareholder annual general meeting per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april ahead curve annual report biocon limited subsidiary independent auditor report member biocon limited report consolidated indian accounting standard ind financial statement audited accompanying consolidated ind financial statement biocon limited holding company subsidiary joint venture collectively referred company group comprise consolidated balance sheet march consolidated statement profit loss including comprehensive income consolidated statement cash flow consolidated statement change equity year ended summary significant accounting policy explanatory information hereinafter referred consolidated ind financial statement management responsibility consolidated ind financial statement holding company board director responsible preparation consolidated ind financial statement term requirement company act hereinafter referred act give true fair view consolidated financial position consolidated financial performance including comprehensive income consolidated cash flow consolidated change equity group accordance accounting principle generally accepted india including ind prescribed section act read relevant rule issued thereunder respective board director company included group responsible maintenance adequate accounting record accordance provision act safeguarding asset group preventing detecting fraud irregularity selection application appropriate accounting policy making judgment estimate reasonable prudent design implementation maintenance adequate internal financial control operating effectively ensuring accuracy completeness accounting record relevant preparation presentation consolidated ind financial statement give true fair view free material misstatement whether due fraud error used purpose preparation consolidated ind financial statement director holding company aforesaid auditor responsibility responsibility express opinion consolidated ind financial statement based audit conducting audit taken account provision act accounting auditing standard matter required included audit report provision act rule made thereunder conducted audit accordance standard auditing specified section act standard require comply ethical requirement plan perform audit obtain reasonable assurance whether consolidated ind financial statement free material misstatement audit involves performing procedure obtain audit evidence amount disclosure consolidated ind financial statement procedure selected depend auditor judgment including assessment risk material misstatement consolidated ind financial statement whether due fraud error making risk assessment auditor considers internal financial control relevant holding company preparation consolidated ind financial statement give true fair view order design audit procedure appropriate circumstance audit also includes evaluating appropriateness accounting policy used reasonableness accounting estimate made holding company board director well evaluating overall presentation consolidated ind financial statement believe audit evidence obtained u sufficient appropriate provide basis audit opinion consolidated ind financial statement opinion opinion best information according explanation given u based consolidation report auditor separate financial statement subsidiary joint venture group noted aforesaid consolidated ind financial statement give information required act manner required give true fair view conformity accounting principle generally accepted india including ind consolidated financial position group march consolidated financial performance including comprehensive income consolidated cash flow consolidated change equity year ended matter comparative financial information group year ended march transition date opening balance sheet april included consolidated ind financial statement based previously issued statutory financial statement prepared accordance company accounting standard rule audited predecessor auditor whose report year ended march march dated april april respectively expressed unmodified opinion consolidated financial statement adjusted difference accounting principle adopted company transition ind audited u b audit financial statement financial information subsidiary joint venture incorporated outside india included consolidated ind financial statement group subsidiary account million net profit million revenue year ended march million total asset march consolidated ind financial statement also include group share net profit million year ended march respect joint venture financial statement subsidiary joint venture incorporated outside india audited auditor whose report furnished u opinion financial report consolidated ind financial statement far relates subsidiary joint venture based aforesaid report auditor opinion consolidated ind financial statement report legal regulatory requirement modified respect matter respect reliance work done report auditor report legal regulatory requirement required section act based audit consideration report auditor separate financial statement subsidiary company joint venture incorporated outside india noted matter paragraph report extent applicable sought obtained information explanation best knowledge belief necessary purpose audit aforesaid consolidated ind financial statement b opinion proper book account required law relating preparation aforesaid consolidated ind financial statement kept far appears examination book report auditor c consolidated balance sheet consolidated statement profit loss consolidated statement cash flow consolidated statement change equity dealt report agreement relevant book account maintained purpose preparation consolidated ind financial statement opinion aforesaid consolidated ind financial statement comply indian accounting standard prescribed section act read relevant rule issued thereunder e basis written representation received director group company incorporated india march taken record respective board director group company incorporated india none director group company incorporated india disqualified march appointed director company term section act f respect adequacy internal financial control financial reporting group operating effectiveness control refer separate report annexure g respect matter included auditor report accordance rule company audit auditor rule opinion best information according explanation given u based consideration report auditor separate financial statement financial information subsidiary company joint venture noted matter paragraph consolidated ind financial statement disclose impact pending litigation consolidated financial position group refer note consolidated ind financial statement ii provision made consolidated ind financial statement required applicable law accounting standard material foreseeable loss longterm contract including derivative contract refer note consolidated ind financial statement iii delay transferring amount required transferred investor education protection fund holding company subsidiary company incorporated india iv company provided requisite disclosure consolidated ind financial statement holding well dealing specified bank note period november december based audit procedure relying management representation report disclosure accordance book account maintained company produced u management refer note consolidated ind financial statement b r co llp chartered accountant firm registration number ww sethuraman partner membership number place bengaluru date april ahead curve annual report biocon limited subsidiary annexure independent auditor report even date consolidated financial statement biocon limited report internal financial control clause subsection section company act act conjunction audit consolidated ind financial statement group year ended march audited internal financial control financial reporting biocon limited holding company subsidiary company company incorporated india date management responsibility internal financial control respective board director holding company subsidiary company company incorporated india responsible establishing maintaining internal financial control based internal control financial reporting criterion established company considering essential component internal control stated guidance note audit internal financial control financial reporting guidance note issued institute chartered accountant india icai responsibility include design implementation maintenance adequate internal financial control operating effectively ensuring orderly efficient conduct business including adherence company policy safeguarding asset prevention detection fraud error accuracy completeness accounting record timely preparation reliable financial information required company act auditor responsibility responsibility express opinion company internal financial control financial reporting based audit conducted audit accordance guidance note audit internal financial control financial reporting guidance note issued icai standard auditing issued icai deemed prescribed section company act extent applicable audit internal financial control issued institute chartered accountant india standard guidance note require comply ethical requirement plan perform audit obtain reasonable assurance whether adequate internal financial control financial reporting established maintained control operated effectively material respect audit involves performing procedure obtain audit evidence adequacy internal financial control system financial reporting operating effectiveness audit internal financial control financial reporting included obtaining understanding internal financial control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk procedure selected depend auditor judgment including assessment risk material misstatement ind financial statement whether due fraud error believe audit evidence obtained sufficient appropriate provide basis audit opinion company internal financial control system financial reporting meaning internal financial control financial reporting company internal financial control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statement external purpose accordance generally accepted accounting principle company internal financial control financial reporting includes policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction recorded necessary permit preparation financial statement accordance generally accepted accounting principle receipt expenditure company made accordance authorisation management director company provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition company asset could material effect ind financial statement inherent limitation internal financial control financial reporting inherent limitation internal financial control financial reporting including possibility collusion improper management override control material misstatement due error fraud may occur detected also projection evaluation internal financial control financial reporting future period subject risk internal financial control financial reporting may become inadequate change condition degree compliance policy procedure may deteriorate opinion opinion holding company subsidiary company company incorporated india material respect adequate internal financial control system financial reporting internal financial control financial reporting operating effectively march based internal control financial reporting criterion established company considering essential component internal control stated guidance note audit internal financial control financial reporting issued icai b r co llp chartered accountant firm registration number ww sethuraman partner membership number place bengaluru date april financial report consolidated balance sheet march amount indian rupee million except share data per share data unless otherwise stated note march march april asset noncurrent asset property plant equipment capital workinprogress investment property goodwill intangible asset intangible asset development investment associate joint venture c financial asset investment ii derivative asset iii financial asset incometax asset net deferred tax asset net noncurrent asset total noncurrent asset current asset inventory financial asset investment ii trade receivables iii cash cash equivalent iv bank balance v derivative asset vi financial asset b current asset b total current asset total equity liability equity equity share capital equity equity attributable owner company noncontrolling interest b total equity noncurrent liability financial liability borrowing ii derivative liability iii financial liability provision noncurrent liability total noncurrent liability current liability financial liability borrowing ii trade payable iii derivative liability iv financial liability b provision b income tax liability net current liability b total current liability total accompanying note integral part consolidated financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april ahead curve annual report biocon limited subsidiary consolidated statement profit loss year ended march amount indian rupee million except share data per share data unless otherwise stated note year ended year ended march march income revenue operation income total income expense cost raw material packing material consumed purchase traded good change inventory traded good finished good workinprogress excise duty employee benefit expense finance cost depreciation amortisation expense expense less recovery product development cost codevelopment partner net total expense profit tax share profit joint venture exceptional item tax share profit joint venture profit tax exceptional item exceptional item net profit tax tax expense current tax less mat credit entitlement deferred tax total tax expense profit year space intentionally left blank financial report consolidated statement profit loss year ended march contd amount indian rupee million except share data per share data unless otherwise stated note year ended year ended march march comprehensive income item reclassified subsequently profit loss remeasurement defined benefit plan income tax effect ii item may reclassified subsequently profit loss effective portion gain loss hedging instrument cash flow hedge income tax effect comprehensive income expense year net tax total comprehensive income year profit attributable shareholder company noncontrolling interest profit year comprehensive income expense attributable shareholder company noncontrolling interest comprehensive income expense year total comprehensive income attributable shareholder company noncontrolling interest total comprehensive income year earnings per share basic diluted accompanying note integral part consolidated financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april ahead curve annual report consolidated statement change equity year ended march amount indian rupee million except share data per share data unless otherwise stated equity share capital march march opening balance change equity share capital closing balance b equity particular attributable owner company non total security revaluation capital general retained sez share treasury foreign cash flow item total controlling premium reserve reserve reserve earnings investment based share currency hedging comprehensive interest reserve reserve payment translation reserve income equity reserve reserve balance april profit year comprehensive income net tax transaction owner directly recorded equity dividend including dividend distribution tax share based payment gain sale share subsidiary net tax refer note purchase treasury share exercise share option balance march financial report biocon limited subsidiary consolidated statement change equity year ended march contd amount indian rupee million except share data per share data unless otherwise stated b equity contd particular attributable owner company non total security revaluation capital general retained sez share treasury foreign cash flow item total controlling premium reserve reserve reserve earnings investment based share currency hedging comprehensive interest reserve reserve payment translation reserve income equity reserve reserve balance march profit year comprehensive income net tax transfer special economic zone sez reinvestment reserve transfer sez reinvestment reserve utilisation ahead curve annual report transaction owner directly recorded equity share based payment tax benefit related gain sale share subsidiary refer note purchase treasury share exercise share option balance march accompanying note integral part consolidated financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april biocon limited subsidiary consolidated statement cash flow year ended march amount indian rupee million except share data per share data unless otherwise stated march march cash flow operating activity profit year adjustment reconcile profit year net cash flow depreciation amortisation tax expense unrealised foreign exchange gainloss sharebased compensation expense provisionreversal provision doubtful debt bad debt written interest expense interest income dividend income net gain financial asset measured fair value profit loss net gain sale investment proceeds insurance company towards loss tangible asset share profit joint venture exceptional item net operating profit working capital change movement working capital decreaseincrease inventory decreaseincrease trade receivables decreaseincrease asset increasedecrease trade payable liability provision cash generated operation direct tax paid net refund net cash flow generated operating activity ii cash flow investing activity purchase tangible asset acquisition intangible asset proceeds sale fixed asset purchase investment proceeds sale investment investment bank deposit inter corporate deposit redemptionmaturity bank deposit inter corporate deposit interest received dividend received net cash flow generated fromused investing activity iii cash flow financing activity purchase treasury share proceeds exercise share option proceeds longterm borrowing repayment longterm borrowing proceeds repayment shortterm borrowing net dividend paid equity share including tax thereon interest paid net cash flow generated fromused financing activity financial report consolidated statement cash flow year ended march contd amount indian rupee million except share data per share data unless otherwise stated march march iv net increasedecrease cash cash equivalent ii iii v effect exchange difference cash cash equivalent held foreign currency vi cash cash equivalent beginning year vii cash cash equivalent end year iv v vi reconciliation cash cash equivalent per statement cash flow cash cash equivalent note balance bank current account unpaid dividend account deposit original maturity less month bank overdraft cash credit note balance per statement cash flow group utilize balance towards settlement respective unpaid dividend liability accompanying note integral part consolidated financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april space intentionally left blank ahead curve annual report biocon limited subsidiary note consolidated financial statement year ended march amount indian rupee million except share data per share data unless otherwise stated company overview reporting entity biocon limited biocon parent company company together subsidiary joint venture associate collectively group engaged manufacture biotechnology product research service company public limited company incorporated domiciled india registered office bengaluru karnataka india company share listed bombay stock exchange bse national stock exchange nse india basis preparation financial statement statement compliance consolidated financial statement prepared accordance indian accounting standard ind per company indian accounting standard rule notified section company act act relevant provision act group consolidated financial statement year ended march prepared accordance company accounting standard rule notified section act read together paragraph company account rule previous gaap group first consolidated financial statement prepared accordance indian accounting standard ind ind firsttime adoption indian accounting standard applied explanation transition ind affected previously reported financial position financial performance cash flow group provided note consolidated financial statement prepared group going concern basis relevant ind effective company annual reporting date march consolidated financial statement authorised issuance company board director april detail group accounting policy included note b functional presentation currency consolidated financial statement presented indian rupee inr also functional currency parent company amount roundedoff nearest million unless otherwise indicated respect subsidiary associate whose operation selfcontained integrated functional currency determined currency primary economic environment entity operates c basis measurement consolidated financial statement prepared historical cost basis except following item certain financial asset liability including derivative instrument measured fair value net defined benefit assetsliability measured fair value plan asset less present value defined benefit obligation use estimate judgement preparation financial statement conformity ind requires management make estimate judgement assumption estimate judgement assumption affect application accounting policy reported amount asset liability disclosure contingent asset liability date financial statement reported amount revenue expense period accounting estimate could change period period actual result could differ estimate appropriate change estimate made management becomes aware change circumstance surrounding estimate change estimate reflected financial statement period change made material effect disclosed note consolidated financial statement judgement information judgement made applying accounting policy significant effect amount recognised financial statement included following note note b assessment functional currency note c financial instrument note e f useful life property plant equipment intangible asset investment property note asset obligation relating employee benefit note share based payment note n provision income tax related tax contingency evaluation recoverability deferred tax asset e assumption estimation uncertainty information assumption estimation uncertainty significant risk resulting material adjustment year ending march included following note financial report note n recognition deferred tax asset availability future taxable profit tax loss carried forward used note impairment financial asset note measurement defined benefit obligation key actuarial assumption note recognition measurement provision contingency key assumption likelihood magnitude outflow resource f measurement fair value number group accounting policy disclosure require measurement fair value financial nonfinancial asset liability fair value categorised different level fair value hierarchy based input used valuation technique follows level quoted price unadjusted active market identical asset liability level input quoted price included level observable asset liability either directly ie price indirectly ie derived price level input asset liability based observable market data unobservable input measuring fair value asset liability group u observable market data far possible input used measure fair value asset liability fall different level fair value hierarchy fair value measurement categorised entirety level fair value hierarchy lowest level input significant entire measurement group recognises transfer level fair value hierarchy end reporting period change occurred information assumption made measuring fair value included following note note sharebased payment arrangement note investment property note c financial instrument significant accounting policy basis consolidation subsidiary subsidiary entity controlled group group control entity exposed right variable return involvement entity ability affect return power entity financial statement subsidiary included consolidated financial statement date control commences date control cease financial statement group consolidated linebyline basis intragroup transaction balance unrealised gain arising intragroup transaction eliminated unrealised loss eliminated extent evidence impairment temporary difference arise elimination profit loss resulting intragroup transaction recognised per ind income tax purpose preparing consolidated financial statement accounting policy subsidiary changed necessary align policy adopted company noncontrolling interest nci nci measured proportionate share acquirees net identifiable asset date acquisition change group equity interest subsidiary result loss control accounted equity transaction ii loss control group loses control subsidiary derecognises asset liability subsidiary related nci component equity interest retained former subsidiary measured fair value date control lost resulting gain loss recognised statement profit loss iii associate joint arrangement equity accounted investees group interest equity accounted investees comprise interest associate joint venture associate entity group significant influence control joint control financial operating policy joint venture arrangement group joint control right net asset arrangement rather right asset obligation liability interest associate joint venture accounted using equity method initially recognised cost includes transaction cost subsequent initial recognition consolidated financial statement include group share profit loss oci equity accounted investees date significant influence joint control cease ahead curve annual report biocon limited subsidiary b foreign currency foreign currency transaction transaction foreign currency translated respective functional currency company exchange rate date transaction average rate average rate approximates actual rate date transaction monetary asset liability denominated foreign currency translated functional currency exchange rate reporting date nonmonetary asset liability measured fair value foreign currency translated functional currency exchange rate fair value determined nonmonetary asset liability measured based historical cost foreign currency translated exchange rate date transaction exchange difference recognised statement profit loss except exchange difference arising translation qualifying cash flow hedge extent hedge effective recognised oci previous gaap exchange difference arising restatement longterm foreign currency monetary item related acquisition depreciable asset added todeducted cost depreciable asset accordance ind first time adoption indian accounting standard group continues accounting treatment respect longterm foreign currency monetary item recognised financial statement march ii foreign operation asset liability foreign operation subsidiary associate joint arrangement including goodwill fair value adjustment arising acquisition translated inr functional currency group exchange rate reporting date income expense foreign operation translated inr exchange rate date transaction average rate average rate approximates actual rate date transaction foreign currency translation difference recognised oci accumulated equity exchange difference translating financial statement foreign operation except extent exchange difference allocated nci c financial instrument recognition initial measurement trade receivables debt security issued initially recognised originated financial asset financial liability initially recognised group becomes party contractual provision instrument financial asset financial liability initially measured fair value plus item fair value profit loss fvtpl transaction cost directly attributable acquisition issue ii classification subsequent measurement financial asset initial recognition financial asset classified measured amortised cost fvoci debt investment fvoci equity investment fvtpl financial asset reclassified subsequent initial recognition except period group change business model managing financial asset financial asset measured amortised cost meet following condition designated fvtpl asset held within business model whose objective hold asset collect contractual cash flow contractual term financial asset give rise specified date cash flow solely payment principal interest principal amount outstanding debt investment measured fvoci meet following condition designated fvtpl asset held within business model whose objective achieved collecting contractual cash flow selling financial asset contractual term financial asset give rise specified date cash flow solely payment principal interest principal amount outstanding initial recognition equity investment held trading group may irrevocably elect present subsequent change investment fair value oci designated fvoci equity investment election made investment investment basis financial asset classified measured amortised cost fvoci described measured fvtpl includes derivative financial asset initial recognition group may irrevocably designate financial asset otherwise meet requirement measured amortised cost fvoci fvtpl eliminates significantly reduces accounting mismatch would otherwise arise financial report financial asset subsequent measurement gain loss financial asset fvtpl asset subsequently measured fair value net gain loss including interest dividend income recognised statement profit loss however see note derivative designated hedging instrument financial asset amortised cost asset subsequently measured amortised cost using effective interest method amortised cost reduced impairment loss interest income foreign exchange gain loss impairment recognised statement profit loss gain loss derecognition recognised statement profit loss debt investment fvoci asset subsequently measured fair value interest income effective interest method foreign exchange gain loss impairment recognised statement profit loss net gain loss recognised oci derecognition gain loss accumulated oci reclassified statement profit loss equity investment fvoci asset subsequently measured fair value dividend recognised income statement profit loss unless dividend clearly represents recovery part cost investment net gain loss recognised oci reclassified profit loss financial liability classification subsequent measurement gain loss financial liability classified measured amortised cost fvtpl financial liability classified fvtpl classified held trading derivative designated initial recognition financial liability fvtpl measured fair value net gain loss including interest expense recognised statement profit loss financial liability subsequently measured amortised cost using effective interest method interest expense foreign exchange gain loss recognised statement profit loss gain loss derecognition also recognised statement profit loss iii derecognition financial instrument financial asset group derecognises financial asset contractual right cash flow financial asset expire transfer financial asset transfer qualifies derecognition ind financial liability part financial liability de recognised group balance sheet obligation specified contract discharged cancelled expires financial liability group derecognises financial liability contractual obligation discharged cancelled expire group also derecognises financial liability term modified cash flow modified term substantially different case new financial liability based modified term recognised fair value difference carrying amount financial liability extinguished new financial liability modified term recognised statement profit loss iv derivative financial instrument hedge accounting group hold derivative financial instrument hedge foreign currency interest rate risk exposure embedded derivative separated host contract accounted separately host contract financial asset certain criterion met derivative initially measured fair value subsequent initial recognition derivative measured fair value change therein generally recognised statement profit loss group designates certain derivative hedging instrument hedge variability cash flow associated highly probable forecast transaction arising change foreign exchange rate interest rate inception designated hedging relationship group document risk management objective strategy undertaking hedge group also document economic relationship hedged item hedging instrument including whether change cash flow hedged item hedging instrument expected offset cash flow hedge derivative designated cash flow hedging instrument effective portion change fair value derivative recognised oci accumulated equity effective portion cash flow hedge effective portion change fair value derivative recognised oci limited cumulative change fair value hedged item determined present value basis inception hedge ineffective portion change fair value derivative recognised immediately statement profit loss hedge longer meet criterion hedge accounting hedging instrument sold expires terminated exercised hedge accounting discontinued prospectively hedge accounting cash flow hedge discontinued amount accumulated equity remains hedge transaction resulting recognition nonfinancial item included nonfinancial item cost initial recognition cash flow hedge reclassified profit loss period period hedged expected future cash flow affect profit loss ahead curve annual report biocon limited subsidiary hedged future cash flow longer expected occur amount accumulated equity immediately reclassified profit loss v treasury share group created employee welfare trust ewt providing sharebased payment employee equity instrument reacquired treasury share recognised cost deducted equity treasury share issued employee ewt amount received recognised increase equity resultant gain loss transferred security premium vi offsetting financial asset financial liability offset net amount presented balance sheet group currently legally enforceable right set amount intends either settle net basis realise asset settle liability simultaneously vii cash cash equivalent cash cash equivalent balance sheet comprise cash bank hand shortterm deposit original maturity three month less subject insignificant risk change value purpose statement cash flow cash cash equivalent consist cash shortterm deposit defined net outstanding bank overdraft considered integral part group cash management viii cash dividend equity holder group recognises liability make cash distribution equity holder distribution authorised distribution longer discretion group per corporate law india distribution authorised approved shareholder corresponding amount recognised directly equity interim dividend recorded liability date declaration company board director property plant equipment recognition measurement item property plant equipment measured cost less accumulated depreciation accumulated impairment loss cost selfconstructed item property plant equipment comprises cost material direct labour cost directly attributable bringing item working condition intended use estimated cost dismantling removing item restoring site located significant part item property plant equipment different useful life accounted separate item major component property plant equipment gain loss disposal item property plant equipment recognised statement profit loss subsequent expenditure capitalised probable future economic benefit associated expenditure flow group ii depreciation depreciation calculated cost item property plant equipment less estimated residual value estimated useful life using straightline method asset acquired finance lease depreciated shorter lease term useful life unless reasonably certain group obtain ownership end lease term freehold land depreciated estimated useful life item property plant equipment current comparative period follows asset management estimate useful life per useful life schedule ii building year year road year year plant equipment including electrical installation lab equipment year year computer server year year office equipment year year research development equipment year year furniture fixture year year vehicle year year leasehold improvement year lease period whichever lower depreciation method useful life residual value reviewed financial yearend adjusted appropriate based technical evaluation consequent advice management belief estimate useful life given best represent period management expects use asset depreciation addition disposal provided prorata basis ie upto date asset ready use disposed financial report e goodwill intangible asset goodwill measurement goodwill arises business combination refer note subsequent measurement cost less accumulated impairment loss ii intangible asset internally generated research development expenditure research activity recognised statement profit loss incurred development expenditure capitalised part cost resulting intangible asset expenditure measured reliably product process technically commercially feasible future economic benefit probable group intends sufficient resource complete development use sell asset otherwise recognised statement profit loss incurred subsequent initial recognition asset measured cost less accumulated amortisation accumulated impairment loss others intangible asset initially measured cost subsequently intangible asset measured cost less accumulated amortization accumulated impairment loss iii subsequent expenditure subsequent expenditure capitalised increase future economic benefit embodied specific asset relates expenditure including expenditure internally generated goodwill brand recognised statement profit loss incurred iv amortisation goodwill amortised tested impairment annually intangible asset amortised straight line basis estimated useful life follows computer software year marketing manufacturing right year customer related intangible year amortisation method useful life residual value reviewed end financial year adjusted appropriate f investment property investment property property held either earn rental income capital appreciation sale ordinary course business use production supply good service administrative purpose upon initial recognition investment property measured cost subsequent initial recognition investment property measured cost less accumulated depreciation accumulated impairment loss based technical evaluation consequent advice management belief period year representing best estimate period investment property quite similar expected used accordingly group depreciates investment property period year straightline basis useful life estimate year different indicative useful life relevant type building mentioned part c schedule ii act ie year gain loss disposal investment property recognised statement profit loss g business combination accordance ind business combination group account business combination acquisition date using acquisition method control transferred company see note cost acquisition measured fair value asset given equity instrument issued liability incurred assumed date exchange cost acquisition also includes fair value contingent consideration deferred consideration goodwill arises tested annually impairment gain bargain purchase recognised oci accumulated equity capital reserve exists clear evidence underlying reason classifying business combination resulting bargain purchase otherwise gain recognised directly equity capital reserve transaction cost expensed incurred h inventory inventory measured lower cost net realisable value cost inventory based firstin firstout formula includes expenditure incurred acquiring inventory production conversion cost cost incurred bringing present location condition case manufactured inventory workinprogress cost includes appropriate share fixed production overhead based normal operating capacity net realisable value estimated selling price ordinary course business less estimated cost completion selling expense net realisable value workinprogress determined reference selling price related finished product raw material component supply held use production finished product written cost except case material price declined estimated cost finished product exceed net realisable value ahead curve annual report biocon limited subsidiary comparison cost net realisable value made itembyitem basis impairment impairment financial asset accordance ind group applies expected credit loss ecl model measurement recognition impairment loss following financial asset measured amortised cost financial asset measured fvoci debt investment loss allowance trade receivables significant financing component measured amount equal lifetime expected credit loss financial asset ecl measured amount equal month ecl unless significant increase credit risk initial recognition case measured lifetime ecl loss allowance financial asset measured amortised cost deducted gross carrying amount asset debt security fvoci loss allowance charged statement profit loss recognised oci ii impairment nonfinancial asset group assesses reporting date whether indication carrying amount may recoverable indication exists asset recoverable amount estimated impairment loss recognised carrying amount asset cgu exceeds estimated recoverable amount statement profit loss goodwill tested annually impairment purpose impairment testing goodwill arising business combination allocated cgus group cgus expected benefit synergy combination group nonfinancial asset inventory deferred tax asset reviewed reporting date determine whether indication impairment indication exists asset recoverable amount estimated impairment testing asset generate independent cash inflow grouped together cashgenerating unit cgus cgu represents smallest group asset generates cash inflow largely independent cash inflow asset cgus impairment loss recognised respect cgu allocated first reduce carrying amount goodwill allocated cgu reduce carrying amount asset cgu group cgus pro rata basis impairment loss respect goodwill subsequently reversed respect asset impairment loss recognised prior period group review reporting date whether indication loss decreased longer exists impairment loss reversed change estimate used determine recoverable amount reversal made extent asset carrying amount exceed carrying amount would determined net depreciation amortisation impairment loss recognised j employee benefit gratuity group provides gratuity defined benefit plan gratuity plan covering eligible employee company indian subsidiary gratuity plan provides lumpsum payment vested employee retirement death incapacitation termination employment amount based respective employee salary tenure employment group liability regard gratuity plan determined actuarial valuation performed independent actuary balance sheet date using projected unit credit method defined benefit plan administered trust formed purpose group gratuity scheme group recognises net obligation defined benefit plan liability balance sheet gain loss measurement net defined benefit liability recognised comprehensive income reclassified profit loss subsequent period actual return portfolio plan asset excess yield computed applying discount rate used measure defined benefit obligation recognised comprehensive income effect plan amendment recognised statement profit loss ii provident fund eligible employee company indian subsidiary receive benefit provident fund defined contribution plan eligible employee respective company make monthly contribution government administered provident fund scheme equal specified percentage eligible employee salary amount collected provident fund plan deposited government administered provident fund company obligation plan beyond monthly contribution iii compensated absence group policy compensated absence accumulating nonaccumulating nature expected cost accumulating compensated absence determined actuarial valuation performed independent actuary balance sheet date using projected unit credit method additional amount expected paidavailed result unused entitlement accumulated balance sheet date expense nonaccumulating compensated absence recognised period absence occur financial report iv sharebased compensation grant date fair value equity settled sharebased payment award granted employee recognised employee expense corresponding increase equity period employee unconditionally become entitled award amount recognised expense based estimate number award related service nonmarket vesting condition expected met amount ultimately recognised expense based number award meet related service nonmarket vesting condition vesting date k provision employee benefit provision recognised result past event group present legal constructive obligation estimated reliably probable outflow economic benefit required settle obligation provision determined discounting expected future cash flow representing best estimate expenditure required settle present obligation balance sheet date pretax rate reflects current market assessment time value money risk specific liability unwinding discount recognised finance cost expected future operating loss provided onerous contract contract considered onerous expected economic benefit derived group contract lower unavoidable cost meeting obligation contract provision onerous contract measured present value lower expected cost terminating contract expected net cost continuing contract provision made group recognises impairment loss asset associated contract l revenue sale good revenue recognized significant risk reward ownership transferred buyer recovery consideration probable associated cost possible return good estimate reliably continuing management involvement good amount revenue measured reliably timing transfer risk reward varies depending individual term sale revenue sale good includes excise duty measured fair value consideration received receivable net return sale tax applicable trade discount allowance ii milestone payment licensing arrangement company enters certain dossier sale licensing supply arrangement certain instance include certain performance obligation based evaluation whether obligation inconsequential perfunctory recognise defer upfront payment received arrangement deferred revenue recognised consolidated statement operation period complete remaining performance obligation arrangement typically also consist subsequent payment dependent achieving certain milestone accordance term prescribed agreement milestone payment contingent achieving certain clinical milestone recognized revenue either achievement milestone milestone considered substantive period continuing performance obligation milestone considered substantive milestone payment creditable future royalty payment milestone deferred released period royalty anticipated paid iii contract research manufacturing service income respect contract involving research service case time material contract contract research fee recognised service rendered accordance term contract revenue relating fixed price contract recognised based percentage completion method determined based effort expended proportion total estimated effort group monitor estimate total contract revenue cost routine basis throughout contract period cumulative impact change estimate contract revenue cost reflected period change become known event loss anticipated particular contract provision made estimated loss respect contract involving sale compound arising contract research service separate invoice raised revenue recognised significant risk reward ownership compound passed buyer comprise amount invoiced compound sold respect service group collect service tax applicable behalf government therefore economic benefit flowing group hence excluded revenue iv sale return allowance group account sale return recording allowance sale return concurrent recognition revenue time product sale allowance based group estimate expected sale return estimate sale return determined primarily group historical experience market group operates v dividend dividend recognised group right receive payment established generally shareholder approve dividend ahead curve annual report biocon limited subsidiary vi rental income rental income investment property recognised statement profit loss straightline basis term lease except rental structured increase line expected general inflation lease incentive granted recognised integral part total rental income term lease vii contribution received customerscodevelopment partner towards plant equipment contribution received customerscodevelopment partner towards item property plant equipment require obligation supply good customer future recognised credit deferred revenue contribution received recognised revenue operation useful life asset group capitalises gross cost asset group control asset government grant group recognizes government grant reasonable assurance condition attached complied grant received government grant received relation asset presented reduction carrying amount related asset grant related income deducted reporting related expense n income tax income tax comprises current deferred income tax income tax expense recognised statement profit loss except extent relates item recognised directly equity case recognised comprehensive income current income tax current year prior period recognised amount expected paid recovered tax authority using tax rate law enacted substantively enacted balance sheet date deferred income tax asset liability recognised temporary difference arising tax base asset liability carrying amount financial statement except taxable temporary difference arising initial recognition goodwill temporary difference arising initial recognition asset liability transaction business combination affect neither accounting taxable profit loss time transaction temporary difference related investment subsidiary associate joint arrangement extent group able control timing reversal temporary difference probable reverse foreseeable future deferred tax asset reviewed reporting date reduced extent longer probable related tax benefit realized deferred income tax asset liability measured using tax rate law enacted substantively enacted balance sheet date expected apply taxable income year temporary difference expected recovered settled effect change tax rate deferred income tax asset liability recognised income expense period includes enactment substantive enactment date deferred income tax asset recognised extent probable future taxable income available deductible temporary timing difference tax loss utilized deferred income tax provided undistributed earnings subsidiary expected earnings subsidiary distributed foreseeable future group offset incometax asset liability legally enforceable right set recognised amount intends either settle net basis realise asset settle liability simultaneously borrowing cost borrowing cost interest cost including exchange difference relating foreign currency borrowing extent regarded adjustment interest cost incurred connection borrowing fund borrowing cost directly attributable acquisition construction asset necessarily take substantial period time get ready intended use capitalised part cost asset borrowing cost recognised expense period incurred p earnings per share basic earnings per share computed using weighted average number equity share outstanding period adjusted treasury share held diluted earnings per share computed using weightedaverage number equity dilutive equivalent share outstanding period using treasury stock method option warrant except result would antidilutive q operating segment operating segment component group engages business activity may earn revenue incur expense including revenue expense relate transaction group component discrete financial information available operating segment reported manner consistent internal reporting provided chief operating decision maker chairperson managing director company responsible allocating resource assessing performance operating segment accordingly identified chief operating decision maker codm operating segment operating result reviewed regularly codm make decision resource allocated segment assess performance financial report property plant equipment capital workinprogress land building leasehold plant research furniture vehicle total capital work improvement equipment development inprogress equipment fixture refer note refer note c refer note f gross carrying amount april addition disposal adjustment foreign currency translation march addition disposal adjustment foreign currency translation march accumulated depreciation april depreciation year disposal adjustment foreign currency translation march depreciation year disposal adjustment foreign currency translation march net carrying amount april march march land includes land held leasehold basis gross carrying amount nil march net carrying amount nil march b year ended march group acquired business pharmaceutical manufacturing unit acacia lifesciences private limited located vishakhapatnam effect october also refer note c plant equipment include computer office equipment foreign exchange gain march long term foreign currency monetary liability relating acquisition depreciable capital asset adjusted cost asset depreciated balance life asset e addition property plant equipment includes addition related research development amounting march f capital workinprogress march mainly comprises new biopharmaceutical manufacturing unit constructed india g detail security certain property plant equipment refer note b e f space intentionally left blank ahead curve annual report biocon limited subsidiary investment property gross carrying amount april march march accumulated depreciation april depreciation year march depreciation year march net carrying amount april march march year company recognised rental income march depreciation charge march statement profit loss investment property fair value investment property march march april intangible asset goodwill intangible asset intangible asset development marketing ip customer total product marketing total intangible manufacturing commercialisation related right asset right intangible development refer note refer note b refer note gross carrying amount april addition adjustment impairment refer note foreign currency translation march addition adjustment foreign currency translation march accumulated amortisation april amortisation year march amortisation year march net carrying amount april march march group acquired intellectual property right system biology pharma service practice along team data scientist strand life science private limited sum effect august b pursuant asset purchase agreement customer executed year ended march group acquired marketing manufacturing right product sum financial report noncurrent investment march march april unquoted equity instrument others energon kn wind power private limited march nil april nil equity share less provision decline temporary value noncurrent investment total unquoted investment equity instrument ii unquoted preference share associate company iatrica inc usa march april series preferred stock u par value u less provision decline temporary value noncurrent investment others vaccinex inc usa march april series b preferred convertible stock u par value u vaccinex inc usa march april series b preferred convertible stock u par value u less provision decline temporary value noncurrent investment energon kn wind power private limited march nil april nil compulsorily convertible preference share par value less provision decline temporary value noncurrent investment total unquoted investment preference share iii unquoted debenture bond others lic housing finance co ltd march nil april nil bond par value hdfc ltd march nil april nil bond par value total unquoted investment debenture bond total noncurrent investment aggregate value unquoted investment aggregate amount impairment value investment company invested national saving certificate unquoted disclosed since amount rounded rupee million financial asset march march april noncurrent interest accrued due deposit b current interest accrued due unbilled revenue receivables ahead curve annual report biocon limited subsidiary deferred tax asset net march march april deferred tax liability property plant equipment investment property intangible asset derivative asset others gross deferred tax liability deferred tax asset employee benefit obligation allowance doubtful debt disallowable expense deferred revenue mat credit entitlement derivative liability tax loss others gross deferred tax asset net deferred tax asset asset noncurrent capital advance duty drawback receivable balance statutory government authority prepayment b current balance statutory government authority prepayment inventory raw material including goodsinbond packing material traded good finished good workinprogress includes good intransit nil march april nil writedown inventory net realisable value amounted march recognised expense year included change inventory traded good finished good workinprogress statement profit loss space intentionally left blank financial report march march april current investment unquoted investment mutual fund birla sun life short term fund growth march nil april nil unit dhfl pramerica banking psu debt fund gr march nil april nil unit axis liquid fund daily dividend reinvestment nil march nil april unit dws banking psu debt fund weekly dividend reinvestment nil march april nil unit edelweiss banking psu debt fund regular plan growth march nil april nil unit hdfc liquid fund daily dividend reinvestment nil march nil april unit hdfc medium term opportunity fund regular plan growth march nil april nil unit hdfc short term opportunity fund regular plan growth march nil april nil unit idfc cash fund daily dividend regular plan nil march nil april unit jp morgan banking psu debt fund weekly dividend reinvestment option nil unit march unit april nil unit reliance banking psu debt fund weekly dividend plan nil march april nil unit reliance banking psu debt fund growth unit march nil unit april nil unit reliance liquidity fund daily dividend reinvestment option nil march nil april unit sbi premier liquid fund regular plan daily dividend nil march april nil unit tata fixed maturity plan series scheme c plan growth nil march nil april unit tata liquid fund plan daily dividend nil march nil april unit uti treasury advantage fund institutional plan daily dividend reinvestment march april unit uti treasury advantage fund march nil april nil unit reliance money manager fund march nil april nil unit kotak treasury advantage fund march nil april nil unit hdfc floating rate income fund march nil april nil unit franklin india ultra short bond fund super institutional plan march nil april nil unit idfc ultra short term fund march nil april nil unit hdfc floating rate income fund march nil april nil unit franklin india ultra short bond fund super institutional plan march nil april nil unit birla saving fund march nil april nil unit icici prudential flexible income fund march nil april nil unit baroda pioneer liquid fund plan daily dividend nil march april nil unit axis liquid fund daily dividend nil march april nil unit utitreasury advantage fund daily dividend reinvestment nil march april nil unit birla sun life saving fund daily dividend regular plan march april unit birla sun life cash plus daily dividend direct plan nil march nil april unit birla sun life cash plus daily dividend nil march nil april unit icici fmp series plan k dividend nil march april nil unit icici prudential flexible income daily dividend march april unit icici prudential liquid regular plan daily dividend nil march nil april unit ahead curve annual report biocon limited subsidiary march march april jp morgan liquid fund daily dividend nil march nil april unit tata floater fund plan daily dividend nil march nil april unit hdfc liquid fund direct plan daily dividend nil march nil april unit hdfc liquid fund regular plan daily dividend nil march nil april unit hdfc liquid fund daily dividend reinvestment nil march april nil unit hdfc floating rate income fund short term dividend reinvestment nil march april unit kotak liquid scheme plan direct plan daily dividend nil march nil april unit kotak liquid fund plan regular plan daily dividend nil march nil april unit reliance money manager fund daily dividend plan nil march april nil unit reliance liquid fund regular plan daily dividend nil march april unit reliance liquid fund cash plan daily dividend nil march nil april unit others inter corporate deposit financial institution aggregate value unquoted investment trade receivables unsecured considered good doubtful allowance credit loss includes due narayana hrudayalaya limited nhl formerly known narayana hrudayalaya private limited director company member board director nhl group exposure credit currency risk loss allowance disclosed note cash bank balance cash cash equivalent balance bank current account unpaid dividend account deposit original maturity less month total cash cash equivalent bank balance deposit maturity less month margin money deposit refer note total bank balance total cash bank balance margin money deposit carrying amount march april subject first charge bank guarantee obtained b group cash hand disclosed since amount rounded rupee million financial report march march april equity share capital authorised march april equity share march april issued subscribed fully paidup march april equity share march april reconciliation share outstanding beginning end reporting period equity share march march million million beginning year issued year outstanding end year ii termsrights attached equity share company one class equity share par value per share holder equity share entitled one vote per share company declares pay dividend indian rupee dividend proposed board director subject approval shareholder ensuing annual general meeting event liquidation company holder equity share entitled receive remaining asset company distribution preferential amount distribution proportion number equity share held shareholder iii detail shareholder holding share company march march holding holding equity share fully paid dr kiran mazumdarshaw glentec international limited per record company including register shareholder member shareholding represents legal beneficial ownership share iv share reserved issue option detail share reserved issue employee stock option plan esop company refer note b equity security premium reserve security premium used record premium received issue share utilised accordance provision company act general reserve general reserve used time time transfer profit retained earnings appropriation purpose retained earnings amount distributed company dividend equity shareholder determined based standalone financial statement company also considering requirement act thus amount reported distributable entirety sez reinvestment reserve sez reinvestment reserve created profit eligible sez unit term provision section aaii incometax act reserve utilised acquiring new plant machinery purpose business term section aa incometax act share based payment reserve group established various equity settled sharebased payment plan certain category employee group also refer note detail plan treasury share equity instrument reacquired treasury share recognised cost deducted equity foreign currency translation reserve exchange difference relating translation result net asset group foreign operation functional currency group reporting currency ie accumulated foreign currency translation reserve cash flow hedging reserve cash flow hedging reserve represents cumulative effective portion gain loss net tax arising change fair value designated portion hedging instrument entered cash flow hedge ahead curve annual report biocon limited subsidiary longterm borrowing march march april deferred sale tax liability unsecured refer note loan bank secured term loan refer note b e f buyer credit refer note c loan advance unsecured nmitli csir loan refer note g financial assistance dsir refer note h financial assistance dst refer note less amount disclosed head current financial liability refer note b amount includes secured borrowing unsecured borrowing amount disclosed head current financial liability refer note b net amount february company obtained order karnataka sale tax authority allowing interest free deferment sale tax including turnover tax period upto year respect sale hebbagodi manufacturing facility amount exceeding interest free liability amount repayable equal half yearly instalment starting february loan repaid year b year ended march company obtained external commercial borrowing facility usd million bank term loan facility secured first priority paripassu charge plant machinery proposed expanded facility line existing facility longterm loan repayable equal quarterly instalment usd million commencing december carry interest rate libor pa company entered interest rate swap convert floating rate fixed rate also refer note c syngene international limited syngene obtained foreign currency denominated long term secured buyer credit loan usd million march usd million april usd million hsbc bank mauritius limited carry interest rate range libor libor pa loan guaranteed hong kong shanghai banking corporation limited india hsbc bank mauritius limited credit facility provided hong kong shanghai banking corporation limited india secured pari passu charge current asset movable fixed asset syngene loan repayable end day day date origination syngene entered external commercial borrowing agreement hong kong shanghai banking corporation limited agent citibank na hsbc bank mauritius limited lead arranger dated march borrow usd million comprising usd million term loan facility facility b usd million term loan facility facility b facility borrowed incur capital expenditure bangalore mangalore premise syngene ii facility usd million carry interest rate libor pa repayable two installment usd million march usd million march facility b usd million carry interest rate libor pa repayable march iii facility provided secured first priority pari passu charge fixed asset second charge current asset syngene e year ended march biocon pharma limited bpl obtained external commercial borrowing usd million bank carrying interest libor pa loan payable unequal quarterly instalment commencing june loan secured first priority paripassu charge plant machinery facility manufacture pharmaceutical bpl entered interest rate swap convert floating rate fixed rate f biocon sdn bhd malaysia biocon malaysia obtained term loan facility usd million consortium bank year ended march biocon sdn bhd refinanced existing term loan standard chartered bank hong kong limited loan repayable quarterly installment commencing march july biocon sdn bhd entered new term loan agreement standard chartered bank hong kong limited amount usd million loan repayable quarterly installment commencing march term loan denominated usd carry interest rate libor pa term loan secured fixed floating charge present future asset charge freehold property biocon malaysia g march company entered agreement council scientific industrial research csir unsecured loan carrying part research development project new millennium indian technology leadership initiative nmitli scheme loan repayable equal annual instalment starting april carry interest rate pa financial report h march department scientific industrial research dsir sanctioned financial assistance sum company part financing one research project assistance repayable form royalty payment three year post commercialisation project five equal annual instalment starting april august department science technology dst drug pharmaceutical research programme dprp sanctioned financial assistance sum company financing one research project loan repayable annual instalment starting july carry interest rate pa j respect financial assistance received aforesaid programme refer note g company required utilise fund specified project required obtain prior approval said authority disposal asset intellectual property right acquired developed programme k group exposure liquidity interest rate currency risk disclosed note march march april financial liability noncurrent interest accrued due b current current maturity longterm borrowing refer note unpaid dividend payable capital good interim dividend equity share provision noncurrent provision employee benefit gratuity refer note b current provision employee benefit gratuity refer note compensated absence provision sale return movement provision gratuity compensated sale return absence opening balance provision recognised reversed year closing balance march march april liability noncurrent deferred revenue b current deferred revenue advance customer book overdraft statutory tax due payable ahead curve annual report biocon limited subsidiary march march april shortterm borrowing banksfinancial institution packing credit foreign currency loan unsecured refer note ii iii iv v packing credit foreign currency loan secured refer note vi vii cash credit secured refer note viii bank overdraft unsecured refer note ix amount includes secured borrowing unsecured borrowing year ended march company obtained unsecured foreign currency denominated loan usd million april nil usd nil carrying interest rate libor pa bank facility repayable within day date origination repaid year ii year ended march company obtained unsecured foreign currency denominated loan usd million april nil usd nil carrying interest rate libor pa bank facility repayable within day date origination repaid year iii year ended march company obtained foreign currency denominated loan usd million carrying interest rate libor pa bank facility repayable within day date origination repaid year ended march iv biocon research limited brl obtained foreign currency denominated loan usd million carrying interest rate libor pa bank april repaid year ended march v syngene obtained foreign currency denominated short term unsecured preshipment credit loan usd million march nil hdfc bank limited carry interest rate libor pa loan repayable end month date origination vi syngene obtained foreign currency denominated short term secured preshipment credit loan usd million march nil hong kong shanghai banking corporation limited carry interest rate libor pa loan repayable end month date origination facility provided secured pari passu charge current asset movable fixed asset syngene vii syngene obtained foreign currency denominated short term secured preshipment credit loan usd million march royal bank scotland n v carried interest rate libor pa loan repayable end month date origination facility provided secured charge fixed asset current asset syngene loan fully repaid current year ended march viii company working capital facility bank carrying interest rate ranging pa facility repayable demand secured paripassu first charge inventory trade receivables ix bpl obtained unsecured overdraft facility bank carrying interest rate pa march march april trade payable trade payable trade payable current group exposure currency liquidity risk related trade payable disclosed note space intentionally left blank financial report march march revenue operation sale product finished good traded good sale service licensing development fee contract research manufacturing service income operating revenue sale process waste others revenue operation income interest income deposit bank financial institution others dividend income current investment net gain sale current investment net gain financial asset measured fair value profit loss nonoperating income cost raw material packing material consumed inventory beginning year add purchase less inventory end year cost raw material packing material consumed change inventory traded good finished good workinprogress inventory beginning year traded good finished good workinprogress inventory end year traded good finished good workinprogress employee benefit expense salary wage bonus contribution provident fund gratuity refer note sharebased compensation expense refer note staff welfare expense finance cost interest expense financial liability measured amortised cost fair value change interest rate swap exchange difference extent considered adjustment borrowing cost ahead curve annual report biocon limited subsidiary march march depreciation amortisation expense depreciation tangible asset refer note amortisation intangible asset refer note less expense capitalised tangible asset expense royalty technical fee rent communication expense travelling conveyance professional charge payment auditor refer note director fee including commission power fuel insurance rate tax fee lab consumables repair maintenance plant machinery building others selling expense freight outwards clearing charge sale promotion expense commission brokerage sole selling agent bad debt written provision reversal doubtful debt net foreign exchange fluctuation net printing stationery research development expense refer note clinical trial development expense csr expenditure refer note miscellaneous expense less adjustment product development expense deferred revenue less expense capitalised intangible asset payment auditor auditor statutory audit fee tax audit fee limited review capacity service certification fee audit limited review fee relation ipo syngene reimbursement outofpocket expense payment year ended march represents fee reimbursement paid predecessor auditor research development expense research development expense research development expense included head b ab less recovery product development cost codevelopment partner net adjustment product development expense deferred revenue product development cost capitalised financial report employee stock compensation biocon esop plan september biocons board director approved biocon employee stock option plan esop plan grant stock option employee company subsidiary joint venture company nomination remuneration committee remuneration committee administers plan trust established specifically purpose called biocon india limited employee welfare trust esop trust esop trust shall make additional purchase equity share company using proceeds loan obtained company cash inflow allotment share employee esop plan shall subscribe allotted number share necessary transferring employee esop trust may also receive share promoter purpose issuance employee esop plan remuneration committee shall determine exercise price less face value share grant iv july company approved grant option face value share employee existing esop plan option grant would vest employee total grant end first second third year date grant existing employee end rd th th year date grant new employee exercise period year grant condition number option granted include service term performance grade employee option exercisable discount market price company share date grant detail grant iv particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year adjustment issuance bonus share year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year range exercise price outstanding option end year grant v april company approved grant employee existing esop plan option grant would vest employee total grant end first second third year date grant existing employee end rd th th year date grant new employee exercise period year grant condition number option granted include service term performance grade employee option exercisable market price company share date grant detail grant v particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year adjustment issuance bonus share year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year range exercise price outstanding option end year ahead curve annual report biocon limited subsidiary grant vi july company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing market price company share existing date preceding date grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year grant vii july company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing market price company share existing date preceding date grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year grant viii july company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing price per national stock exchange last day month preceding month first grant space intentionally left blank financial report particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year grant ix june company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing price per national stock exchange preceding day date grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year grant x june company approved grant employee existing esop plan option grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing price per national stock exchange preceding day date grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted range exercise price outstanding option end year ahead curve annual report biocon limited subsidiary assumption used determination fair value stock option black scholes model follows particular march march weighted average exercise price expected volatility historical volatility life option granted vesting exercise period year expected dividend per share average riskfree interest rate expected dividend rate expected volatility based historical volatility market price company publicly traded equity share expected term option grant b rsu plan march biocons remuneration committee approved biocon restricted stock unit rsus syngene rsu plan grant rsus employee company subsidiary syngene remuneration committee administers plan trust established specifically purpose called biocon limited employee welfare trust rsu trust purpose march company transferred equity share syngene rsu trust april company approved grant employee rsu plan rsus grant would vest employee total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee exercise price rsus nil particular march march number weighted number weighted unit average unit average exercise price exercise price outstanding beginning year granted year forfeited year exercised year expired year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted assumption used determination fair value stock option black scholes model follows particular march march weighted average exercise price expected volatility historical volatility life option granted vesting exercise period year expected dividend per share average riskfree interest rate expected dividend rate expected volatility based historical volatility market price syngenes publicly traded equity share expected term option grant c syngene esop plan july syngene employee welfare trust trust created welfare benefit employee director syngene board director approved employee stock option plan syngene october trust subscribed equity share face value per share syngene using proceeds interest free loan obtained syngene march trust hold march march equity share face value adjusted consolidation share bonus issue march trust transferred march march nil equity share employee exercise stock option financial report grant pursuant scheme syngene granted option eligible employee syngene syngene employee stock option plan option entitles one equity share option grant vest employee total grant end second third fourth year date grant respectively exercise period three year grant vesting condition include service term performance employee option exercisable exercise price per share face value per share detail grant particular march march number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year forfeited year exercised year outstanding end year exercisable end year weighted average remaining contractual life year weighted average fair value option granted weighted average share price date exercise assumption used determination fair value stock option black scholes model follows particular march march dividend yield exercise price volatility life option granted vesting exercise period average riskfree interest rate march march summary movement respect share held esop trust follows opening balance add share purchased esop trust less share exercised employee closing balance option granted eligible exercise end year option granted eligible exercise end year summary movement respect equity share syngene held rsu trust follows opening balance less share exercised employee closing balance march march earnings per share eps earnings profit year attributable shareholder company share basic outstanding share less weighted average share held esop trust weighted average share used computing basic eps add effect dilutive option granted yet exercised yet eligible exercise weighted average share used computing diluted eps earnings per share basic diluted ahead curve annual report biocon limited subsidiary march march exceptional item net impairment loss intangible asset refer note recognition deferred revenue refer note b loss account fire refer note less recoverable insurance company pursuant uncertainty respect ability group license product development commercialization certain territory biocon sa recorded impairment carrying value intangible asset amounting b consequent agreement customer resulted change nature group future obligation rhinsulin program deferred revenue relating program recognised income consolidated financial statement year ended march c year ended march syngene international limited syngene completed initial public offering ipo offer sale equity share company gain arising sale equity share net related expense cost equity share amounting recorded credit equity consolidated financial statement net consequential tax gain mat credit transaction recorded previous year due uncertainty utilisation current year pursuant change income tax law business restructuring company belief able utilize mat credit entitlement accordingly year ended march company recorded mat credit entitlement included income tax expense standalone financial statement however consolidated financial statement entitlement recognised credit equity along underlying dilution gain sale equity stake syngene impact group control pursuant fire incident december certain fixed asset inventory content one building syngene damaged syngene lodged initial estimate loss insurance company survey currently ongoing year ended march syngene written net book value asset aggregating recognised minimum insurance claim receivable equivalent amount current year group received initial disbursement insurance company adjusted amount recoverable insurance company addition group process determining claim business interruption accordingly recorded claim arising therefrom stage e current year biocon sa bsa biocon sdn bhd biocon malaysia entered assignment license agreement pursuant bsa transferred right interest obligation insulin analog ipr biocon malaysia consequent transfer bsa recorded net gain standalone book offered tax swiss tax law restructuring impact consolidated financial statement except exceptional tax cost representing tax payable bsa locally included within income tax expense year ended march disclosure specified bank note sbns year group specified bank note denomination note defined mca notification gsr e dated march detail specified bank note sbn held transacted period november december denomination wise sbns note per notification given amount particular sbns total denomination note closing cash hand november permitted receipt permitted payment amount deposited bank closing cash hand december purpose clause term specified bank note shall meaning provided notification government india ministry finance department economic affair number e dated november financial report related party transaction related party control exists related party transaction taken place year listed sl name related party relationship description april balance april balance balance transaction march march march march april incomeexpenses payable incomeexpenses payable payable transaction receivable transaction receivable receivable remuneration paid key management personnel refer note kiran mazumdarshaw chairperson managing director salary perquisite john shaw vicechairman director salary perquisite arun chandavarkar joint managing director ceo salary perquisite siddharth mittal president finance chief salary perquisite financial officer kiran kumar company secretary salary perquisite upto dec rajiv balakrishnan company secretary salary perquisite wef jan b others glentec international enterprise owned key rent expense paid ahead curve annual report limited management personnel biocon foundation trust key management csr expenditure personnel board trustee narayana hrudayalaya enterprise director sale good limited formerly known company member trade receivables narayana hrudayalaya board director private limited remuneration key managerial personnel include provision made gratuity compensated absence obtained actuarial basis company whole b sharebased compensation expense allocable key management personnel march included remuneration disclosed c disclosure include related party per ind related party disclosure company act year transaction biocon india limited employee welfare trust trust key management personnel board trustee e transaction related party priced arm length basis none balance secured f group purchased consumables mazumdar farm proprietary firm relative director disclosed since amount rounded rupee million space intentionally left blank biocon limited subsidiary march march april contingent liability commitment extent provided contingent liability claim company acknowledged debt includes direct taxation ii indirect taxation includes matter pertaining dispute central excise custom duty service tax iii litigation group involved taxation dispute lawsuit proceeding etc including patent commercial matter arise time time ordinary course business management view claim tenable material adverse effect group financial position result operation b guarantee corporate guarantee given central excise department ii guarantee given bank behalf group contractual obligation group ii commitment estimated amount contract remaining executed capital account provided net advance b operating lease commitment company lessee vehicle company taken vehicle certain employee operating lease expire period upto january gross rental expense year aggregate march committed lease rental future follows later one year later one year later five year space intentionally left blank financial report employee benefit plan group defined benefit gratuity plan per payment gratuity act employee india legislation employee completed five year service entitled specific benefit level benefit provided depends employee length service salary retirementtermination age based actuarial valuation obtained respect following table set status gratuity plan amount recognised group financial statement balance sheet date defined benefit fair value net defined obligation plan asset benefit assetliability balance april current service cost interest expenseincome amount recognised statement profit loss remeasurements return plan asset excluding amount included interest expense income actuarial gainloss arising demographic assumption financial assumption experience adjustment amount recognised comprehensive income employer contribution benefit paid balance march defined benefit fair value net defined obligation plan asset benefit asset liability balance april current service cost interest expense income amount recognised statement profit loss remeasurements return plan asset excluding amount included interest expense income actuarial gain loss arising demographic assumption financial assumption experience adjustment amount recognised comprehensive income employer contribution benefit paid balance march march march april noncurrent current space intentionally left blank ahead curve annual report biocon limited subsidiary ii assumption used gratuity valuation march march april interest rate discount rate expected return plan asset salary increase attrition rate retirement age year assumption regarding future mortality experience set accordance published statistic mortality table weighted average duration defined benefit obligation year march year defined benefit plan expose group actuarial risk longevity interest rate risk iii sensitivity analysis sensitivity defined benefit obligation change weighted principal assumption particular march march increase decrease increase decrease discount rate salary increase attrition rate sensitivity significant actuarial assumption computed varying one actuarial assumption used valuation defined benefit obligation one percentage keeping actuarial assumption constant although analysis take account full distribution cash flow expected plan provide approximation sensitivity assumption shown march march plan asset invested insurer managed fund expected contribution fund year ending march approximately march maturity profile defined benefit obligation particular million st following year nd following year rd following year th following year th following year year business combination year ended march group acquired business pharmaceutical manufacturing unit acacia lifesciences private limited located vishakhapatnam effect october going concern basis consideration paid cash transaction accounted ind business combination business combination purchase price allocated identifiable asset liability fair value following table present allocation purchase price particular amount net tangible asset customer related intangible total purchase price space intentionally left blank financial report financial instrument fair value risk management accounting classification fair value carrying amount fair value march fvtpl fvtoci amortised total level level level total cost financial asset noncurrent investment derivative asset current investment trade receivables cash cash equivalent bank balance financial asset financial liability borrowing trade payable derivative liability financial liability march fvtpl fvtoci amortised total level level level total cost financial asset derivative asset current investment trade receivables cash cash equivalent bank balance financial asset financial liability borrowing trade payable derivative liability financial liability april fvtpl fvtoci amortised total level level level total cost financial asset derivative asset current investment trade receivables cash cash equivalent bank balance financial asset financial liability borrowing trade payable derivative liability financial liability ahead curve annual report biocon limited subsidiary b measurement fair value fair value liquid mutual fund based quoted price derivative financial instrument valued based quoted price similar asset liability active market input directly indirectly observable market place sensitivity analysis fair value forward contract foreign currency reasonably possible change reporting date one significant observable input holding input constant would following effect march march profit loss profit loss significant observable input increase decrease increase decrease spot rate foreign currency movement interest rate bps movement c financial risk management group exposure following risk arising financial instrument credit risk liquidity risk market risk risk management framework group risk management carried treasury department policy approved board director board provides written principle overall risk management well policy covering specific area foreign exchange risk interest rate risk credit risk use derivative nonderivative financial instrument investment excess liquidity credit risk credit risk risk counterparty meet obligation financial instrument customer contract leading financial loss credit risk arises principally operating activity primarily trade receivables financing activity including deposit bank financial institution financial instrument customer credit risk managed business unit subject group established policy procedure control relating customer credit risk management audit risk management committee respective company established credit policy new customer analysed individually creditworthiness group standard payment delivery term condition offered group review includes external rating available publicly available financial information outstanding customer receivables regularly monitored shipment major customer generally covered letter credit form credit insurance group establishes allowance impairment represents estimate expected loss respect trade receivables maximum exposure credit risk reporting date primarily trade receivables amounting march april movement allowance impairment respect trade receivables year follows allowance credit loss march march opening balance allowance credit loss recognised reversed closing balance single customer accounted trade receivables march significant concentration credit risk credit risk cash cash equivalent derivative limited group generally transacts bank financial institution high credit rating assigned international domestic credit rating agency investment primarily include investment liquid mutual fund unit bond nonconvertible debenture ii liquidity risk liquidity risk risk group encounter difficulty meeting obligation associated financial liability settled delivering cash another financial asset group approach managing liquidity ensure far possible sufficient liquidity meet liability due normal stressed condition without incurring unacceptable loss risking damage company reputation financial report group belief working capital sufficient meet current requirement accordingly liquidity risk perceived addition group maintains following line credit syngene obtained long term secured buyer credit loan usd million march usd million march carrying interest rate range libor pa libor pa repayable end day day date origination b syngene obtained short term secured preshipment credit loan usd million march nil carry interest rate libor pa repayable end month date origination c syngene obtained short term unsecured preshipment credit loan usd million march nil carry interest rate libor pa repayable end month date origination cash credit facility bank carrying interest rate ranging pa facility repayable demand secured paripassu charge inventory trade receivables e bpl obtained unsecured overdraft facility bank carrying interest rate pa table provides detail regarding undiscounted contractual maturity significant financial liability march particular less year year year year total longterm borrowing shortterm borrowing trade payable financial liability total table provides detail regarding undiscounted contractual maturity significant financial liability march particular less year year year year total longterm borrowing shortterm borrowing trade payable financial liability total table provides detail regarding undiscounted contractual maturity significant financial liability april particular less year year year year total longterm borrowing shortterm borrowing trade payable financial liability total iii market risk market risk risk fair value future cash flow financial instrument fluctuate change market price foreign exchange rate interest rate equity price foreign currency risk group operates internationally major portion business transacted several currency consequently group exposed foreign exchange risk operating borrowing activity foreign currency group hold derivative instrument foreign exchange forward option contract mitigate risk change exchange rate foreign currency exposure space intentionally left blank ahead curve annual report biocon limited subsidiary currency profile financial asset financial liability march march march usd eur others total financial asset trade receivables cash cash equivalent financial asset financial liability noncurrent borrowing current borrowing derivative liability trade payable financial liability net financial asset liability march usd eur others total financial asset trade receivables cash cash equivalent financial asset financial liability noncurrent borrowing current borrowing derivative liability trade payable financial liability net financial asset liability sensitivity analysis sensitivity profit loss change exchange rate arises mainly foreign currency denominated financial instrument impact component equity arises foreign exchange forwardoption contract designated cash flow hedge particular impact profit loss impact component equity march march march march usd sensitivity inrusd increase inrusd decrease eur sensitivity inreur increase inreur decrease derivative financial instrument following table give detail respect outstanding foreign exchange forward option contract particular march march million foreign exchange forward contract buy usd usd inr inr european style option contract periodical maturity date usd usd inr inr european style option contract periodical maturity date usd usd conversion myr inr inr european style option contract periodical maturity date eur eur inr inr financial report cash flow fair value interest rate risk company main interest rate risk arises longterm borrowing variable rate expose company cash flow interest rate risk year ended march march company borrowing variable rate mainly denominated usd interest rate risk exposure exposure company borrowing interest rate change end reporting period follows particular march march april variable rate borrowing fixed rate borrowing total borrowing b sensitivity company policy maintain borrowing fixed rate using interest rate swap achieve necessary therefore subject interest rate risk defined ind since neither carrying amount future cash flow fluctuate change market interest rate capital management key objective group capital management ensure maintains stable capital structure focus total equity uphold investor creditor customer confidence ensure future development business group focused keeping strong total equity base ensure independence security well high financial flexibility potential future borrowing required without impacting risk profile group company goal continue able return excess liquidity shareholder continuing distribute annual dividend future period amount future dividend equity share balanced effort continue maintain adequate liquidity status capital structure march follows particular march march total equity attributable owner company percentage total capital longterm borrowing shortterm borrowing total borrowing percentage total capital total capital equity borrowing firsttime adoption ind consolidated financial statement prepared accordance ind purpose transition previous gaap ind group followed guidance prescribed ind first time adoption indian accounting standard ind effect april transition date preparing ind balance sheet april presenting comparative information year ended march group adjusted amount reported previously financial statement prepared accordance previous gaap note explains transition previous gaap ind affected group balance sheet financial performance optional exemption availed mandatory exception preparing consolidated financial statement group applied mentioned optional exemption mandatory exception optional exemption availed deemed cost joint venture per ind changing proportionate consolidation method equity method entity may measure investment joint venture date transition aggregate carrying amount asset liability entity previously proportionately consolidated including goodwill arising acquisition resultant amount regarded deemed cost investment joint venture initial recognition group opted avail exemption business combination ind provides option apply ind business combination prospectively transition date specific date prior transition date ahead curve annual report biocon limited subsidiary group elected apply ind prospectively business combination occurring transition date business combination occurring prior transition date restated share based payment ind sharebased payment applied equity instrument sharebased payment transaction vested april cashsettled sharebased payment transaction group applied ind liability settled april mandatory exemption availed estimate per ind entity estimate accordance ind date transition ind shall consistent estimate made date accordance previous gaap unless objective evidence estimate error group estimate ind consistent requirement key estimate considered preparation financial statement required previous gaap listed fair valuation financial instrument carried fvtpl fvoci impairment financial asset based expected credit loss model determination discounted value financial instrument carried amortised cost classification measurement financial asset ind requires entity assess classification financial asset basis fact circumstance existing date transition standard permit measurement financial asset accounted amortised cost based fact circumstance existing date transition retrospective application impracticable accordingly group determined classification financial asset based fact circumstance exist date transition measurement financial asset accounted amortised cost done retrospectively except impracticable hedge accounting hedge accounting applied prospectively transition date transaction satisfy hedge accounting criterion ind financial instrument date transition hedging relationship cannot designated retrospectively supporting documentation cannot created retrospectively result hedging relationship satisfied hedge accounting criterion date transition reflected hedge consolidated financial statement ind space intentionally left blank financial report b reconciliation following reconciliation provides effect transition ind previous gaap accordance ind firsttime adoption ind previous gaap adjustment ind reconciliation equity april asset noncurrent asset property plant equipment capital workinprogress investment property goodwill intangible asset intangible asset development investment associate joint venture financial asset derivative asset ii financial asset incometax asset net deferred tax asset net noncurrent asset total noncurrent asset current asset inventory financial asset investment ii trade receivables iii cash cash equivalent iv bank balance v derivative asset vi financial asset current asset total current asset total equity liability equity equity share capital equity equity attributable owner company noncontrolling interest total equity noncurrent liability financial liability borrowing ii derivative liability iii financial liability provision noncurrent liability total noncurrent liability current liability financial liability borrowing ii trade payable iii derivative liability iv financial liability provision income tax liability net current liability total current liability total ahead curve annual report biocon limited subsidiary previous gaap adjustment ind ii reconciliation equity march asset noncurrent asset property plant equipment capital workinprogress investment property goodwill intangible asset intangible asset development investment associate joint venture financial asset derivative asset ii financial asset incometax asset net deferred tax asset net noncurrent asset total noncurrent asset current asset inventory financial asset investment ii trade receivables iii cash cash equivalent iv bank balance v derivative asset vi financial asset current asset total current asset total equity liability equity equity share capital equity equity attributable owner company noncontrolling interest total equity noncurrent liability financial liability borrowing ii derivative liability iii financial liability provision noncurrent liability total noncurrent liability current liability financial liability borrowing ii trade payable iii derivative liability iv financial liability provision income tax liability net current liability total current liability total financial report previous gaap adjustment ind iii reconciliation statement profit loss year ended march income revenue operation income total income expense cost raw material packing material consumed purchase traded good increase decrease inventory finished good traded good workinprogress excise duty employee benefit expense finance cost depreciation amortisation net expense less recovery product development cost codevelopment partner net total expense profit tax share profit exceptional item share net profit joint venture profit tax exceptional item exceptional item net profit tax tax expense current tax less mat credit entitlement deferred tax total tax expense profit year comprehensive income item subsequently reclassified profit loss remeasurement gainslosses defined benefit plan income tax effect ii item may subsequently reclassified profit loss net movement cash flow hedge income tax effect total comprehensive income year net tax total comprehensive income year iv reconciliation total equity note march april equity previous gaap attributable shareholder company adjustment difference account revenue recognition net related cost impact derivative accounting translation adjustment exchange gainloss ii viii impact borrowing cost iii consolidation esop trust x adjustment iv income tax adjustment correction earlier year vi total adjustment equity ind attributable shareholder company ahead curve annual report biocon limited subsidiary v reconciliation net profit net profit reconciliation note year ended march net profit attributable owner company per previous gaap adjustment difference account revenue recognition net related cost impact derivative accounting exchange gainloss ii impact borrowing cost iii adjustment iv impact profit sale syngene share net tax v income tax impact adjustment correction earlier year vi total adjustment b profit year c ab comprehensive income oci actuarial loss defined benefit obligation gratuity vii effective portion cash flow hedge viii noncontrolling interest ix subtotal total comprehensive income year c note reconciliation difference account revenue recognition net related cost primarily due difference timing revenue recognition ind compared previous gaap deferral licensing income account continuing obligation ii impact due derivative accounting per ind exchange gain loss account change functional currency subsidiary iii impact account restructuring debt iv adjustment account employee benefit expense share based payment actuarial gainslosses mark market adjustment mutual fund v profit sale syngene share recognised credit equity impact group control vi income tax impact adjustment correction earlier year vii actuarial loss defined benefit obligation gratuity taken comprehensive income ind compared statement profit loss previous gaap viii effective portion cash flow hedge taken comprehensive income ix impact ind adjustment noncontrolling interest x group consolidated esop trust deconsolidated neobiocon fz llc pursuant ind consolidated financial statement space intentionally left blank financial report tax expense march march amount recognised statement profit loss current tax mat credit entitlement deferred tax expense income related origination reversal temporary difference tax expense year b reconciliation effective tax rate profit tax less exceptional item net profit tax exceptional item tax statutory income tax rate march tax effect amount deductibletaxable calculating taxable income difference overseas tax rate weighted deduction research development expenditure exempt income deduction nondeductible expense tax loss tax exceptional item share profit joint venture others income tax expense c tax loss unused tax loss deferred tax asset recognised potential tax impact expiry date financial year tax loss never expire space intentionally left blank ahead curve annual report biocon limited subsidiary recognised deferred tax asset liability following movement deferred tax asset liability presented consolidated balance sheet year ended opening recognised recognised recognised closing march balance profit loss oci equity balance deferred tax liability property plant equipment investment property intangible asset derivative asset others gross deferred tax liability deferred tax asset defined benefit obligation allowance doubtful debt disallowable expense deferred revenue mat credit entitlement derivative liability tax loss others gross deferred tax asset year ended opening recognised recognised recognised closing march balance profit loss oci equity balance deferred tax liability property plant equipment investment property intangible asset derivative asset gross deferred tax liability deferred tax asset defined benefit obligation allowance doubtful debt disallowable expense deferred revenue mat credit entitlement derivative liability tax loss others gross deferred tax asset space intentionally left blank financial report interest entity subsidiary group subsidiary march set unless otherwise stated share capital consisting solely equity share held group proportion ownership interest held equal voting right held group country incorporation registration also principal place business name entity country ownership interest held ownership interest held principal activity incorporation group noncontrolling interest march march april march march april syngene international limited india research service biocon research limited india research development biocon pharma limited india biopharmaceutical manufacturing biocon biologics india limited india nil nil biopharmaceutical manufacturing biocon academy india profit organisation biocon sa switzerland research development biocon sdn bhd malaysia biopharmaceutical manufacturing biocon biologics limited united nil sale biosimilar product kingdom biocon pharma inc united state nil sale pharmaceutical product biocon fz llc dubai nil trading biopharmaceutical product b noncontrolling interest summarised financial information syngene international limited noncontrolling interest material group amount disclosed subsidiary intercompany elimination summarised balance sheet particular march march april noncurrent asset current asset total asset noncurrent liability current liability total liability net asset accumulated noncontrolling interest summarised statement profit loss particular march march revenue operation profit year comprehensive income total comprehensive income total comprehensive income allocated noncontrolling interest dividend paid noncontrolling interest summarised statement cash flow particular march march cash flow used operating activity cash flow used investing activity cash flow used financing activity net increase decrease cash cash equivalent ahead curve annual report biocon limited subsidiary c interest joint venture group one joint venture name neobiocon fz llc neobiocon incorporated dubai march holding march equity stake accounted using equity method opinion director material group neobiocon share capital solely consisting equity share held directly ownership interest proportion voting right held summarised balance sheet neobiocon follows particular march march april noncurrent asset current asset total asset noncurrent liability current liability total liability net asset percentage ownership interest accumulated group share net asset summarised statement profit loss neobiocon particular march march revenue operation profit year comprehensive income total comprehensive income share profit joint venture dividend received space intentionally left blank financial report segment reporting based management approach defined ind chief operating decision maker codm evaluates group performance based analysis various performance indicator business segment geographic segment accordingly information presented along business segment geographic segment accounting principle used preparation financial statement consistently applied record revenue expenditure individual segment set significant accounting policy business segment group primarily enterprise small molecule smv biologics branded formulation bf research service research april march particular smv biologics bf research unallocated elimination total revenue external revenue intersegment revenue total revenue cost segment cost intersegment cost result corporate expense income including interest operating profit depreciation amortisation finance cost share profit joint venture segment result income tax current deferred noncontrolling interest profit tax information segment asset unallocable corporate asset total asset segment liability unallocable corporate liability noncontrolling interest total liability space intentionally left blank ahead curve annual report biocon limited subsidiary april march particular smv biologics bf research unallocated elimination total revenue external revenue intersegment revenue total revenue cost segment cost intersegment cost result corporate expense income including interest operating profit depreciation amortisation finance cost share profit joint venture segment result exceptional item income tax current deferred noncontrolling interest profit tax information segment asset unallocable corporate asset total asset segment liability unallocable corporate liability noncontrolling interest total liability geographical segment revenue net april april march march india united state america rest world total noncurrent asset march march india malaysia rest world total note noncurrent asset excludes financial instrument deferred tax significant client customer individually account revenue year ended march march segment revenue result expense directly attributable allocated business segment reasonable basis shown unallocated corporate expense segment asset liability segment asset include operating asset used business segment consist principally fixed asset current asset segment liability comprise liability directly allocated respective segment asset liability allocated segment shown part unallocated corporate asset liability respectively financial report additional information required schedule iii act enterprise consolidated subsidiaryassociatesjoint venture name entity net asset share profit loss share comprehensive share total comprehensive march year ended income year ended income year ended march march march amount amount amount amount consolidated consolidated consolidated consolidated total net asset profit loss comprehensive comprehensive income income holding company biocon limited subsidiary indian syngene international limited biocon research limited biocon pharma limited biocon biologics india limited biocon academy foreign biocon sa ahead curve annual report biocon sdn bhd biocon biologics limited biocon pharma inc biocon fz llc joint venture foreign neobiocon fz llc associate foreign iatrica inc usa noncontrolling interest gross total adjustment arising consolidation total additional information required schedule iii act enterprise consolidated subsidiaryassociatesjoint venture contd name entity net asset share profit loss share comprehensive share total comprehensive march year ended income year ended income year ended march march march amount amount amount amount consolidated consolidated consolidated consolidated total net asset profit loss comprehensive comprehensive income income holding company biocon limited subsidiary indian syngene international limited biocon research limited biocon pharma limited biocon biologics india limited biocon academy foreign biocon sa biocon sdn bhd biocon biologics limited biocon pharma inc biocon fz llc joint venture foreign neobiocon fz llc associate foreign iatrica inc usa noncontrolling interest gross total adjustment arising consolidation total financial report biocon limited subsidiary note company entered transaction sale product private company year ended march amounting respectively required prior approval central government section company act transaction entered prevailing market price approved board director company year ended march company filed application central government approval transaction compounding noncompliance pending central government march corporate social responsibility per section company act company meeting applicability threshold need spend least average net profit immediately preceding three financial year corporate social responsibility csr activity gross amount required spent company year b amount spent year sl particular cash yet paid total cash construction acquisition asset ii purpose event reporting period april board director company approved issue bonus share proportion ie two bonus equity share every one fully paidup equity share held record date subject approval shareholder company postal ballot b april board director company proposed final dividend per equity share prebonus share basis proposed dividend subject approval shareholder annual general meeting per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number ww sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership din din siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f bengaluru bengaluru april april space intentionally left blank ahead curve annual report forward looking statement biocon fy annual report annual report disclosed forwardlooking information enable investor comprehend prospect take informed investment decision report statement written oral periodically make contain forward looking statement set anticipated result based management plan assumption tried wherever possible identify statement using word anticipates estimate expects project intends plan belief word similar substance connection discussion future performance market data ranking used various chapter based several published report internal company assessment cannot guarantee forward looking statement realized although believe prudent assumption achievement result subject risk uncertainty even inaccurate assumption known unknown risk uncertainty materialize underlying assumption prove inaccurate actual result could vary materially anticipated estimated projected reader bear mind undertake obligation publicly update forwardlooking statement whether result new information future event otherwise conceptualized developed team corporate communication biocon seemaahujabioconcom trisys communication infotrisyscomcom biocon limited th km hosur road electronic city bangalore india e corporatecommunicationsbioconcom w wwwbioconcom